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ABSTRACT 
Cellular Mechanisms of Neurovascular Breakdown and Neuronal Dysfunction Following 
Recurrent Group A Streptococcus Infections in Mice 
 
Maryann Priscilla Platt 
 Autoimmune encephalitic (AE) syndromes represent a unique manifestation of 
autoimmunity: the immune system recognizes the brain as foreign, and interferes with neuronal 
function. AE syndromes are characterized by hallucinations, paranoia, anxiety, seizures, and 
autonomic dysregulation, and progress over a matter of weeks as autoantibodies targeting the brain 
bind more densely to their CNS targets. Development of AE has been linked to peripheral tumors 
and infection, both of which provide structural mimetics to CNS antigens to incite an immune 
response in the periphery. How these brain-specific antibodies reach the CNS remains unclear. 
 In rare cases, Group A Streptococcus (GAS, S. pyogenes) infections can cause CNS 
autoimmunity targeting the basal ganglia, termed post-infectious basal ganglia encephalitis (BGE), 
manifesting as motor (Sydenham’s chorea) and psychiatric (Pediatric Autoimmune 
Neuropsychiatric Disorders Associated with Streptococcus, PANDAS) abnormalities. In a mouse 
model of post-infectious BGE, we have shown that repeated intranasal GAS infections generate 
robust T cell infiltration into the CNS, concomitant with blood-brain barrier breakdown, microglial 
activation, and olfactory synapse degradation. However, the different T cell subtypes that enter the 
brain, how they enter the CNS, and their relative contributions to neural dysfunction and 
neuroinflammation remain unclear.  
 Th17 lymphocytes are heavily implicated in many autoimmune diseases, but whether the 
inflammatory post-infectious BGE reaction induces functional deficits in odor processing and 
requires Th17 lymphocytes was unknown. Here we demonstrate that mice lacking Th17 
lymphocytes display both reduced BBB impairment and antibody infiltration. Furthermore, 
multiple GAS infections induce deficits in odor processing, which are partially ameliorated in 
Th17 cell-deficient mice. Notably, neuroinflammation and some excitatory synaptic loss persist, 
due to the presence of Th1 lymphocytes. Th17 lymphocytes are therefore critical for both selective 
CNS entry of autoantibodies and neural circuit impairment during post-infectious BGE. By 
examining the regulation of chemokine ligand expression in GAS-inoculated mice, we determined 
that CCL20/CCR6 and CCL2/CCR2 chemokine axes are implicated in T cell homing to the brain. 
In chemokine receptor mutant CCR6+/- CCR2-/- mice, T cell infiltration is reduced by 86.2%, and 
microglial activation is blunted. These findings suggest that CCL2/CCR2 and CCL20/CCR6 
signaling may play a role in T cell homing to the brain and neuroinflammation. Finally, we first 
assessed behavioral and immune responses in two different GAS exposure models. It was clear 
that while behavioral abnormalities can be recapitulated in mice given subcutaneous GAS 
immunizations, this elicited relatively weak cellular and humoral immune responses. By contrast, 
mice given intranasal GAS inoculations showed minimal behavioral abnormalities, but elicited 
robust humoral and cellular immune responses. 
 Taken together, these data demonstrate the pivotal role of Th17 lymphocytes in brain 
pathology and olfactory processing deficits after recurrent GAS infections in our mouse model. 
Our intranasal inoculation model supports the conclusion that post-infectious BGE is autoimmune 
in nature, despite the absence of behavioral symptoms in this model. Using multiple mouse models 
of post-infectious BGE may allow us to study distinct facets of disease pathogenesis. Finally, this 
work underscores the ability of T cells to incite neuroinflammation, provides a useful clinical 
diagnostic test in olfactory functional assessments, and lends support to T cell immunotherapy 
strategies in patients with post-infectious BGEs. 
   i 
Table of Contents 
 
List of Figures           iii 
Acknowledgements          vii 
Preface           x 
Chapter 1: Autoimmune encephalitic syndromes linked to infection   1 
1.1  Autoimmune encephalitis disease pathogenesis     2 
1.2  Blood-brain barrier function in health and disease    11 
1.3  Immune system activation in autoimmune encephalitis    22 
1.4  Lessons from animal models of autoimmune encephalitis   33 
1.5  Concluding remarks        43 
 
Chapter 2: Materials and Methods        45 
 2.1 Experimental procedures, protocols, and reagents    45 
 2.2 Behavioral tests         60 
 2.3 Statistical analyses and figure preparation     63 
 
Chapter 3: Th17 lymphocytes drive post-Streptococcal neurovascular dysfunction  64 
 3.1 Introduction         64 
 3.2 Deletion of RORgt eliminates Th17 fraction     67 
 3.3 Th17 cells enhance BBB permeability in a size-dependent manner  74 
 3.4 Neuroinflammation induces synaptic dysfunction in olfactory circuits  80 
 3.5 Olfactory circuit deficits after recurrent GAS infections are Th17- and   88 
sex-dependent 
 3.6 Concluding remarks        91 
 
Chapter 4: Chemokine signaling recruits T cells to the CNS     98 
 4.1 Introduction         98 
 4.2 Temporal dynamics of CCL2 and CCL20 expression    100 
 4.3 Chemokines CCL2 and CCL20 expressed in olfactory tissues after   101 
GAS infections 
 4.4 CCR2 and CCR6 guide T cells into the CNS after recurrent GAS inoculations 103 
 4.5 Concluding remarks        108 
 
Chapter 5: General discussion        114 
 5.1 T cell homing depends on concentration gradients of many signaling   115 
molecules 
   ii 
 5.2 Sex specificity in immune and circuit-level processing deficits   117 
 5.3 Size- or route-dependent BBB dysfunction induced by Th17 lymphocytes 120 
 5.4 The invitations to the T cell party       123 
 5.5 Microglia: more than neuroinflammation      125 
 5.6 Host and pathogen genetic contribution to post-infectious BGE and other  128 
 AE syndromes 
 5.7 Concluding remarks        130 
 
References           131 
 
Appendix A: Comparison of route of GAS exposure: neuroinflammation and   149 
 behavioral studies 
 A.1 Different immunological responses to intranasal versus subcutaneous   150 
GAS exposure 
 A.2 Humoral anti-GAS and anti-brain immune responses induced by s.c.   151 
   and i.n. GAS 
 A.3 Behavioral phenotypes after s.c. or i.n. GAS exposure    154 
 A.4 Concluding remarks        157 
 
Appendix B: Dendritic cells infiltrate the CNS after recurrent GAS inoculations  161 
 B.1 Dendritic cells infiltrate the CNS after recurrent GAS inoculations  161 
 B.2 Concluding remarks        163 
 
Appendix C: T cells localize along olfactory axon tracts after recurrent GAS   164 
 inoculations 
 C.1 Olfactory axon tracts connect OE with OB     164 





   iii 
List of Figures 
 
Chapter 1 
Figure 1.1: Pathogenesis of autoimmune encephalitis     3 
Figure 1.2: Schematic of cross-reactive antibodies from recurrent GAS infections  9 
Figure 1.3: Molecular components of the blood-brain barrier in endothelial cells  13 
Figure 1.4: Four main hypothesized routes of IgG leakage in AE    19 
Figure 1.5: Differentiation and effector cytokine production by T cell subpopulations 26  
Figure 1.6: Labeling or deletion of Th17 cells in the RORgt-GFP mouse line  27 
Figure 1.7: Schematic representation of chemokine ligand-receptor binding pairs  31 
Table 1.1: Animal models of AE syndromes and associated immunological and                 34 
neurological findings 




Table 2.1: PCR primer sequences, reaction conditions, and equipment used   47    
for genotyping 
Table 2.2: Antibody information and dilutions used for immunohistochemistry  52 
Table 2.3: Antibody information and dilutions for Western blots    55 
Table 2.4: Reaction components and cycling information for reverse transcription   57 
reaction to create cDNA from olfactory tissues 
Table 2.5: Primer sequences and reaction components for qPCR reactions   57 
Table 2.6: Odorant stimuli used in electrophysiology recordings    59 
 
Chapter 3 
Figure 3.1: Olfactory bulb glomerular connectivity in healthy or inflammatory   66 
conditions 
   iv 
Figure 3.2: Immunocompromised RORgt-/- mice are more susceptible to sepsis   67  
than RORgt+/- mice 
Figure 3.3: Sex-specific Th17 driven peripheral immune cell infiltration   68 
Figure 3.4: T cells infiltrate the brains of RORgt+/- and RORgt-/- mice after recurrent  70 
GAS infections 
Figure 3.5: Flow cytometric analysis of lymphocytes recruited to brain and   71 
NALT/OE after recurrent GAS infections 
Figure 3.6: T cells recruited to the olfactory epithelium after recurrent GAS   72 
infections in RORgt+/- and RORgt-/- mice. 
Figure 3.7: Flow cytometric analysis of splenic CD4+ T cells confirms that   73 
immune response is local to olfactory tissues 
Figure 3.8: Increased permeability to a small molecular weight tracer in    75 
GAS-inoculated brains 
Figure 3.9: Increased deposition of IgG in OB regions in RORgt+/- but not    76 
RORgt-/- mice inoculated with GAS 
Figure 3.10: BBB permeability after recurrent GAS inoculations is size-restricted  77 
Figure 3.11: Tight junction (TJ) protein abnormalities after GAS infection in   78 
RORgt+/- and RORgt-/- brains 
Figure 3.12: Fc receptor mRNA expression changes in olfactory tissues after   80 
recurrent PBS or GAS inoculations 
Figure 3.13: Neuroinflammation by activated microglia/macrophages after   81 
GAS inoculations 
Figure 3.14: GAS-induced synapse protein degradation is Th17-independent  82 
Figure 3.15: GAS-inoculated RORgt+/- and RORgt-/- mice are hyposmic   83 
Figure 3.16: Electrophysiological recordings from mitral cell populations   84 
Figure 3.17: Heatmaps showing mitral cell activation and suppression responses  85 
Figure 3.18: Th17-dependent ablation of mitral cell odor response in    86 
GAS-inoculated mice 
Figure 3.19: Percentage of significantly active cell-odor pairs in female    87 
RORgt+/- and RORgt-/- mice after GAS infections 
   v 
Figure 3.20: Heatmaps of mitral cell activation and suppression responses in   89 
male mice 
Figure 3.21: Aberrant mitral cell firing properties with increasing odor concentration  91     
in GAS-inoculated male mice 
Figure 3.22: Inflammatory Th17 response after GAS infections drives selective   94 
BBB permeability, microglial activation, and aberrant mitral cell function 
 
Chapter 4 
Figure 4.1: Chemokine receptor expression on T cell subsets    99 
Figure 4.2: T cells accumulate in anterior brain over the course of several infections 100 
Figure 4.3: qRT-PCR screen for chemokine and cytokine expression after recurrent  101 
GAS infections in olfactory tissues 
Figure 4.4: Olfactory expression of CCL2 and CCL20 confirmed by in situ   102 
hybridization 
Figure 4.5: Blunted T cell infiltration in CCR6 chemokine receptor mutant mice  104 
Figure 4.6: CCR2 signaling recruits T cells to the brain, but does not affect   105    
T cell differentiation 
Figure 4.7: Interrupted chemokine axes influence T cell homing to brain   106 
Figure 4.8: Attenuated neuroinflammation in chemokine receptor mutants   108 
Figure 4.9: Olfactory tissues in close proximity within the skull    109 
Figure 4.10: Chemokine expression influences T cell homing to the CNS after   111 
recurrent GAS inoculations 
 
Appendix A 
Figure A.1 CD4+ T cells in brains of subcutaneously immunized SJL/J mice  151 
Figure A.2 Microglial activation is not GAS-specific in the s.c. GAS    152 
immunization protocol 
Figure A.3 Sera harvested from i.n. or s.c. GAS-exposed mice react with GAS   153 
bacterial proteins and endothelial and brain antigens 
   vi 
Figure A.4 GAS immunized mice have largely intact BBB     154 
Figure A.5 Behavioral battery in i.n. and s.c. GAS-exposed mice show mild phenotypes 156 
 
Appendix B 
Figure B.1 Dendritic cell populations increase the CNS after recurrent GAS inoculations 161 
Figure B.2 T cell and dendritic cell populations are present in GAS-inoculated mice 162 
 
Appendix C 





   vii 
Acknowledgements 
 First and foremost, I would like to thank my PI, Dritan Agalliu, for being probably the most 
fitting mentor I could have asked for to oversee my PhD. He has been patient with me over the 
years, taking time to troubleshoot experiments and discuss future directions, even with my less-
than-fully-baked ideas. Dritan provided technical support at the bench, worked late nights in lab 
alongside me, and encouraged me to take advantage of scientific and cultural opportunities both 
in Irvine and New York. He has been so supportive scientifically and on a personal level as a 
mentor, and I admire his commitment to training all of his mentees. I am a better scientist and a 
better person for having been in Dritan’s lab. I rate him a 5/5 for PhD mentors.  
 I thank my thesis committee members, Drs. Ai Yamamoto, Lori Zeltser, and Christoph 
Kellendonk, for mentoring me over the years and taking me in after moving from UC Irvine to 
Columbia. Their helpful comments and constructive criticism helped shape this project for many 
years, and I am grateful they were willing to serve on my committee for its duration. Many thanks 
go to Dr. Zsuzsanna Fabry for serving as my outside examiner.  
 For their moral support and help in troubleshooting, I’d like to acknowledge members of 
the Agalliu lab since my joining in 2014: Drs. Sarah Lutz, Justin Lengfeld, Jenna Mazzoni, 
Saptarshi Biswas, and Azzurra Cottarelli; Sanjid Shahriar, Francesca Garretti, Joon Kim, Julian 
Smith, and Sigal Kofman. For preliminary studies on the PANDAS project, I’m indebted to Dr. 
Erica Smith, Martin Hsu, and Daniel Knowland, whose analyses built the legs for this thesis to 
stand on. Ongoing work by Tyler Cutforth, Nicole Ampatey, and Charlotte Wayne drives this 
project forward in both the human and mouse worlds, connecting bench to bedside. I look forward 
to reading about your discoveries in the coming years. I am grateful for the undergraduates I trained 
that contributed to this project: Alison Tran at UC Irvine, Fernanda Pacheco at Columbia 
   viii 
University, and Sarah Chaudhry at Barnard College performed hours of sectioning and imaging 
for their own projects. 
 Thank you to our collaborators at the University of Minnesota and at Duke University. 
Work done in collaboration with Pat Cleary and Thamotharampillai Dileepan at the University of 
Minnesota forms the basis for many of these studies. I’d also like to thank the Franks lab at Duke 
University for taking me in not once, but twice, and letting me monopolize their recording rig for 
seven total weeks. Kevin Bolding, Shiva Nagappan, Brendan Ryu, and of course Kevin Franks 
provided invaluable guidance on surgery, recording, and data analysis, as well as moral support. 
Many, many thanks go out to my friend Dr. Rachel Cohen in Durham for housing me and sharing 
her running routes, oatmeal, chicken, and sweet potatoes.  
 I’m grateful to the faculty and students in the INP program at UC Irvine, as well as my 
adopted cohort at Columbia that took me in after the move to New York, and to the many 
neuroscientist friends I gained on both coasts. Encouragement from previous mentors, especially 
Drs. Lynn Westling, Jan Naegele, Glenn Rosen, and Al Galaburda, helped me see that science was 
a viable path, and inspired me to follow my passion. 
 For all their support and love, I’d like to thank my parents, my family, and my friends. My 
parents helped me move across the country not once, but twice for graduate school, listened to my 
elevator pitch at every holiday for six years, and provided unending moral support. To my nieces 
and nephew, may you follow your passions as far as they lead you; to my sister Katy and my 
brother Jody, thank you for blazing every trail, constantly striving for more, and for showing me 
what pursuit of passion looks like. To my boyfriend Tony, thank you for your bottomless support, 
for relishing victories large and small, and for talking about every single piece of data here.  
   ix 
 I would like to thank the parents of children with PANDAS who initially motivated me to 
work on this project. Your perseverance in the face of adversity is truly inspiring; I am honored to 
have played a small role in your lives. Finally, I have to thank the thousands of research animals 
who sacrificed their lives for this work, and for basic and translational research that underlies all 
scientific discovery.   
   x 
Preface 
 
 Portions of Chapter 1 in this work, describing immune dysfunction in autoimmune 
encephalitis and routes of antibody and immune cell entry into the CNS, are slightly expanded 
from a published review article [50]. Text, figures, and tables from this article have been updated 
to include discoveries since its publication.  
 Some experiments were performed partly or wholly by other members of the Agalliu 
laboratory. Erica Smith generated cDNA from olfactory tissues, performed the chemokine screen, 
and assisted with behavioral analysis for intranasally inoculated mice. Erica also performed some 
initial pilot experiments in the CCR6 and RORgt mouse lines not described here. Charlotte Wayne 
performed flow cytometry for cytokine expression in lymphocytes from CCR2+/- and CCR2-/- 
mice. Nicole Ampatey performed much of the Th17 analysis in CCR6+/- and CCR6-/- mice. Alison 
Tran helped perform much of the behavioral and histological analyses on subcutaneously 
immunized mice; Fernanda Pacheco analyzed BBB breakdown after subcutaneous GAS 
immunization, and Sarah Chaudhry analyzed the spatial distribution of the Th17 fraction in the 
brain, in addition to frequent assistance with genotyping.  
 This work is dedicated to my two whip-smart, independent grandmothers: Mary Anne and 
Priscilla.  
 
   1 
Chapter 1: Autoimmune encephalitic syndromes linked to infection 
 Antibody-mediated autoimmunity, the hallmark of several autoimmune encephalitides 
(AE) that produce movement and psychiatric disorders, is triggered when antibodies recognize 
neuronal epitopes as foreign proteins [1-3]. Antibodies directed against neuronal antigens can arise 
in the periphery when target proteins are expressed ectopically on tumor cells. Disease 
pathogenesis involves three distinct facets: (1) peripherally-generated antibodies capable of cross-
reacting with neuronal epitopes (2) that gain access to targets in relevant brain regions, and (3) 
persist in the brain long enough to perturb neuronal signaling. First, what initially prompts 
autoantibody formation remains a subject of debate, although there is evidence for two main 
triggers: (1) ectopic neuronal epitope expression on peripheral tumors, and (2) infectious triggers. 
The link between N-methyl-D-aspartate (NMDA) receptor encephalitis and ovarian teratoma 
ectopically expressing the antigen was reported in the initial description of NMDA receptor 
encephalitis (NMDARE) by Dalmau and colleagues [4, 5]. AE has also been linked to various 
infectious triggers, including bacteria, viruses, fungi, and other parasites [6-8]. However, an 
underlying infection is the causative agent in only a small fraction of AE cases; in about half of 
cases, a trigger is never identified [9-11].  
The blood-brain barrier (BBB) normally excludes circulating antibodies from the CNS [12, 
13], including CNS autoantibodies present in a minority of the healthy population, from cross-
reacting with neuronal epitopes [14, 15]. While mechanisms of BBB breakdown are well-
documented in multiple sclerosis (MS), a CNS autoimmune disease where T cells and antibodies 
target CNS myelin, it is unclear how peripherally-generated antibodies against brain targets might 
access the parenchyma in AE. Spatial breakdown of the BBB may be indicative of 
symptomatology, given that antibody reaction with different brain structures will produce different 
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symptom spectra (e.g., motor symptoms induced by BBB breach and antibody deposition in the 
basal ganglia vs memory impairment from barrier leakage in the hippocampus). Frank brain 
lesions are uncommon in AE patients, and brain imaging is frequently normal [16-18], indicating 
that antibody entry into the brain may result from dynamic, short-term BBB breakdown. 
Many AE syndromes have protracted clinical courses because of frequent misdiagnosis. It 
remains unclear how peripherally-generated autoantibodies persist in the CNS; either the BBB is 
continually permeable to antibodies allowing their continuous entry into the CNS, or plasma cells 
or B cells enter the brain parenchyma and synthesize antibodies intrathecally, allowing for disease 
persistence after resolution of BBB breakdown. In this chapter, I will review development and 
disease course in various AE disorders, what we have learned from animal models of AE, and the 
role of the immune system in these and other CNS autoimmune diseases.  
 
1.1 Autoimmune encephalitis disease pathogenesis 
Since the discovery of NMDA receptor linkage to AE by Dr. Josep Dalmau in 2007, many 
clinical and basic discoveries have defined some general mechanisms of these diseases [2, 4, 5, 
17-21]. Dozens of neuronal targets of AE have been identified since, and most of these proteins 
are surface receptors involved in synaptic transmission (Figure 1.1). However, some targets are 
expressed intracellularly. In about half of all AE cases, an underlying cause is never identified. 
These cases are typically diagnosed as limbic encephalitis (LE) with no demyelinating lesions, or 
acute disseminated encephalomyelitis (ADEM), an inflammatory demyelinating disease with no 
infectious involvement. Diagnosis of autoimmune or other encephalitides can be challenging, and 
symptoms can involve a host of motor, affective, and psychological presentations. A subacute 
onset of fever, confusion, personality changes, memory loss, seizures, and weakness or ataxia are  
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Figure 1.1 Pathogenesis of autoimmune encephalitis. Autoimmune encephalitis occurs when antibodies specific for 
brain epitopes enter the CNS, where they bind target antigens and interfere with neuronal signaling. Many distinct 
autoantibody targets have been identified to date, with selected examples of  antibodies from CSF reacting with 
neurons in vitro [22]. 
 
common, with slight variations in both presentation and symptom onset. CSF pleocytosis is a 
hallmark of AE, but clinical presentation can also vary with age, as seen in Herpes virus 
encephalitis and NMDARE [23, 24]. Frequently, imaging studies of acute AE patients are either 
nonspecific or unremarkable, differentiating these syndromes from multiple sclerosis (MS) and 
other encephalopathies, where PET or MRI often reveals classical lesions [16]. Brain MRI aids in 
differential diagnosis between different encephalitic syndromes and MS, as ADEM typically 
presents with abrupt onset and symmetrical lesion areas usually involving the thalamus, while MS 
onset is more gradual, with distinct, non-symmetrical lesions that involve the brainstem [25]. 
Lesions in LE patients are typically bilateral and involve the medial temporal lobes [18]. ADEM 
and other AE disorders will sometimes have a history of infection or vaccination preceding 
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symptom onset, which can also aid in narrowing down specific autoantigens that may trigger 
disease.  
Initial identification of several AE syndromes stemmed from links to specific cancer 
populations. The original cohort of NMDARE patients all presented with both psychosis 
symptoms as well as ovarian or mediastinal teratomas. These tumors contained neural tissue 
ectopically expressing NMDAR NR2 subunits on the tumor surface, which provides a potential 
initiation point for autoimmunity outside the CNS [4].  In a cohort of GABAB receptor encephalitis 
patients, 50% had small cell lung cancer ectopically expressing the antigen [26]. Morvan syndrome 
and limbic encephalitis have also been linked to thymoma in a subset of patients (19-30%) [27, 
28]. In patients with tumors and ensuing paraneoplastic syndrome, removal of the inciting tumor 
is necessary for treatment [4, 17, 29-32]. Immunotherapy alone without tumor resection frequently 
results in deterioration [17, 32]. 
 Several precipitating infectious triggers have also been identified recently, including 
bacteria, viruses, and, rarely, fungi. Specifically, AE has been linked to Group A Streptococcus 
(GAS, S. pyogenes) bacteria [33, 34], influenza virus [35], Japanese encephalitis virus [8, 36], 
Herpes virus [24, 37-39], and fungi [40]. Herpes virus has been linked to later development of 
NMDARE in a subset of patients [24, 37]. These are all quite common pathogens, and tend not to 
cause encephalitis in healthy, immunocompetent individuals. Infectious triggers such as GAS are 
hypothesized to cause autoimmunity by either direct molecular mimicry of GAS antigens and 
autoantigens, or by recurrent inflammation combined with BBB breach that allows aberrant 
immune targeting of the CNS.  
 Presence of autoantibodies in serum is an imperfect diagnostic tool. First, it has been 
estimated that approximately 2-10% of the healthy population have circulating anti-brain 
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antibodies [14, 15, 41]. It is also possible to isolate antinuclear antibodies from ~30% of the healthy 
population [15, 42], and anti-endothelial cell antibodies from ~2% of healthy patients  [43]. 
Second, the BBB normally excludes circulating antibodies from the brain parenchyma, limiting 
their pathogenic power. Presence of autoantibodies in the CSF is a more specific indicator of AE, 
with much greater sensitivity and specificity than serum antibodies [18]. These important findings 
raise the question of how CNS barriers, including the BBB, break down during AE to allow 
circulating autoantibodies into the brain parenchyma.  
 Genetic studies have shown linkages to several loci in AE patient cohorts. Several immune 
alleles confer specific risk for AE syndromes, specifically, major histocompatibility complex-II 
(MHC-II) alleles. Anti-LGI1 encephalitis is highly associated with 27 SNPs, most significantly 
with a 13.66-fold odds ratio in patients carrying the rs2858870 SNP in HLA-II. Imputation of HLA 
alleles in this cohort showed linkage to DRB1*07:01, DQA1*02:01 and DQB1*02:02 [44]. In a 
separate cohort, HLA DRB7 and DRB4 were strongly linked to non-tumor anti-LGI1 encephalitis 
patients, but not patients with tumors [45]. In a German NMDARE cohort, HLA typing showed 
linkage to MHC II allele B*07:01 [44], but no HLA allele associations were identified in a Korean 
cohort [46]. No significant linkages were identified between the two AE syndrome cohorts [44]. 
This implies that different AE syndromes may develop via unique genetic vulnerabilities, perhaps 
tied to risk factors for infection or specific neoplasms.  
 
1.1.1 Group A Streptococcus triggers robust immune responses and autoimmune encephalitis 
While the evidence that microbial infections trigger for AE is limited, Group A 
Streptococcus (GAS, S. pyogenes) infections cause autoimmune sequelae in many target tissues, 
including heart, kidney, or CNS that are manifested as acute rheumatic fever (ARF), 
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glomerulonephritis, or Sydenham’s chorea, respectively [47]. ARF is the most common of these 
outcomes, and while its prevalence has waned with the advent of antibiotics, it remains a public 
health concern in many developing countries. The most prominent risk factors for ARF include 
overcrowded living conditions, undernutrition, and family history of rheumatic fever or rheumatic 
heart disease [48]. Patients typically develop fever, arthralgia, lethargy, and/or chest pain, which 
is treated with antibiotics and anti-inflammatory drugs to resolve latent infection and 
inflammation. Preventative treatments for ARF primarily involve antibiotics to treat preceding 
GAS pharyngitis, which limits the burden on the immune system. Several vaccines against GAS 
are being developed, but large variation among serotypes has hindered progress on this front [49].  
Untreated GAS infections have long been linked to later development of movement 
disorders in a minority of children, as identified in 1686 by Thomas Sydenham [50]. Sydenham’s 
chorea (SC) presents in a minority of children as uncontrolled, jerky movements of the arms, legs, 
trunk, or face, sometimes in conjunction with rheumatic fever. It was not until 1998 that Dr. Susan 
Swedo at the National Institutes of Mental Health (NIMH) described a subset of 50 children from 
a larger cohort of SC patients with acute psychiatric symptoms, which she termed Pediatric 
Autoimmune Neuropsychiatric Disorders Associated with Streptococcus (PANDAS) [34]. Her 
description of PANDAS maintains a close association with prior GAS infection, but presents with 
psychiatric symptoms rather than purely motor disturbances characteristic of SC [34]. In patients, 
post-Streptococcal autoimmunity can have a wide variety of symptoms. Children presenting with 
the following symptoms are considered for a PANDAS diagnosis: swift or overnight onset of 
symptoms; pediatric patient age; bedwetting or urinary urgency; obsessions or compulsions; 
separation anxiety; choreiform movements; and changes in mood or behavioral disturbances [34]. 
There has been some resistance to PANDAS diagnosis clinically, and controversy still persists. 
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Clinicians have raised objections for a multitude of reasons, namely: reliance on a list of 
unvalidated criteria for differential diagnosis; no specific laboratory tests; weak genetic 
associations; lack of direct evidence of autoimmunity; and the prevalence of GAS infections in 
children complicated separation of PANDAS from pediatric onset of Tourette’s disorder or 
obsessive-compulsive disorders (OCD) [51-54]. Careful consideration of obsessive-compulsive 
OCD, Tourette’s, and rheumatic fever must be ruled out before considering a diagnosis of 
PANDAS. 
 
1.1.2 Human genetics in SC and PANDAS 
It is hypothesized that predisposition to post-Streptococcal autoimmunity has a genetic 
component, since rheumatic heart disease, Sydenham’s chorea, and PANDAS are sex-skewed [34, 
47, 49]. ARF affects both sexes equally, but later development of rheumatic heart disease is skewed 
toward to females [55]. SC tends to affect girls more, but PANDAS is more prevalent in boys [56]. 
Females are more prone to autoimmune diseases in general, so it comes as little surprise that there 
would be a sex linkage in these diseases. Genome wide association studies (GWAS) have 
implicated major histocompatibility class (MHC) class I and class II alleles in ARF, SC, AE, 
ADEM, multiple sclerosis, and systemic lupus erythematosus risk [25, 57-59]. Specifically, HLA 
DRB1*15:01 has been linked to SC, MS, SLE, and ADEM, identifying a common genetic risk 
factor in this group of autoimmune diseases [59, 60]. HLA alleles DRB1*15:01, DRB1*15:03, 
DQB1*06:02, DQA*01:02, and DPA*03:01 also confer risk in MS and ADEM [25, 61]. 
Conversely, HLA DQB1*06:02 is protective for rheumatic heart disease in adult populations, 
rheumatic fever, SC, and recurrent GAS tonsillitis in children [59, 60, 62] Genetic linkage to ARF 
is also strong for several cytokine and other immune effector molecules, as well as Fc receptor 
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gene polymorphisms (FcgRIIA-R/R-131 and FcgRIIA-R/H-131 polymorphisms) [57, 59, 63-69]. 
Small numbers of patients with SC or PANDAS limits the power GWAS studies for genetic 
susceptibility, but future studies using whole exome sequencing and gene burden analysis methods 
to probe candidate pathways may provide an avenue to identify genetic risk factors for these 
diseases. 
Since GAS is posited to be the initiating agent in causing autoimmunity in PANDAS and 
SC, it is important to link infectious agents with later development of psychiatric illness. Several 
studies using large population registers have demonstrated a link between childhood infections 
and psychiatric disorders later in life. The first linked childhood GAS infections of later 
development of mental disorder, specifically OCD and tics (relative risk 1.51 and 1.35, 
respectively) in a Danish population. Non-Streptococcal infections also increased relative risk of 
OCD and tics, but to a lesser extent (1.28 and 1.25, respectively) [70]. The second found that in a 
Taiwanese population, severe or recurrent GAS infections raised relative risk for tics and ADHD 
(1.63 and 1.16, respectively) later in life [69]. Finally, among a Danish population, increasing 
numbers of antibiotic agents used on a particular patient raised relative risk for psychiatric 
hospitalization and prescription of psychotropic medication later in life [71]. Recent GWAS 
studies have also demonstrated a genetic predisposition for recurrent childhood infections linked 
to SNPs in the TNFα and IL-6 genes [6, 56, 72, 73]. Alleles conferring risk (HLA DRB1*01:01, 
DRB1*07:01) and protection (HLA DQB1*06:02) specifically for recurrent GAS infections in 
children were recently identified [62]. These population-based studies support a link between 
childhood infections and later development of psychiatric diseases. Since GAS is an obligatory 
human pathogen, genetic predisposition towards both recurrent primary infections and GAS-
induced autoimmunity can cause long lasting effects much later in life than previously thought. 
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1.1.3 GAS genetics and Superantigens 
Bacterial infections generate an antibody pool targeting various epitopes on the bacterial 
surface. It is hypothesized that a small subset of antibodies produced during GAS infections are 
the initial causative agents for the subsequent autoimmunity [63, 74, 75]. This is hypothesized to 
occur via molecular mimicry, where structural similarity between the targeted bacterial and self- 
antigens promotes cross-reactivity [76-78]. Structural similarity between the coiled-coil region of 
cardiac myosin and the antigenic M protein on the bacterial surface may promote cross-reaction 
of M-specific antibodies with myosin (Figure 1.2a). Mutated GAS strains have been generated 
where irregularities in M coiled-coil structure are smoothed; these strains induce antibodies with 
less cross-reactive affinity for myosin, as well as decreased binding to serum fibrinogen and 
inflammatory effects [79]. Further studies using sera from PANDAS and SC patients support 
cross-reactivity with dopamine D2 receptor (Figure 1.2b), neuronal lysoganglioside, and tubulin  
 
Figure 1.2 Schematic of cross-reactive antibodies from recurrent GAS infections. a In rheumatic fever, structural 
similarity between GAS Emm protein and cardiac myosin is thought to underlie cross-reaction by molecular mimicry. 
b Autoantibodies target the dopamine D2 receptor in Sydenham’s chorea. 
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[10, 63, 80, 81]. Ex vivo studies with also showed cross-reactivity between patient sera and 
cholinergic neurons in the striatum, providing another potential target for autoantibody binding in 
the basal ganglia [82]. Furthermore, epitope spreading after the initiation of autoimmunity could 
lead to numerous cross-reactive antibodies stemming from an inflammatory environment [65].  
One study on a rat model of rheumatic heart disease (rat autoimmune valvulitis) showed 
an increased infiltration of cardiac tissue by T cells and macrophages, as well as cardiac 
arrhythmia, after increasing numbers of immunizations with recombinant M protein. This study 
examined changes in endothelial cell expression of vascular cell adhesion molecule-1 (VCAM-1), 
which is required for adhesion of immune cells to endothelial cells, after exposure to inflammatory 
factors in sera from immunized rats. In vitro restimulation led to upregulated VCAM-1 expression, 
suggesting that T cells may use VCAM-1 to arrest on cardiac vasculature and infiltrate the 
activated endothelium. [83]. While other microbes may exert a similar effect on the immune 
system, direct evidence of immune sensitization leading to autoimmunity is lacking.  
Strain differences in GAS bacteria have also been postulated to contribute to variability in 
both prevalence and manifestation of GAS-induced autoimmunity. Broad groups of emm genes 
refer to their tropism for particular organs; A, B, and C strains are considered particularly 
specialized to the throat, while D strains are specialized to skin, and E is broadly pathogenic [63, 
84]. Expression and antigenicity of superantigen proteins (SAgs), which induce a massive cytokine 
release from T cells upon binding and recognition, varies between GAS strains. In clinical isolates 
from different types of GAS infections (invasive, pharyngitis, and acute rheumatic fever cases), 
SpeB SAg activity was markedly lower in the ARF clinical isolates, suggesting that a balance 
between different SAgs is important for development of autoimmunity [85]. Children with 
recurrent GAS tonsillitis have markedly reduced antibody titers against SpeA, indicating faulty or 
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incomplete antibody production against the pathogen [62]. SAgs bind to the portion of the b-chain 
T cell receptor that does not undergo V(D)J recombination, allowing activation of a huge number 
of T cells [86]. SAgs also bind to and activate MHC-II on antigen presenting cells, although less 
efficiently than SAg binding to the Vb T cell receptor (TCR) [63]. SAgs bind to human MHC-II 
much more efficiently than mouse MHC-II, providing an important caveat for the present studies. 
Because GAS is an exclusive human pathogen, it will be important to extend these findings using 
a mouse line in which the MHC-II gene is humanized. 
Robust immune reactions to GAS are necessary to fight infection and clear bacteria from 
host tissues. Interaction of human genetic predisposition towards autoimmunity in general, family 
history of GAS-induced autoimmunity (including ARF), and GAS strain genetics may all 
contribute to increased risk for GAS-induced AE disease. In addition, BBB breakdown 
independent of bacterial infection seems to be an important contributor to disease. These studies 
emphasize that the contribution of the immune system to PANDAS and SC pathogenesis needs to 
be more fully elucidated.  
 
1.2 Blood-brain barrier function in health and disease  
The blood-brain barrier (BBB) encompasses several unique properties of brain endothelial 
cells (BECs) that limit trafficking of a variety of blood-borne solutes such as ions, nutrients, toxins, 
proteins, immune cells, and antibodies into the brain parenchyma to allow for proper neuronal 
function [12, 87]. The BBB is comprised of three main characteristics. First, expression of tight 
junction (TJ) proteins effectively seal together adjacent BECs, preventing leakage of serum 
proteins through the paracellular space. Second, basal rates of transcytosis are very low in BECs, 
and proteins that form fenestrae are not expressed, limiting bulk transport by vesicular trafficking 
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through BECs. Third, expression of specialized transmembrane transporters on the BEC 
membrane facilitates trafficking of nutrients such as glucose into the parenchyma, and limits transit 
of waste products or potential toxins (Figure 1.3a) [88]. BBB properties regulate the ionic 
composition of brain interstitial fluid, allowing for proper neuronal function. Glial cells are closely 
associated with the EC basolateral face, with astrocyte endfeet covering the outer face of ECs, and 
pericytes spaced sporadically along the vessel length. Astrocytes play a large role in regulating 
water balance and ionic composition of the neuronal milieu, and can signal directly to neurons, 
ECs, and adjacent astrocytes via gap junctions [89]. This section reviews the cellular and molecular 
composition of various barrier interfaces insulating the brain parenchyma from circulating blood, 
as well as mechanisms of barrier breakdown in inflammation and disease states. 
 
1.2.1 Mechanisms of BBB dysfunction in neuroinflammatory diseases 
 Barrier function of CNS endothelial cells can be impaired by several factors: inflammatory 
cytokines, hormones (e.g., epinephrine), and substances of abuse (e.g., alcohol, cocaine, and 
methamphetamine) [11, 89]. Tight junction (TJ) complexes are comprised of tetraspanin integral 
membrane proteins Claudin5 and Occludin, which interdigitate on their extracellular loops to seal 
the walls of adjacent BECs together (Figure 1.3a) [12, 87]. These transmembrane proteins are 
linked via scaffolding proteins such as ZO-1 and Cingulin to the actin cytoskeleton [90]. In the 
healthy CNS, TJ complexes are subject to low rates of turnover through membrane recycling 
machinery [91, 92]. In disease states, however, rates of TJ internalization increase, and TJ strands 
become vulnerable to formation of gaps between adjacent ECs (Figure 1.3b, Figure 1.4c) [91-
93]. In inflamed BECs in vitro, TJ proteins show a punctate, rather than continuous, pattern around 
cell - cell junctions, corresponding to an increase in vesicular endocytosis [94]. In CNS 
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neurological diseases such as stroke and MS, TJs can be internalized within the BEC by forming 
1-3 µm - long protrusions perpendicular to the direction of the TJ strand [91]. Internalization of TJ 
proteins Claudin5, Occludin, and ZO-1 can occur via Clathrin-dependent (Occludin, ZO-1) or 
Caveolin1+ vesicle-dependent (Claudin5, Occludin, ZO-1) mechanisms [90, 95]. In an animal 
model of MS (experimental autoimmune encephalomyelitis, EAE), live imaging of tight junctions 
in the spinal cord showed that TJs are remodeled initially by formation of protrusions before the  
 
 
Figure 1.3 Molecular components of the blood-brain barrier in brain endothelial cells (BECs). In healthy vasculature 
(top), ECs limit bulk diffusion of solutes from blood into brain by expression of tight junction proteins that seal 
together adjacent ECs, as well as suppressing transcytotic vesicular transport. Specialized transporters and pumps 
permit active and passive transport of select solutes. Under inflammatory conditions (bottom), tight junction proteins 
are internalized, and caveolae and cell adhesion molecules are upregulated, promoting BBB permeability.  
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onset of clinical signs, followed by gap formation at the peak of disease, corresponding to the 
degree of BBB damage [92]. Similarly, ZO-1 internalization precedes EAE symptom onset and 
indicates future lesion formation [94]. Although TNFa induces gaps in TJs by upregulating NF-
kB and myosin light-chain kinase in vitro, which induce internalization of TJs via Cav1+ vesicles 
[96, 97], several in vivo studies have failed to demonstrate a role of Cav1+ vesicles in remodeling 
TJs in neurological disease models [91, 92].  
 Inflammatory cytokines can act directly on TJ proteins to destabilize them, and IL-6 is 
elevated in many CNS inflammatory diseases [98]. Inflammatory cytokines can degrade TJs, 
change their phosphorylation state, or affect turnover rate. In EAE, monocytes induce expression 
of tissue plasminogen activator (tPa) by activated ECs, which proteolytically degrades Occludin 
[99]. Th17 cells secrete inflammatory cytokines IL-17A and IL-22, which directly disrupt TJs 
[100]. IL-1b indirectly destabilizes TJs by upregulating Matrix Metalloprotease-9, whereas 
VEGF-A degrades both Claudin-5 and Occludin [101, 102]. These cytokines have been shown to 
disrupt BBB function during neuroinflammation in stroke and EAE, but it is unclear whether they 
are upregulated in AE. Recent cytokine profiling of CSF from patients with viral or autoimmune 
encephalitis revealed that several Th1 cytokines (TNFa, IFNg, CXCL9, and CXCL10) were 
upregulated after viral encephalitis, but not in AE [98]. Healthy brain vasculature expresses low 
levels of leukocyte adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 and -2 (ICAM-1 and ICAM-2), and activated leukocyte cell 
adhesion molecule (ALCAM) which are upregulated in neuroinflammation to promote T cell 
trafficking into the parenchyma [103, 104]. Cell adhesion molecules influence TJ stability, as 
deletion of ALCAM leads to decreased expression of several TJ proteins including ZO-1, 
Occludin, and Claudin5, resulting in increased BBB permeability [105].  
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Changes in transcytosis can also increase BBB permeability (Figure 1.3b). Increased rates 
of transcytosis are responsible for barrier permeability at early (~6 h), as well as later (48 h) time 
points post-stroke in a mouse model for the disease (t-MCAO) [91]. EAE studies in  Caveolin-1-/- 
mice have demonstrated preferential trafficking of some T cell subtypes (Th17 lymphocytes) 
through ECs rather than between them via disrupted TJs during initiation of disease [92]. Notably, 
some Th1 lymphocytes preferentially traffic via Cav1+ vesicles in EAE [92]. Caveolin-1-/- mice 
show reduced EAE clinical scores and demonstrate decreased CD4+ cellular infiltrate compared to 
wild-type (WT) littermates [106]. While caveolar transcytosis is less selective, receptor-mediated 
endocytosis facilitates transport of specific cargo across BECs in vesicles (e.g., the transferrin 
receptor and the insulin receptor bind transferrin-iron complexes and insulin, respectively). This 
pathway has been co-opted to enhance biological treatment passage across the BBB by fusing 
drugs to receptor targets via a Trojan horse mechanism [107, 108]. Biological therapies using 
fusion proteins have been used to treat murine models of stroke, lysosomal storage disorders, 
Alzheimer’s disease, and glioma [107]. Transcytosis can also occur through Clathrin-dependent 
mechanisms, although these vesicles seems to be less important for immune cell trafficking [95]. 
Taken together, there seems to be interplay between transcytotic leakage machinery and other 
inflammatory signals in BECs. 
 Transporters work ceaselessly to supply neurons with nutrients, ions, and gases needed for 
neuronal transmission, and to remove toxins from the CNS. ECs express a wide variety of 
transporters on their apical (vessel-facing) and basolateral (brain-facing) surfaces, including the 
glucose transporter GLUT1. Perhaps the largest superfamily of transporters is the ATP-binding 
cassette (ABC) superfamily, which encompasses 48 members grouped into 7 subfamilies. ABC 
transporters are especially efficient pumps that move xenobiotics and metabolites against their 
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concentration gradient, and can function as importers or exporters [109]. Notably, in a recent study, 
even physical disruption of TJs by focused ultrasound could not overcome the action of ABC 
transporters to deliver the tyrosine kinase inhibitor erlotinib in humans [110]. Mutations in 
transporter genes cause several serious conditions, including cystic fibrosis, Tangier disease, and 
Stargardt disease [88, 109]. In the CNS, mutations that interfere with the function of ABCA 
transporter genes, including cholesterol transporters ApoE and ApoA-I, are particularly associated 
with Alzheimer’s disease [109]. Conversely, brain tumor cells frequently upregulate expression of 
multidrug resistance ABC transporters, which block drug treatment [109].  
 Endothelial cells are particularly vulnerable to endotoxins secreted by infectious agents. 
Antigenic surface proteins on Gram-positive bacterial and lipopolysaccharide from Gram-negative 
bacteria change EC barrier properties [111]. Environmental toxins (e.g., bis(tributyltin) oxide) and 
food additives can increase BBB permeability, as evidenced by serum protein leakage studies 
[112]. The gut microbiome also modulates barrier function [113]. Inflamed astrocytes and 
microglia antagonize each other to amplify release of cytokines IL-1β, TNFα, IL-1α and MIP-1α, 
leading to breakdown of the EC monolayer [114]. In AE cases with many autoantibodies in the 
blood circulation, transient BBB permeability by TJ breakdown, transcytosis, or Fc-mediated 
transport may provide opportunistic access to brain targets.   
 
1.2.2 Glial contributions to BBB structure and function 
 Interactions between endothelial cells, astrocytes, and pericytes are critical for BBB 
development and maintenance. Astrocyte endfeet completely encircle CNS blood vessels, and 
pericytes are spaced evenly along the vessel length. Close association with both of these cell types 
are required for acquisition and maintenance of CNS barrier properties [115]. During embryonic 
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development, pericytes invade the CNS together with sprouting endothelial cells starting on 
embryonic day (E) 12, prior to birth of astrocytes at E18 [116]. Pericyte-deficient Pdgfrb-/- 
embryos showed incomplete tight junction formation, vessel permeability to tracers, and increased 
expression of cell adhesion molecules that are normally downregulated over the course of barrier 
maturation [116]. Wnt/b-catenin signaling in ECs shapes the vascular tree [117], and then pericytes 
help suppress genes that promote fenestration in peripheral vessels, thus promoting acquisition of 
barrier properties. Pericytes form adherens junctions with ECs via expression of N-cadherin 
(Cadherin-2) to maintain their close association to the vessel wall [115]. Astrocytes help control 
the flux of ions, water, and nutrients by expressing ion and water transporters (e.g., Aqp-4), as well 
as maintaining BEC barrier properties throughout adulthood by secreting Wnts, retinoic acid, sonic 
hedgehog, and Angiopoietin-1 [13]. Inflamed astrocytes and microglia antagonize each other to 
amplify release of cytokines IL-1β, TNFα, IL-1α and MIP-1α, leading to breakdown of the EC 
monolayer in vitro [114]. Astrocytes are also required for recovery from injury, where they 
proliferate and form a glial scar that limits immune cell infiltration, BBB leakage, and regrowth of 
neurites through damaged brain areas [118].  
 
1.2.3 Regional variability in BBB permeability 
 The BBB is not uniformly restrictive over the entirety of the CNS vasculature. Several 
studies suggest that endothelial barriers in the brain and spinal cord (SC) are functionally different, 
based on differences in expression of some barrier-specific proteins and their functional 
permeability. ECs in the SC have lower levels of adherens junction (Cadherin-5 and b-catenin) 
and tight junction (Occludin, ZO-1) proteins, as well as increased permeability to small molecular 
weight tracers, compared to brain endothelium [119]. ECs in the brain and SC also differ in their 
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affinity for immune cells. Activated encephalitogenic T cells in the cervical SC rapidly arrest on 
vasculature without crawling, whereas in the brain, T cells roll along brain ECs before arresting. 
Adhesion in the SC is mediated by interaction of a4-integrin and VCAM-1 to arrest, followed by 
LFA-1 to transmigrate through the vessel wall [103, 120]. Higher expression of sphingosine-1-
phosphate receptor in SC ECs may also facilitate immune cell transmigration as compared to other 
CNS regions during EAE [121]. Within the brain, the olfactory bulb (specifically the olfactory 
nerve layer) and neurogenic niches also have relatively higher baseline permeability compared to 
other CNS regions (excepting the circumventricular organs that have leaky blood vessels); vessels 
in these regions become highly permeable following viral infections [122-124], which may 
predispose them to infiltration of immune cells or antibodies in addition to viral particles. Neurons 
in the circumventricular organs actively sample osmolality and hormone levels in the blood, and 
thus would be hindered by presence of a barrier. These brain regions display high vascular 
permeability in healthy animals [125]. 
 
1.2.4 Blood-cerebrospinal fluid barrier (BCSFB) 
 Epithelial cells within the choroid plexus form a tight barrier termed the blood-
cerebrospinal fluid barrier that restricts diffusion of serum proteins and immune cells from the 
leaky blood vessel of the choroid plexus into the cerebrospinal fluid (CSF) [126]. The molecular 
composition of tight and adherens junctions within the BCSFB is slightly different from junctions 
in the BBB, with Occludin and ZO-1 expressed in both barriers, but with mainly Claudin1 and E-
Cadherin expressed in choroid plexus epithelial cells [126, 127]. Several key junctional proteins 
are present in choroid epithelial cells at high levels both in embryonic and adult stages, suggesting 
this barrier matures early in development [128]. These junctions creates a physical barrier to 
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paracellular diffusion and polarizes epithelial cells with distinct luminal and abluminal 
components (Figure 1.4a). Additionally, epithelial cells of the BCSFB express transporter proteins 
that regulate transit of certain plasma proteins and ions across this barrier and maintain the 
composition of CSF [127, 128]. The BCSFB is less tightly regulated than its brain counterpart, 
and is more easily permeabilized in disease states. During EAE, Th17 cells cross the BCSFB  
 
Figure 1.4 Four main hypothesized routes of IgG leakage in AE. a Choroid plexus epithelial cells are vulnerable to 
inflammatory cytokines, promoting leakage of solutes into the CSF. b The olfactory route along olfactory axons has 
been shown to preferentially transport viruses into the brain, as well as providing a route for therapeutic delivery. c 
Blood vessels break down in multiple ways in inflammation, allowing spatially and temporally restricted leakage into 
the brain. d Fc receptors on endothelial cells maintain a low concentration of IgG in the parenchyma; this concentration 
gradient may reverse in disease states. Reprinted from [50]. 
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several days before BBB damage in the “first wave” of T cell entry into the CNS [129]. This entry 
step is essential for initiating the CNS immune response, as demonstrated by EAE resistance in 
CCR6- deficient mice where Th17 cells that cannot cross the BCSFB [129]. In mouse models of 
systemic lupus erythematosus (SLE), VCAM-1 and ICAM-1 expression is elevated on choroid 
epithelium, and large populations of B and T immune cells infiltrate the choroid [130-132]. 
Interestingly, there is variability in T cell and B cell infiltration between different spontaneous 
SLE mouse strains, indicating that distinct disease mechanisms may be at play in the human 
condition [131]. The role of infiltrating immune cells is still debated, but the BCSFB is clearly 
activated and disrupted by increased cytokine expression [130, 132-134]. In a mouse model of 
neuroinflammatory lupus, the choroid plexus becomes permeable via the transcellular route, as 
tight junctions remain intact. Immune cells can also cross the BCSFB in this mouse model, and 
later in disease, the choroid plexus may function as a tertiary lymphoid structure [135]. It is 
possible that B cells or antibodies cross this barrier more efficiently than the BBB and enter the 
CSF, but data from in vitro and animal models are lacking. 
   
1.2.5 Olfactory nerve projections into the brain as a route for immune cell entry  
 The proximity of the olfactory bulb to the nasal mucosa makes it both a vulnerable niche 
to insult and infection of the brain, and an attractive option for delivery of therapeutics that cannot 
otherwise traverse the BBB [136, 137]. Many viruses and bacteria co-opt the olfactory route for 
brain infection, and more than 40 substances have been shown to enter the brain in this manner 
(Figure 1.4b) [138, 139]. Viruses such as the Venezuelan equine encephalitis virus initially 
infiltrate the CNS via olfactory sensory neuron axons, where they induce BBB permeability, thus 
promoting a second wave of infection as virion particles enter the brain from the leaky vasculature 
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[140]. Herpes simplex virus-1 infection is very prevalent, and can asymptomatically infect the 
brain via the olfactory or hematogenous route, with olfactory transmission more common in 
younger patients [37]. A subset of patients develops acute encephalitis, which can be treated with 
antivirals, but leaves the brain vulnerable to secondary sequelae [37, 141]. In children, Herpes 
simplex encephalitis is more commonly a result of primary infection, but in adults, maintenance 
and reactivation of viral reservoirs in neurons is hypothesized to be the driving cause of 
encephalitis [37]. Recent linkage of HSE with later development of NMDARE provides an 
intriguing link between infectious trigger and encephalopathies. The neurotrophic Nipah virus also 
infects hamster olfactory sensory neurons, then travels from the OB along olfactory circuitry 
before spreading throughout the brain [142]. Finally, after an initial injury to nasal mucosa, 
Staphylococcus aureus infects olfactory sensory neurons and spreads to the OB within 6 hours 
[143].  
In addition to pathogen infection, the intranasal route has been successfully used to deliver 
drugs, large proteins, and stem cells into the brain [136], largely due to rapid diffusion via 
perivascular spaces [144]. The intranasal route is particularly suited to access the brain for several 
reasons: diffusion along heavily vascularized nasal mucosa that also contains lymphatic vessels; 
direct transport along olfactory sensory axons; and direct transport via the trigeminal nerve into 
the brainstem. Although the nasal mucosa is heavily vascularized, the mean capillary density and 
relative permeability to hydrophilic tracers is significantly greater in the respiratory epithelium of 
the nose than the olfactory sensory regions; sensory regions of the OE thus provide easier access 
to the brain due to slower clearance rates into the blood stream [145]. Interestingly, the olfactory 
route is also used by immune cells to exit the CNS through the OB in a CCL19- and CCL21-
dependent manner and drain to deep cervical lymph nodes in order to dampen CNS-specific 
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immune responses in the periphery [146-148]. There are no data, however, on whether antibodies 
are transported via the olfactory route to gain access to the CNS from sites of infection in the 
olfactory mucosa.  
 
1.3 Immune system activation in autoimmune encephalitis 
 Aberrant immune responses underlie AE pathogenesis, and multiple facets of the immune 
system may play a role in disease initiation and progression. Two main branches of the immune 
system function in tandem to clear infections. First, the innate immune system is ontologically 
older and functions much the same way each time it encounters a pathogen. Macrophages and NK 
cells are the main cellular components of the innate immune system, and macrophages are the 
main phagocytes recruited to infection. Common protein motifs on the surfaces of pathogens bind 
complement proteins, which are constantly circulating in the bloodstream [149]. Complement 
signaling quickly amplifies after binding invading pathogen, which recruits other immune cells to 
the site of infection. Complement deposition on invading pathogens marks them for destruction 
and facilitates antigen presentation to the adaptive immune system.  
 Second, the adaptive immune system, comprised of cellular (dendritic cells, T cells) and 
humoral (B cells and antibodies) arms, is capable of “remembering” previous pathogens and 
mounting an expedited immune response when re-exposed to the same challenge. Dendritic cells 
(DCs) of the cellular adaptive immune system continuously patrol the body, phagocytose debris, 
and return with processed antigen to lymph nodes to activate a cellular response to an invading 
pathogen. In the lymph nodes, DCs form an immunological synapse with immature T cells, which 
prompts T cells to terminally differentiate, leave the lymph node, and navigate to the site of 
infection. Once there, T cells encounter their cognate antigen and secrete inflammatory molecules 
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(cytokines) directing other immune cells to neutralize the pathogen and clean up cellular debris. 
DCs also activate B cells to express antigen-selective receptors, and once they encounter their 
cognate antigen, B cells secrete pathogen-specific antibodies [149, 150]. antibodies bound to 
pathogen facilitate clearance by other phagocytic cells. B cells can then differentiate into plasma 
cells, which secrete large quantities of antibody and then usually die within a few days [151]. 
However, a subset of both T and B cell populations recruited to an infection will persist and can 
be rapidly recruited to fight the same pathogen at a later time. Thus, the immune system adapts to 
more efficiently neutralize pathogens it has encountered before. Aberrant responses by the 
adaptive immune system seem to underlie the major causes of AE; reviewed here are major cellular 
components of the immune system (B cells, T cells, microglia/macrophages, and dendritic cells) 
and their links to AE, as well as molecular signaling pathways thought to be implicated in immune 
cell trafficking in AE. 
 
1.3.1 Aberrant antibody production and B cells 
B cell homing in antibody-driven neuroinflammatory diseases has been a topic of 
significant interest, given that B cells and plasma cells secrete antibodies. B cells are implicated in 
the pathogenesis of several CNS autoimmune disorders by the persistent presence of oligoclonal 
immunoglobulin G (IgG) in cerebrospinal fluid (CSF). Approximately 95% of MS patients have 
oligoclonal IgG bands, and the presence of IgM bands (approximately 40% of MS patients) is 
predictive of poor clinical outcomes. B cell targeted therapy like Rituximab is currently the most 
effective MS treatment, indicating a role for B cells in pathogenesis of the human condition [152]. 
B cells are efficient antigen presenting cells (APCs), and evidence suggests that MS patient-
derived B cells present self-antigen more competently than healthy B cells, indicating that B cells 
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also contribute to pathogenesis in an antigen-dependent manner. Finally, B cells from MS patients 
secrete inflammatory cytokines (TNFα, IFNγ, IL-12, and IL-6) that direct T cell differentiation, 
thus influencing the T cell population in the CNS [152]. Therapies that target B cells but not plasma 
cells are effective in improving clinical outcomes, indicating that antibody-independent B cell 
activities play a role in disease progression. Some mouse models of MS, including EAE, are T cell 
driven diseases, which limits translation of mouse data on the role of B cells in EAE disease course 
to humans [153].  
 In AE syndromes, the question of B cell infiltration in the CNS is less clear than it is in 
MS/EAE literature. Oligoclonal bands are present in CSF samples from neuropsychiatric systemic 
lupus erythematosus (NPSLE) [133], NMDARE [154, 155], and Sydenham’s chorea [156], 
implying the presence of intrathecal antibody synthesis. NMDARE postmortem or biopsy brain 
samples have also showed CD138+ infiltrates near choroid plexus, around blood vessels and in the 
brain parenchyma [157], with a very small fraction of monoclonal antibodies derived from 
NMDARE patient CSF B cells (9/170, 5.3%) specific for NR1 [158]. However, seroprevalence of 
NMDAR antibodies in healthy patient populations (5-15%, increasing with age) complicates study 
of these autoantibodies [159]. One study of immune cells in tonsils removed from PANDAS 
patients showed elevated expression of TNFα and eotaxin-3, and decreased expression of IP-10, 
IL-8, IL-17A, IFNγ, and IL-12 compared to non-autoimmune GAS pharyngitis patient tonsils 
[160]. There was no difference in CD19, BAFF, or BAFFR expression (B cell and B cell subset 
markers) in PANDAS tonsils [161], and no studies to date have examined immune cell populations 
in PANDAS CNS. Efficacy of steroid and plasma exchange therapies in PANDAS patients suggest 
that if B cells or plasma cells are involved, they are probably producing autoantibodies 
peripherally, and the antibodies themselves infiltrate the BBB, and that B cells remain excluded 
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from the parenchyma [162]. In animal models of PANDAS, B cell chemokine CCL19 mRNA is 
upregulated 3.6-fold in olfactory bulb, and CCL21 is upregulated 16-fold compared to healthy 
controls, but no B cells were detected in CNS tissues by immunohistochemistry (Maryann Platt, 
see Chapter 4). The extent to which B cells or plasma cells drive PANDAS pathogenesis remains 
unclear, and if they act systemically or within the CNS parenchyma to either produce antibodies 
or present antigen. 
   
1.3.2 T cell-driven brain autoimmunity 
 T cells differentiate into one of several terminal subsets from naïve precursors in response 
to antigen presentation by dendritic cells. Each T cell subset is induced by different cytokines in 
conjunction with unique transcription factors (Figure 1.5). Evidence from human and rodent 
models of MS and AE strongly implicate CD4+ and CD8+ T cells in various steps in pathogenesis. 
EAE, driven by CD4+ T cells, provides robust evidence that different populations of T cell infiltrate 
in the CNS are capable of initiating and propagating disease [92, 100, 106, 163-165]. Recent data 
also demonstrate that different populations of T cells preferentially traffic through TJs or Cav1+ 
vesicle transport, suggestive of different adhesion molecule profiles [92, 106]. T cell subtypes 
express unique panels of chemokine receptors and different inflammatory cytokines, so 
recruitment of mixed T cell populations results in heterogenous inflammatory cytokine pools local 
to inflammation. GAS infections in mice trigger robust Th1 and Th17, but minimal Treg and Th2 
populations in the nose [166]. Strains of mice with knockout of either T cell subpopulations or 
cytokine genes have delineated specific roles for T cell subtypes (Th1, Th17, Tregs) and 
inflammatory cytokines (IL-17 family, IL-1b, IFNg, GM-CSF) [97, 164, 165, 167-172]. 
Specifically, it has been shown that IL-17A (or the Th17 cells that secrete this cytokine) are  
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Figure 1.5 Differentiation and effector cytokine production of T cell populations. T cell subtypes are induced to 
differentiate by unique combinations of transcription factors, resulting in cytokine secretion. 
 
important but not essential for EAE disease initiation and progression; expanded pools of IFNg-
producing cells can inefficiently induce disease [165, 169, 173] . Therefore, Th17 cells play a 
pivotal role in promoting severe CNS autoimmunity. Th2 cells, characterized by IL-4 production, 
are anti-inflammatory and have a protective effect on overall disease course, similar to Tregs, 
which limit activation and proliferation of other T cell subtypes in the inflammatory 
microenvironment [165]. Indeed, depletion of either of these T cell subtypes increases 
susceptibility to EAE [167, 174].  
 In other AE syndromes, Th17 have been shown to play a similar role in exacerbating 
immune responses. T cells (of unknown subset) can be found in the parenchyma of treatment-
refractory NMDARE patient brain samples, and IL-17A levels in CSF correlate with poor disease 
prognosis and relapse [175, 176]. Mouse models of neuromyelitis optica (NMO) show that primed 
   27 
Th17 cells are capable of efficiently initiating disease, while primed Th1 are less effective and 
yield less severe disease [177]. Sera and CSF from acute disseminated encephalomyelitis (ADEM) 
patients showed elevated levels of Th1- and Th17-associated cytokines, implying a role for 
autoimmune mechanisms [98]. Taken together, research on both human and mouse 
neuroinflammatory disorders demonstrates a link between Th17/IL-17 family cytokines and 
diseases severity. The extent to which Th17 cells are involved in AE pathogenesis remains unclear.  
 
Figure 1.6 Labeling or deletion of Th17 cells in the RORgt-GFP mouse line. Heterozygous mice develop normally, 
and differentiated Th17 cells are labeled with GFP. Homozygotes do not develop Peyer’s patches or lymph nodes, 
and Th17 cells cannot differentiate. Adapted from [178]. 
 
One useful genetic tool to provide insight into the role of Th17 cells in these diseases is the RORgt-
eGFP mouse line [179]. As depicted in Figure 1.6, the knockout-knockin mutation in this line has 
a dual effect: heterozygotes have one copy of RORgt replaced with GFP, which labels 
differentiated Th17 cells with GFP; in homozygous mutant mice, Th17 cells cannot differentiate. 
This genetic tool allows for assessment of Th17 populations during disease course, and for 
assessing contribution of Th17 populations to disease pathogenesis. 
   
1.3.3 Microglia and macrophages in neuroinflammatory autoimmune diseases 
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Microglia are the resident immune cell population of the brain, and can both phagocytose 
like peripheral macrophages and present antigen like dendritic cells. Microglia express high levels 
of CX3CR1 (fractalkine receptor), and are capable antigen presenting cells in their own right. They 
use innate adaptive signaling (e.g., complement) for both homeostatic purposes (e.g., synaptic 
sculpting) and in pathogen response [180]. Microglia, like macrophages, also pump out 
chemokines to activate adaptive immune responses when they sense infection. Throughout 
development and in adulthood, microglia are highly dynamic, and even at rest continuously sample 
their extracellular environment to clean up debris and search for inflammatory signals [181].  
The role of microglia in the pathogenesis of AE syndromes is unclear. The main roles of 
microglia seem to be twofold: first, potentiating inflammatory responses from infiltrating immune 
cells; second, aberrant engulfment of synapses through faulty complement deposition during 
neuroinflammation. Microglia proliferate in response to systemic inflammation induced by LPS, 
which may be translatable to inflammation induced by infection [182]. Upon BBB disruption or 
local inflammation, highly ramified resting microglia round up and shorten their processes to take 
on a reactive shape [183]. Microglia express chemokine receptors CX3CR1, CXCR3, and CCR2, 
and receive the strongest signals from neurons expressing ligands CX3CL1, CCL21, and CCL2, 
respectively [184, 185]. Upon activation by inflammatory signals (e.g., fibrinogen from plasma, 
matrix metalloprotease-9, CCL2, CCL21), activated microglia act as potent phagocytes, and 
secrete inflammatory factors (IL-1b, TNFa, NOS, and ROS, in classically inflammatory 
microglia, and VEGF, TGFb and IL-10 in a more anti-inflammatory context) [183]. These 
cytokines recruit macrophages, leukocytes, and other microglia to the site of inflammation, 
potentiating the response. In a mouse model of NPSLE, microglia were shown to mediate aberrant 
neuronal signaling by release of TNFa in a coculture system [186].  
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The role of microglia in synapse degradation for AE is unclear. In NPSLE, indirect 
evidence of interferon-dependent microglial synapse degradation in hippocampi (not due to 
peripheral immune infiltration) provides one such link [187]. The IFNa/b receptor IFNAR is 
known to regulate microglial activation state, and inflamed NPSLE brains show increased 
phagocytosis of tagged tau debris in this model [187]. Close proximity of activated microglia to 
stripped synapses in a mouse model of post-infectious BGE also supports a role for microglia in 
aberrant synaptic pruning in disease [93]. More work on the potential roles of microglia in AE 
diseases is needed. 
Perivascular macrophages express similar chemokine receptors as peripheral macrophages, 
which allows them to present antigen and reactivate lymphocytes in inflammation. Chemokine 
signaling is probably involved in localization of perivascular macrophages and microglia to their 
compartments, but the precise mechanisms remain poorly understood [188]. Peripheral 
macrophages and monocytes are key players in neuroinflammation in EAE models of MS. Their 
infiltration after BBB breach is well-documented, and they secrete cytokines and chemokines 
exacerbating damage to the CNS. Assessing the distinct contributions of microglia vs parenchymal 
macrophages in homeostasis and during neuroinflammatory diseases is a subject of ongoing 
research, as these two cell types are almost indistinguishable based on morphology and surface 
marker expression. To date, the only reliable differentiator is TMEM119, which is expressed on 
mouse and human microglia and absent from infiltrating macrophages [189, 190]. 
 
1.3.4 Dendritic cells in neuroinflammatory diseases 
Recent work has defined a dendritic cell (DC) niche in CNS inflammation. Many of these 
results include extensive characterization of infiltrating DCs as separate from CNS-resident 
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microglia, as activated microglia are capable of presenting antigen and secrete many of the same 
inflammatory cytokines as DCs. DCs are required for antigen presentation to infiltrating T cells, 
and can reactivate MOG-directed T cells even in the absence of additional antigen, as shown by 
elegant selective ablation experiments in putative CNS APC populations [191]. Persistent DC 
presence in the CNS leads to more severe clinical pathology, indicating that CCR7-mediated 
signaling is critical to control disease pathogenesis [146]. Vascular endothelial growth factor 
(VEGF)-mediated lymphangiogenesis in the cribriform plate facilitates chemokine-mediated 
clearance of DCs that accumulate in the anterior portion of the brain [192]. It is unclear how DCs 
transmigrate across the BBB, but in EAE many immune cells cross the barrier following its breach 
by Th17 lymphocytes. 
 
1.3.5 The role of chemokine signaling in immune cell trafficking to the CNS in neuroinflammation  
Chemokines are small (8-14 kDa) secreted signaling molecules that bind to GPCR 
receptors expressed on the surface of immune cells. There are over 50 chemokine ligands and 19 
receptors described to date. Chemokine receptors can be promiscuous or exclusive, depending on 
the receptor and, in some cases, on cell type [193]. Chemokines are classified as CC, CXC, CX3C, 
and XC according to sequences of cysteines and intervening amino acids (X) in a conserved region. 
Some chemokine receptors are constitutively expressed on immune cell populations, while some 
receptors are upregulated only in inflammatory conditions [193]. Various immune cell populations 
may constitutively express a receptor that can be transiently induced in other populations, and 
there is much redundancy and cross-talk built into the signaling system, as demonstrated by Figure 
1.7. Chemokine signaling connects lymphatic and blood endothelium with the CNS milieu and 
infiltrating immune cells [12, 194]. Reciprocal signaling is indispensable for initiating 
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neuroinflammation and dampening the 
immune response to control symptoms. 
Because redundancy is high in chemokine 
networks, examination of the contribution 
of individual chemokine/receptor 
signaling pairs can be a challenge. Once 
bacterial infection occurs, the adaptive 
immune system begins to mount a 
response to destroy the pathogen. Once 
directed by DCs, T cells migrate from 
lymph nodes to the site of infection, 
guided by chemokine cues. Chemokine 
gradients are maintained by tethering 
chemokine ligands to the endothelial 
extracellular matrix or to 
glycosaminoglycans [188]. Chemokine signaling is essential to pathogenesis of many diseases, 
including MS, nephritis, atherosclerosis, asthma, and cancer. 
 Research on T cell trafficking in EAE has clarified the role of chemokines in disease 
progression, and  has been instructive for potential chemokine cues in AE. CCL20/CCR6 signaling 
is important for EAE initiation and neo-lymphogenesis, and is required for initial entry of Th17 
through the choroid plexus during the first wave of T cell entry into the CNS [129]. The second 
wave of Th1 infiltration is mostly governed by increased CCL2 expression. Over the course of 
EAE, the inflammatory chemokines CCL2 and CCL5 are upregulated, and constitutive cytokines 
Figure 1.7 Schematic representation of chemokine 
ligand-receptor binding pairs Chemokines and their 
receptors can be promiscuous or exclusive. Reprinted 
from [193]. 
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CXCL10, CXCL12, CCL19, CCL20 and CCL21 are expressed at higher levels on ECs [188, 195]. 
Some of these chemokines are also expressed on other cell types during EAE, with CCL2, 
CXCL12, CXCL19 upregulated in astrocytes, and CXCL19 expressed on microglia [195]. Treg 
cells harvested from mice with EAE can self-potentiate in areas of active inflammation by 
secreting both CCL1 and expressing its receptor, CCR8; this effectively dampens local 
inflammation and suppresses lesion formation [174]. Indirect evidence for antigen-specific T cell 
recruitment to the CNS in AE was demonstrated using CSF samples from AE patients. Patient 
CSF was enriched for CCL2 and CXCL10, as well as for white blood cells expressing CXCR3, 
the cognate receptor for CXCL10 [196]. Taken together, these data detail mechanistic links that 
tie neuroinflammation seen in AE to generally accepted mechanisms of neuroinflammation and 
CNS T cell infiltration.  
 Like T cells, B cells respond to chemokine cues through CCR7 signaling. CCL19 and 
CCL21 guide B cells to and from draining lymph nodes as needed [193]. Upregulation of CXCL13 
near MS lesions [153], and of CCR6 on activated B cells [197] identifies chemokine axes that may 
be instrumental in B cell recruitment or localization to the brain. Monocytes constitutively express 
CCR2, and respond to CCL2 secreted by astrocytes to home to inflammatory lesions in MS and 
EAE [198-200]. Monocyte infiltration is a critical step in EAE pathogenesis, and interrupted 
CCL2/CCR2 signaling in CCR2-/- mice blunts disease progression. CCL2 is constitutively 
expressed by neurons at low levels basally. Under hypoxic conditions, neurons will upregulate 
CCL2 signaling to surrounding microglia, but without increased macrophage populations in the 
CNS, implying that there may be a threshold of CCL2 required for macrophages to cross the BBB 
into the brain [184, 188]. In EAE, DCs are recruited to the spinal cord, cerebellum, cortex, and 
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olfactory bulb in EAE by CCL2/CCR2 interactions [201, 202], and use CCR7/CCL21 and CCL19 
signaling to exit the CNS and drain to peripheral lymph nodes [146]. 
 CXCR4 expression is upregulated on CD19+ NPSLE B cells compared to controls, and 
symptom severity correlated with higher CXCR4 expression and with CNS involvement. Elevated 
expression of its ligand CXCL12 in kidney glomeruli was highly correlated with lupus nephritis 
disease severity [203, 204]. However, clinical studies of B cell treatment in NPSLE patient 
populations are inconclusive in their efficacy, or have low sample sizes.   
 
1.4 Lessons from animal models of autoimmune encephalitis 
 Numerous rodent studies have expanded our understanding of the molecular events 
involved in antibody generation and pathogenicity. Rodent models for NMDARE, basal ganglia 
encephalitis (BGE), GAD65 encephalitis, LGI-1 and Caspr2 encephalitis, and Morvan syndrome 
vary widely in both their methods of antigen exposure and disease parameters recapitulated. 
Expansion of the EAE immunization model to expose mice to foreign (or self-) antigens greatly 
expanded understanding of disease processes [80, 205, 206]. Conversely, passive infusion and 
adoptive transfer models clarified how autoantibodies harvested from patients may interact with 
an intact CNS [19, 206-211]. Animal models for post-Streptococcal AE have been focused on 
demonstrating the ability of GAS to prime development of an autoimmune reaction by stimulating 
adaptive cellular and humoral immune responses. A summary of current literature on rodent AE 
models is summarized in Table 1.1, and reviewed here in more depth for several AE subtypes. 
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Table 1.1 (Previous page) Animal models of AE syndromes and associated immunological and neurological findings. 
Updated from [50].  
 
1.4.1 Mechanisms of NMDA receptor encephalitis 
NMDARE models almost exclusively utilize intracerebral infusion of serum antibodies 
harvested from acutely ill patients into rodents in an attempt to replicate behavioral symptoms. 
Infusion of autoantibodies from NMDARE patients into lateral ventricles of mice causes impaired 
recognition memory after 10 days of antibody infusion, which is reversible upon antibody washout 
[209]. IgG binding is strongest in the hippocampus, which has a very high density of NMDAR, 
supporting the hypothesis that NMDAR clustering and internalization may underlie memory 
deficits with minimal effects on aggression, locomotion, and anxiety-like behavior [209, 210, 212, 
213]. On the circuit level, mice infused with NMDARE sera were more susceptible to seizures 
than controls [210, 214], with similar delta-brush EEG patterns detectable in human NMDARE 
patients and sera-infused mice [18, 211]. NMDAR antibodies are only detectable in rodent brains 
after intravenous injection of patient antibodies with parallel LPS injection or in ApoE-/- mice with 
a defective BBB, illustrating the necessity of BBB breakdown for pathogenic binding [158, 207, 
212].  
Ex vivo and in vitro studies have proven invaluable for determining the mechanism of 
action of NMDAR Abs. NMDAR Ab binding interferes with EphrinB2-EPHB2R signaling that 
tethers NMDA receptors to their synaptic sites. Autoantibody binding thus releases NMDA 
receptors from the synapse, causing them to diffuse off synaptic boutons and become internalized. 
Accumulation of intracellular NMDAR and loss of surface NMDAR after treatment with patient 
antibodies is reversible with antibody washout. Treatment with EphrinB2 together with anti-
NMDAR antibodies also rescues loss of NMDA receptors in vitro and in vivo [213]. It appears 
that internalized NMDARs are not targeted for lysosomal degradation, due to lack of involvement 
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of Rab proteins (endolysosomal mediators) in NMDAR internalization [215]. In recordings from 
acute hippocampal slices, NMDAR antibodies decreased NMDAR-dependent hippocampal long-
term potentiation (LTP) in a manner similar to commercial blocking antibodies directed against 
extracellular domains of NR1 and NR2 subunits. Hippocampal CA1 neurons from mice infused 
intraventricularly with patient antibodies showed reduced excitability [214], and dentate gyrus 
granule cells showed smaller evoked activity, impaired LTP, and increases spike thresholds after 
NMDAR Ab exposure [19, 216]. Cultured neurons treated with patient antibodies showed both 
reduction in synaptic puncta and selective reduction in NMDA currents with no effect on AMPA, 
GABA, or kainate signaling [158, 212].  
Substantial evidence supports the hypothesis that NMDAR Ab binding leads to cross-
linking and internalization, but not necessarily destruction, of the receptor, causing deficits in 
synaptic and circuit function. Importantly, these models also bypass the BBB; NMDAR antibodies 
are efficiently excluded from the hippocampus if delivered intravenously [207]. ApoE-/- mice 
intravenously injected with NMDAR antibodies demonstrate Ab binding to CNS targets and 
decreased locomotion compared to either mice injected with control IgG, or WT mice injected 
with NMDAR antibodies [207]. Herpes simplex virus (HSV) infection is hypothesized to cause 
BBB permeability [39]; in an animal model of HSV encephalitis, a subset of mice developed anti-
NMDAR antibodies and reduced NR1 subunit density in hippocampus [38]. There is a clear need 
to develop more animal models for NMDARE that incorporate study of BBB breach to more 
closely mirror the human syndrome.  
 
1.4.2 Synaptic antigens linked to AE 
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Autoantibodies against proteins involved in g-amino butyric acid (GABA)-ergic 
transmission, including anti-glutamic acid decarboxylase (GAD) 65, anti-GAD67, GABAA 
receptor, GABAB receptor, and anti-amphiphysin, are the putative autoantibodies for cerebellar 
ataxia, stiff person syndrome, and Batten’s disease [1, 217]. GABAB receptor (GABABR) 
encephalitis is linked to small cell lung cancer, and patient CSF binds strongly to rodent tissue 
sections [26]. Slice recordings from neurons exposed to GABABR antibodies showed decreased 
firing reversible by washout [218].  GABAA receptor (GABAAR) encephalitis antibodies have 
been shown histologically both on tissue sections and cultured neurons to bind to neuropil and cell 
surface, confirming specificity to their target through agreement with commercial GABAA 
antibody staining patterns [219]. Intracerebral infusion experiments have been conducted using 
patient samples of autoantibodies for these targets, with conflicting results. Bath application of 
anti-GAD65 antibodies increased inhibitory post-synaptic potential (IPSP) frequencies in cultured 
neurons [220]. Cerebellar infusion of GAD65 antibodies in rodents interfered with GABA 
synthesis in cerebellar basket cell terminals, leading to Purkinje cell hyperactivity. however, 
hippocampal infusion of anti-GAD65 yields no changes in synaptic transmission in acute 
hippocampal slice preparations that demonstrated strong effects after anti-NMDAR Ab infusion 
[221]. It is possible that anti-GAD65 antibodies do not strongly target hippocampal cells, or that 
they cannot reach their intracellular target before they are degraded or removed from the interstitial 
space. Rats infused with autoantibodies against amphiphysin, rather than GAD65, have been 
shown to exhibit behavioral symptoms of stiff-person syndrome [222]. Anti-amphiphysin 
antibodies are more strongly associated with tumors elsewhere in the body compared to many 
other AEs [223]. Methodological differences between groups and debate about pathogenicity of 
GAD65 autoantibodies has complicated interpretation of results to date. This is because GAD65 
   38 
autoantibodies are prevalent, albeit at lower concentrations, in many type 1 diabetic patients with 
no neurological abnormalities. Careful screening is essential in determining a donor population for 
research samples in order to exclude likely non-pathogenic antibodies that present in diabetic 
patients. 
GQ1b autoantibodies have been implicated in Miller Fisher syndrome, but limited research 
on the central effects of these antibodies hinders the understanding of disease pathogenesis. GQ1b 
antibodies have been shown to induce complement deposition; the combination of complement 
with antibody deposition is necessary for neuromuscular junction dysfunction in vivo [224]. 
Binding of the antibody-complement complex induces local Ca2+ flux into neurons in vitro, which 
alters mitochondrial function and excites the neuron [224]. Mechanistically, this provides an 
interesting insight into the potential role of the innate vs the adaptive immune system in AE action.  
Antibodies targeting components of the voltage gated potassium channel (VGKC) complex 
have historically been lumped together as targeting the whole scaffolding complex, with little 
distinction given to individual proteins that comprise the VGKC, since the scaffold complex 
precipitated together with the channel in the original identification [20, 225, 226]. Recent work 
has defined individual targets that comprise or associate with the VGKC: Caspr2, LGI1, and 
Contactin2 [20]. Most investigation into the VGKC complex antibodies used rodent tissue or 
cultured cells to assess reactivity of patient sera or CSF. Sera from AE patients both react with rat 
[227] and mouse [21] hippocampal sections, as well as HeLa cells transfected with potassium 
channels Kv1.1 and Kv1.2, but not with Caspr2-/- mouse brain sections [21]. Adoptive transfer of 
patient sera or purified anti-Caspr2 IgG into mice showed that repeated immunizations with patient 
IgG increased quantal size and K+-dependent amplitude of excitatory post-synaptic potentials 
(EPSPs) in peripheral nerves, but did not alter behavior [228].  
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Comparatively more is known about the mechanisms of action of LGI1 antibodies in brain. 
Deletion of LGI1 in all neurons, as well as conditional deletion in forebrain glutamatergic neurons 
using an Emx-Cre driver, resulted in epilepsy and perinatal lethality (by P25 and P32, respectively) 
[229, 230]. Postnatal deletion of LGI1 using the CaMKIIa-Cre driver resulted in later-onset, 
slightly less severe epilepsy, with premature lethality around P150 [229]. Mechanistically, LGI1 
protein links presynaptic potassium channels and postsynaptic AMPAR scaffolding proteins; 
disruption in LGI1 structure or function selectively interferes with AMPAR-mediated signaling 
[230], illustrating its necessity for normal AMPAR-mediated brain function [229, 230]. 
Intraventricular infusion of purified patient LGI1 IgG caused hyperexcitability of hippocampal 
dentate gyrus granule cells and CA1 neurons, as well as memory deficits [231]. While there has 
been some progress in identifying potential mechanisms of action for these antibodies, initial 
confusion about target proteins hampered progress and left many questions unanswered. 
 
1.4.3 Animal models of GAS-induced AE 
 The first group of rodent models of GAS-induced AE mirrors the EAE immunization 
model with an antigenic target (bacterial homogenate) in conjunction with complete Freund’s 
adjuvant to activate the immune system and B. pertussis toxin to transiently permeabilize the BBB 
(Figure 1.8, left). In this model, mice and rats develop a strong humoral response against GAS 
and show behavioral abnormalities by motor and psychiatric metrics. GAS-immunized mice 
display increased rearing and decreased locomotion, as well as increased repetitive and 
perseverative behaviors, impaired pre-pulse inhibition and reduced serum serotonin concentrations 
in the prefrontal cortex, compared to controls [80, 205, 206, 232]. Histological examination of 
brain tissue in various studies has revealed IgG deposition in the deep cerebellar nuclei and  
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Figure 1.8 Comparison of two routes of GAS exposure to induce autoantibodies in rodent models. Left, repeated 
subcutaneous immunization with GAS-Complete Freund’s adjuvant (blue and red arrows every 14 days) in 
combination with intravenous pertussis toxin (blue arrow on day 0 only) induces mild immunological abnormalities 
but replicated behavioral findings. Right, recurrent weekly intranasal inoculation with live GAS induces strong 
immune phenotypes. Behavioral findings are, to this point, unknown. Below, table comparing various outcome 
measures between the two models. Updated from [50]. 
 
hippocampus in mice, and the striatum, cortex, and thalamus in rats [80, 205, 206]. Serum isolated 
from immunized rodents bound to both cerebellar targets and human dopamine D1/D2 receptors 
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by either Western blot or ELISA [80, 206]. Motor and anxiety-like phenotypes are dominant 
outcomes in this model, with peripheral immune responses playing a minimal role. Comparison of 
findings from GAS-primed models reviewed here to Poly I:C or LPS injections show some 
overlap, indicating that systemic inflammation may be driving some of the psychiatric findings 
(reviewed in [233]). 
 A second mouse model that directly produces anti-GAS antibodies utilizes intranasal 
inoculations with live GAS bacteria (Figure 1.8, right). In the mouse, intranasal (i.n.) infections 
with live GAS bacteria polarize T cells in the nasal associated lymphoid tissue (NALT) toward a 
Th17 phenotype. This T cell subtype is both essential for mucosal immune protection against 
bacteria, and strongly implicated in many autoimmune diseases. Multiple GAS infections  
strengthen this Th17 immune response due to induction of IL-6 and TGF-b, two proinflammatory 
cytokines that drive Th17 differentiation [50, 93, 234]. IL-6 is essential for clearance of bacteria 
after i.n. infection; IL-6-/- mice are capable of mounting a Th1 immune response to i.n. bacterial 
challenge but cannot control the infection [235]. This model has been used to demonstrate that 
repeated i.n. GAS infections induce migration of GAS-specific Th17 cells and other T cell 
subtypes from the olfactory epithelium (OE) into the olfactory bulb (OB) [93]. Presence of T cells 
in the CNS after recurrent GAS infections also permeabilizes capillaries in several CNS regions, 
including the OB, amygdala, and hypothalamus, permitting deposition of serum IgG. BBB 
permeability in this case is largely a result of disorganization of tight junction proteins [93]. This 
intranasal model produces profound changes in olfactory circuitry by reducing vGluT2 expression 
(and, thus, excitatory input) at the presynaptic terminals of olfactory sensory axons [93]. This 
initiates a cascade of signaling abnormalities at the initial terminus of olfactory sensory axons. 
This model of GAS-induced autoimmunity demonstrates a central role for the adaptive cellular 
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immune response (e.g., GAS-specific Th17 cells in the CNS) in disrupting BBB function, thus 
promoting entry of antibodies into the CNS to allow for changes in synaptic signaling. Although 
a cellular adaptive immune response has not, to date, been identified in SC or PANDAS patients, 
GAS-specific Th17 cells can be found in the tonsils of human patients [93], making Th17 cells a 
potential causative agent in either initiation or persistence of AE pathogenesis.  
Finally, direct injection of sera from PANDAS or SC patients allows for investigation of 
what cell populations are targeted by human autoantibodies. Systemic subcutaneous injection of 
monoclonal anti-GAS IgM, but not IgG, antibodies resulted in antibody deposition in striatum and 
cortex that colocalized with Fcaµ receptors. Behavioral changes and alterations in neuronal 
activity induced by IgM were rescued by IVIg treatment [236]. Intrastriatal infusion of serum IgG 
from Tourette’s patients resulted in behavioral and motor stereotypy [236], while PANDAS sera 
infusion resulted in IgG deposition on cholinergic (ChAT+), but not parvalbumin+ or nNOS+ 
striatal neurons [82]. The literature is conflicting on motor and histological findings after 
intrastriatal infusion of SC sera [237, 238]. Taken together, adoptive transfer of serum IgG from 
GAS-immunized mice into naïve recipients, or direct intracerebral infusion of human sera into 
rats, recapitulates some of the behavioral deficits in recipients. No effects were observed in rodents 
infused with IgG-depleted sera [81, 206]. There has been some investigation of what targets are 
recognized by infused PANDAS and SC antibodies, but more work is needed to resolve debate in 
this area [80, 81, 237-239]. These studies open up an avenue for further exploration of striatal 
involvement in these diseases.  
Differences between mouse and rat GAS-induced AE models may reflect key genetic 
differences between the species, especially those related to the MHC locus and T cell function. All 
studies used inbred animals (Lewis rats, SJL or C57Bl/6 mice), so congenicity is very high in these 
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variable regions, but differences between strain and species may be magnified. It is also possible 
that different findings in mouse and rat studies could be due to variability in the humoral immune 
response to GAS between species or slight differences in the respective immunization protocols. 
Additionally, infectious load in animal colonies influences the immune response to immune 
challenge, requiring titration of adjuvants or infectious load [167]. Taken together, subcutaneous 
GAS immunization models have provided useful information regarding humoral immune response 
after bacterial infection, and demonstrate a link between GAS exposure and behavioral 
abnormalities. However, these are somewhat artificial models for immune system activation, as 
human GAS pharyngitis occurs primarily by the i.n. route. Moreover, these barrier-compromised 
AE models cannot address the question of how circulating antibodies might gain access to their 
CNS targets [6].  
 
1.5 Concluding remarks 
 Both human studies and rodent models of AE strongly implicate the immune system in 
pathogenesis. While rodents provide a useful model system to study immune response to both an 
inciting infectious agent as well as autoimmune complications at later timepoints, mice are 
inherently poor models of the complex psychiatric symptoms characteristic of the AE patient 
population. Work that has been done thus far in rodent models has relied heavily on direction from 
EAE, and while it has yielded valuable insights, the role of the BBB remains underappreciated in 
these models. There are several different pathways for blood-borne solutes (antibodies, 
inflammatory cytokines, and immune cells) to enter the brain, and how antibodies may be 
permitted to enter the CNS is still unclear. Once in the brain, antibodies have been shown to induce 
defective neuronal signaling either through direct binding to their target, or indirectly by causing 
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destabilization or internalization of neurotransmitter receptors. Neuroinflammation is also central 
to AE pathogenesis. The humoral and cellular immune systems must coordinate to breach the 
BBB, promote inflammatory infiltrate in the CNS, and generate brain-targeting antibodies. 
Systematic examination of each of these different routes of barrier breach will clarify both 
mechanisms of disease and new therapeutic targets. Still, work using tissues or intact animals 
exposed to pathogenic autoantibodies has pushed the field toward understanding the basic cell 
biological processes underlying disease.  
 The importance of learning from human studies in these rare diseases is crucial, and 
reducing phenomena to mouse models as true to type as possible will continue to provide 
translatable data. Maintaining a link between the bench and the bedside remains a critical point of 
reference in this field, and verification of findings at multiple levels (cellular, molecular, 
behavioral) will lend weight to data in a relatively niche field.  
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Chapter 2: Materials and Methods 
2.1. Experimental procedures, protocols, and reagents 
All experiments were approved by the Institutional Animal Care and Use Committees at Columbia 
University (AAAX3452) and Duke University (#A220-15-08). Animals used for breeding and 
subcutaneous GAS immunization experiments were housed in the William Black building 
vivarium. Mice used for intranasal inoculation experiments were transferred to a BSL2+ vivarium 
facility in the Irving Cancer Research Center. Mice used for electrophysiological recording 
experiments were housed at Duke University in the Sands Research Building vivarium; recording 
experiments were conducted in the Bryan Research Building in the Franks lab. 
 
2.1.1 Mice 
Experimental mice were maintained on a 12-hour light/dark cycle with lights on from 6am to 6pm. 




Female P25 SJL/J (Strain 000686) mice were obtained for subcutaneous immunization 
experiments from Jackson Labs (Bar Harbor, ME). This strain is predisposed to autoimmunity and 
is frequently used for EAE. SJL/J mice frequently develop reticulum small-cell carcinomas with 
Hodgkin’s disease-like phenotypes by one year of age. Mice were housed in groups of four or five 
in the William Black building vivarium.  
 
RORgtGFP/GFP 
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Male and female RORgteGFP/+ [179] (B6.129P2(Cg)-Rorctm2Litt/J, Strain 007572) were obtained 
from Jackson Labs. In this strain, the coding region for RORcgt, a transcription factor necessary 
for Th17 differentiation, is replaced with eGFP. RORgteGFP/+ mice have fluorescently labeled Th17 
cells (referred to as RORgt+/-). RORgteGFP/eGFP mice are unable to differentiate Th17, and have 
limited induction of peripheral lymph nodes and Peyer’s patches (referred to as RORgt-/-). RORgt+/- 
mice were interbred to obtain WT, RORgt+/-, and RORgt-/-progeny. Future mating pairs consisted 
of RORgt+/- crossed to RORgt-/- to obtain equal ratios of RORgt+/- and RORgt-/- progeny to be used 
in experiments. 
 
CCR6 and CCR2 chemokine receptor knockouts 
CCR2-/- [240] (B6.129S4-Ccr2tm1lfc/J, Strain 004999) and CCR6-/- [241] (B6.129P2-Ccr6tm1Dgen/J, 
Strain 005793) males were obtained from Jackson Labs and backcrossed to WT C57Bl6/J for five 
generations prior to use for experiments. Chemokine receptor homozygous mutant mice were 
interbred to obtain double mutants. CCR6-/- and RORgt-/- mice were interbred to obtain CCR6-/-on 
the RORgt+/- background to track Th17 populations in the absence of CCR6 signaling. These 




All mice were toe-clipped for identification and genotyping at P7-P9. Toe and/or tail samples were 
lysed overnight at 56°C with 400 µl lysis buffer (100 mM Tris HCl pH 8.0, 5 mM EDTA pH 8.0, 
0.2% SDS, and 200 mM NaCl with 100 µg/ml proteinase K). DNA was extracted by adding 400 
µl phenol/chloroform/isoamyl alcohol (25:24:1, v/v/v, Fisher) then vigorously mixed and 
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centrifuged at 13,200 rpm for 15 minutes at 25°C in an Eppendorf 5415D centrifuge.  DNA was 
precipitated from 350 µl of the aqueous phase in 1 ml 95% ethanol by inverting the tube. The DNA 
pellet was dissolved in 100 µl TE buffer (10 mM Tris HCl pH 7.4 and 1 mM EDTA pH 8.0) 
overnight at 56°C.  
 
PCR 
PCR reactions were run with known positive, negative, and no-DNA controls in all reactions. 
Reaction components, equipment, primer sequences, and PCR protocols varied by gene target and 
are listed in Table 2.1 below. PCR products were separated on a 1.5% agarose gel with 0.5% 
ethidium bromide at 80 V for 40 minutes.  
 
Table 2.1 PCR primer sequences, reaction conditions, and equipment used for genotyping. 
 
2.1.3 Group A Streptococcus intranasal inoculations 
Male and female littermates received a total of five weekly Group A Streptococcus infections 
prepared as described previously [93] beginning at age P21-28. Briefly, log-phase GAS cultures 
















Common%forward CCC%CCT%GCC%CAG%AAA%CAC%T 2x%DreamTaq%Master%Mix 12.5 94 3:00 1 WT 174
Wild%type%reverse GGA%TGC%CCC%CAT%TCA%CTT%ACT%TCT Common%forward%primer 0.5 94 :30 Mutant 241
Mutant%reverse CGG%ACA%CGC%TGA%ACT%TGT%GG Wild%type%reverse%primer 0.5 50 1:00
Mutant%reverse%primer 0.5 72 1:00
ddH2O 10 72 2:00 1
Genomic%DNA 1 4 Hold 1
Wild%type%forward CCA%CAG%AAT%CAA%AGG%AAA%TGG 10x%Taq%buffer 5 94 3:00 1 WT 424
Wild%type%reverse CCA%ATG%TGA%TAG%AGC%CCT%GTG 10mM%dNTPs 1 94 :30 Knockout 280
50mM%MgCl2 1 65 :30
Knockout%forward CTT%GGG%TGG%AGA%GGC%TAT%TC 125nM%Forward%primer 0.5 72 :30
Knockout%reverse AGG%TGA%GAT%GAC%AGG%AGA%TC 125nM%Reverse%primer 0.5 72 5:00 1
Taq%enzyme 0.25 4 Hold 1
ddH2O 39.5
Genomic%DNA 2
Wild%type%forward CCC%TAG%AAG%AGG%TCA%GAA%ACT%TCA%C 2x%DreamTaq%Master%Mix 12.5 94 3:00 1 WT 228
Knockout%forward GGG%TGG%GAT%TAG%ATA%AAT%GCC%TGC%TCT Common%forward%primer 0.5 94 :30 Knockout 442
Common%reverse AAA%ACC%CAA%GTG%TTG%GTG%GCA%TGA%G Wild%type%reverse%primer 0.5 57 1:00
Mutant%reverse%primer 0.5 72 1:00
ddH2O 10 72 8:00 1
Genomic%DNA 1 4 Hold 1
Transgene%forward TGC%TGG%TTG%TTG%TGC%TGT%CTC%ATC 2x%DreamTaq%Master%Mix 12.5 94 3:00 1 Transgene 550
Transgene%reverse GGG%GGT%GTT%CTG%CTG%GTA%GTG%GTC Common%forward%primer 0.5 94 :30
Wild%type%reverse%primer 0.5 65 :30
Mutant%reverse%primer 0.5 72 :30
ddH2O 10 72 2:00 1
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(2x108 CFU) were harvested, washed once in sterile PBS, then resuspended in 110 µl PBS without 
Ca2+ and Mg2+. Heat-killed (HK-) GAS was used for some inoculations as described below. For 
these inoculations, GAS cultures were grown and harvested as described, then heat-killed for at 
least 30 minutes in an 85°C water bath. HK-GAS samples were streaked on blood agar plates to 
confirm absence of live bacteria, in parallel with a positive control from prior to heat treatment. 
 For inoculations, mice were lightly anesthetized with isoflurane (2.5% for induction in 1.5-
2 L/min medical air), quickly removed from the induction chamber, and allowed to passively 
inhale the inoculum droplet dispensed from a pipet into one nostril. Mice are obligate nose-
breathers, so once mice recovered from the anesthesia, the process was repeated to inoculate the 
other nostril. A small aliquot of the same PBS was used for vehicle inoculations. Mice were 
weighed at each inoculation. GAS dose is titrated up over the first two infections, so mice received 
inoculations of 4 µl per nostril on the first week, 6 µl per nostril on the second week, then 7.5 µl 
per nostril for all subsequent inoculations. This schedule minimizes death from sepsis and reduces 
the chance of bacterial aspiration into the lungs during inoculation.  
 
2.1.4 Group A Streptococcus subcutaneous immunizations 
Female P28 SJL/J mice received three total subcutaneous immunizations in the chest (near axial 
lymph nodes) as described in [80, 81, 205]. Briefly, 110 µl of 2x108 CFU heat-killed GAS was 
homogenized with a mortar and pestle, then diluted into 5 ml PBS. This was mixed in Hopper 
glass syringes with an equal volume of Complete Freund’s adjuvant containing 200 µg 
Mycobacterium tuberculosis H37Ra (DIFCO laboratories). Mice received 100 µl emulsion on 
experimental day 0, day 14, and day 28, in conjunction with 400 ng Bordetella pertussis toxin (List 
biological laboratories, Campbell, CA) intravenously on day 0. Vehicle control mice received 
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PBS/CFA emulsion and B. pertussis injections, and healthy control mice remained untreated. None 
of the control mice exhibited gross behavioral abnormalities or signs of illness. 
 
2.1.5 Flow cytometry 
Mice used for flow cytometry received an equal amount of heat-killed (HK) GAS for the last 
infection in lieu of live bacteria to protect the experimenter during tissue dissection. Mice were 
deeply anesthetized 24 h after the final infection with isoflurane and perfused briefly with ice-cold 
sterile PBS. Brain, spleen, NALT, and olfactory epithelia were dissected into DMEM on ice and 
homogenized through a 40 µm nylon mesh cell strainer with the back of a 10 ml syringe plunger. 
Lymphocytes from brain and NALT samples were collected from the interface of a 30%-70% 
Percoll gradient, then washed once in T cell media (RPMI with 10% fetal bovine serum, 1x 
penicillin/streptomycin, 1x glutamine, 1x non-essential amino acids, and 50 µM β-
mercaptoethanol), and transferred to a 24-well tissue culture plate for cytokine stimulation or 
transferred to FACS tubes for transcription factor staining. Spleens were homogenized through a 
40 µm nylon mesh cell strainer with a 1 ml syringe plunger, avoiding any areas of obvious necrosis. 
Splenocytes were collected in 5 ml DMEM and centrifuged to pellet the cells. Splenocytes were 
then treated with 2 ml red blood cell lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) 
for three minutes, and lysis was quenched with 8 ml DMEM. Splenocytes were washed once in 5 
ml T cell media, then plated in a 24-well tissue culture plate for cytokine stimulation or transferred 
to FACS tubes for transcription factor staining. 
 For cytokine staining, cells were stimulated in vitro with 500x Cell Stimulation Cocktail 
(eBiosciences 00-4975-03) diluted to 1x in T cell media for 4h at 37°C, then transferred to FACS 
tubes. One third of each NALT/OE lymphocyte sample were pooled for used as single-stain and 
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FMO controls where possible; splenocytes were always used as a second set of single stain 
controls. The remaining CNS and NALT lymphocytes were transferred to FACS tubes as 
experimental samples; ~107 splenocytes were transferred to FACS tubes as splenocyte 
experimental samples. All washes were performed at 4°C using an Eppendorf 5810R centrifuge. 
Cells were washed once in FACS buffer (1% bovine serum albumin in PBS), then blocked in 
CD16/CD32 Fc block (BD Biosciences, 553141) diluted 1:200 in FACS buffer. Cells were washed 
once, then stained using the following antibodies to surface antigens: rat anti-CD4 BV605 (BD 
Horizon 562891, 1:100), rat anti-CD45 BV421 (BD Horizon 563890, 1:100), and Fixable Viability 
Dye eFluor-780 (eBiosciences 65-0865-14, 1:4000). Cells were then fixed and permeabilized with 
BD Cytofix/Cytoperm (BD Biosciences, 554714) and left in 1x Perm/wash buffer overnight. The 
following day, intracellular cytokines were stained with rat anti-IL-17A PE (BD Pharmingen, 
559502), rat anti-IFNg APC (BD Pharmingen, 554413), and rat anti-IL-10 FITC (BD Pharmingen, 
554466) antibodies diluted 1:100. Cells were washed once with Perm/wash buffer, once with 
FACS buffer, then resuspended in 200 µl FACS buffer for analysis. 
 For Treg staining, cells were collected into FACS tubes without in vitro restimulation, 
blocked, and stained for the same surface antigens as above, then fixed and permeabilized using 
the Transcription Factor Fixation/Permeabilization kit (eBiosciences, 512343 and 522356). 
Following fixation, cells were washed then stained with rat anti-FoxP3 PerCP-Cy5.5 
(eBiosciences, 45-5773-80, 1:100). Cells were then washed once with wash buffer, once with 
FACS buffer, resuspended in 200 µl FACS buffer, and analyzed. All samples were analyzed on a 
BD FACSCelesta (Columbia Stem Cell Initiative Flow Cytometry Core). Gates for surface stains 
were set with single-stain and no-stain controls; cytokine stain gates were set using fluorescence-
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minus-one controls on tissue-matched lymphocytes. Compensation and analysis were performed 
using FlowJo software.  
 
2.1.6 Immunohistochemistry 
Mice used for immunohistochemical staining were anesthetized with isoflurane and perfused 
thoroughly with PBS followed by 4% PFA. Brains and livers were extracted and post-fixed for 6 
h, washed three times in PBS for 30 minutes, then cryoprotected in 30% sucrose overnight and 
embedded in Tissue Plus O.C.T. Compound (Fisher Health Care 4585). Olfactory epithelia in the 
nose were decalcified with three 24 h washes in 0.5 M EDTA pH 8.0, then cryoprotected overnight 
in 30% sucrose and embedded in OCT. Brain and OE blocks were stored at -80°C until use. Tissues 
were then sectioned at 12 µm on a Leica cryostat and stored at -80°C until use. For staining, slides 
were air-dried for 20 minutes then placed horizontally in a humidified chamber. Slides were 
washed once in PBS for 10 minutes to remove excess OCT, then blocked for 1 hour in blocking 
buffer (10% BSA, 0.1% Triton-X-100 in 1x PBS). Primary antibodies listed in Table 2.2 were 
diluted in 0.1% Triton-X-100 in PBS with 1% BSA. Primary antibody solutions were incubated 
overnight at 4°C. Slides were washed three times for ten minutes with PBST (0.1% Triton-X-100 
in PBS), then primary antibodies were targeted using associated fluorescently tagged secondary 
antibodies (1:1000 for Alexa488 and Alexa594, 1:500 for Alexa647). Biotinylated tracer 
fluorescence was amplified with Streptavidin conjugated to Alexa594 (1:1000, Life 
Technologies). Secondary antibodies were diluted in PBST and incubated for two hours at room 
temperature. Nuclei were then labeled with DAPI (4′,6-diamidino-2-phenylindole, 1:20,000 in 
PBST) for 10 minutes, then slides were washed twice with PBST and twice with PBS. Slides were 
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coverslipped with Vectashield (Vector Labs, H-1000), sealed with clear nail polish, and stored at 
-20°C. 
Target Catalog Info Dilution 
Caveolin-1 Abcam ab18199 1:2000 
vGluT2 Millipore AB2251-I 1:2000 
GAD67 Abcam MAB5406 1:1000 
CD4 BD Pharmingen 553727 1:100 
Iba1 WAKO 016-20001 1:500 
CD68 Abcam ab53444 1:2000 
Claudin5 Invitrogen 431600 1:500 
ZO-1 Life Technologies 617300 1:500 
GFP Life Technologies A11122 1:2000 
GLUT1 Millipore 400060-50UG 1:4000 
GLUT1 (in 2019) Thermo Scientific RB-9052-P1 1:2000 
Occludin Invitrogen 711500 1:500 
OMP WAKO 544-10001 1:2000 
Aquaporin4 Sigma A5971  1:500 
LYVE1 Abcam ab14917 1:150 
Group A Streptococcus Fitzgerald 20C-CR7058RAP 1:2000 
 
Table 2.2 Antibody information and dilutions used for immunohistochemistry. 
 
 
In some cases, vasculature was stained with BSL-FITC (Bandeiraea Simplicifolia lectin-
FITC, 1:250, Vector Laboratories, FL-1101). For BSL staining, all solutions were prepared using 
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PBS with Ca2+ and Mg2+, and slides were post-fixed for ten minutes with 4% PFA following BSL-
FITC staining. Imaging of brain sections was performed with a Zeiss LSM700 confocal 
microscope or a Zeiss AxioImager. 
 
2.1.7 In situ hybridization 
Digoxigenin-labeled probes were synthesized from plasmids grown on appropriate selection media 
obtained from TransOMIC using the Roche Applied Science in vitro transcription kit (Sigma, 
11175025910). Unincorporated nucleotides were removed using a G50 column (GE Healthcare, 
27533001), and probes were resuspended and stored at -20°C.  
 Mice used for in situ hybridization were perfused with PBS only, brains and olfactory 
epithelia dissected and removed, and immediately embedded in OCT and frozen on dry ice, then 
stored at -80°C. Sections were cut onto glass slides with samples from two mice from different 
treatment groups o the same slide to minimize variation between groups. For staining, slides were 
air-dried for 20 minutes before immersion in 4% PFA for 15 minutes, followed by three 5-minute 
PBS washes. Slides were acetylated (1.25% triethanolamine, 0.175% HCl, 0.25% acetic 
anhydride) for 10 minutes with constant stirring. Slides were blocked for 4-6 hours with 
hybridization buffer [50% formamide, 5x SSC, 5x Denhardt’s solution, 250 µg/ml baker’s yeast 
RNA (Sigma R6750), 100 µg/ml salmon sperm DNA (ThermoFisher, 15632011)]. Probes were 
diluted as below in hybridization buffer, then 100 µl probe solution was applied to slides and 
coverslipped (Hybrislip hybridization covers, Grace Bio 726024) for hybridization at 72°C 
overnight in a humidified chamber.  
 For alkaline phosphatase enzymatic labeling, slides were then washed for 1 h at 72°C in 
0.2x SSC, 5 min at 25°C in 0.2x SSC, and 5 min at 25°C in buffer B1 (0.1 M TrisCl pH 7.5, 0.15 
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M NaCl). Slides were blocked at room temperature in 10% heat-inactivated normal goat serum 
(HINGS) in buffer B1 for 1 h in a humidified chamber. DIG-labeled probes were then targeted 
with an alkaline phosphatase-conjugated anti-DIG antibody (Sigma, 11093274910; 1:5000 in 
buffer B1 with 1% HINGS) overnight at 4°C. The following day, slides were equilibrated with 
four 15-minute washes with buffer B3 (0.1 M TrisCl pH 9.5, 0.1 M NaCl, 50 mM MgCl2, filtered 
with a 0.45 µm filter). Slides were then inverted on parafilm-covered humidified trays react with 
200 µl AP substrate, buffer B4 [0.24 mg/ml levamisole, 75 mg/ml 4-Nitro blue tetrazolium 
chloride (NBT, Roche 11383213001), 50 mg/ml BCIP 4-toluidine salt (BCIP, Roche 
11383221001)]. The AP reaction was allowed to develop overnight protected from light, then 
checked and buffer B4 refreshed if the reaction was incomplete after 24 h. To quench the AP 
reaction, the chamber was flooded with water and slides were coverslipped with Glycergel warmed 
to 60°C (DAKO, C0563).  
 For fluorescent labeling of DIG-tagged probes, slides were progressed through the 
stringency buffers 5x SSC, 0.2x SSC, and buffer B1 as above, then endogenous peroxidase was 
quenched for 1 h with 3% hydrogen peroxide in methanol. Slides were then blocked with 0.5% 
TNB solution in buffer B1 [(Roche block, Sigma, 11096176001) w/v, dissolved at 72°C with 
vortexing every 15 minutes] for 1 h at room temperature.  After three five-minute washes in TNT 
buffer (0.05% Tween-20 in buffer B1), DIG-labeled probes were targeted with an anti-DIG POD 
antibody [(Sigma 11207733910) 1:500 in 0.5% TNB solution] overnight in a humidified chamber 
at 4°C. The following day, slides were washed three times with TNT buffer, then fluorescence was 
amplified using Cy3 amplification for 10 minutes (Cy3 reagent 1:100 in amplification diluent). 
Slides were again washed three times with TNT buffer, then blocked with 10% BSA in PBST to 
begin immunostaining for vascular markers. Vascular antibodies were used as described above, 
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then slides were coverslipped and imaged on a Zeiss AxioImager or Zeiss LSM700 confocal 
microscope. 
 
2.1.8 Tracer injections 
Blood-brain barrier permeability was assessed using intravenous injection of fluorescent tracers. 
Tight junction integrity was measured using a small molecular weight dye, biocytin-
tetramethylrhodamine (TMR, ThermoFisher, T12921, Waltham, Massachusetts, USA). At 48 h 
after the last infection, animals were anesthetized with 2% isoflurane in medical air and injected 
in the tail vein with 100 µl biocytin-TMR (5 mg/ml) in PBS with Ca2+ and Mg2+. Animals were 
allowed to recover for thirty minutes in their home cage prior to perfusion for 
immunohistochemistry as described above.  
 
2.1.9 Western blotting 
Brains were collected from mice after perfusion with PBS. Collected tissue was homogenized in 
RIPA buffer (25mM Tris pH 7.5, 150mM NaCl, 1mM EDTA, 1% TritonX-100, 0.1% SDS) 
containing 1x protease and phosphatase inhibitors (ThermoFisher, 87785) using a mechanical  
Target Catalog Info Dilution 
ZO-1 ThermoFisher 33-9100 1:1000 
Occludin Invitrogen 711500 1:250 
Caveolin-1 Abcam ab18199 1:1000 
Cadherin-5 Abcam ab33168 1:100 
VCAM-1 Abcam ab134047 1:100 
 
Table 2.3 Antibody information and dilutions for Western blots. 
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homogenizer followed by 10-20 pulses of sonication. Lysates were then centrifuged for 2 minutes 
at 4,000rpm at 4°C, and protein concentration in the supernatant was quantified using the Pierce 
BCA protein assay kit (Thermo Scientific, 23225) run in parallel with BSA standards from 0.125-
2 mg/ml (Bio-Rad). Protein samples were diluted in Laemmli buffer to 3 µg/µl. Protein samples 
(15 µl or 50 µg total protein) and prediluted protein ladder (8 µl, Bio-Rad, 1610374) were loaded 
into 12% or 4-15% precast gradient gels and separated by SDS-PAGE in 0.5 M glycine 4 M Tris 
with 1% SDS. Bands were stacked into the gel at 100V for ten minutes, then run out to separation 
at 150V for an additional 40 minutes. Protein gels were transferred onto polyvinylidene difluoride 
membranes (preactivated in methanol for two minutes then rinsed in water) in 0.5 M glycine 4 M 
Tris at 150 V for 65 minutes on ice. Membranes were trimmed to size, blocked for one hour in 
blocking buffer (1x Odyssey blocking buffer for PBS, LICOR), then incubated in primary 
antibodies diluted according to Table 2.3 in blocking buffer overnight at 4°C. Following 
primaryantibody binding, membranes were washed three times with 1x PBS 0.1% Tween-20 for 
5 minutes each. IRDye-680 and IRDye-800 conjugated secondary antibodies were used to 
visualize primary antibody staining (1:20,000, LICOR). Secondary antibodies were diluted in 
blocking buffer and incubated for one hour at room temperature. Membranes were washed three 
times in PBS-0.1% Tween-20 and twice in PBS prior to visualization. Protein levels in brain 
lysates were measured by fluorescent western blot analysis and quantitation was performed using 
the LICOR (LICOR, Lincoln, NE) system, as described in [91].  
 
2.1.10 qRT-PCR 
cDNA libraries were created from mRNA harvested from OB, OE, and NALT tissue. Olfactory 
tissues were dissected out quickly following a brief perfusion with PBS and snap-frozen on dry  
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Reaction component Volume (µl) Step Temperature (ºC) Time 
        
10x Reverse transcriptase buffer 2 1 25 10:00 
25x dNTP mix (100 mM) 0.8 2 37  120:00 
10x RT random primers 2 3 85 5:00 
MultiScribe reverse transcriptase 1 4 4 Hold 
RNAse inhibitor 1    
Nuclease-free H2O 11.2    
RNA sample (0.3 µg/µl) 3    
       
Total 20    
 
Table 2.4 Reaction components and cycling information for reverse transcription reaction to create cDNA from 
olfactory tissues. Olfactory bulb, epithelium, and NALT samples were processed in parallel. 
 
ice in Eppendorf tubes. RNA was extracted with the RNEasy Midi Kit (QIAGEN) according to 
package instructions, and stored in TE buffer (10 mM Tris HCl, 0.1 mM EDTA, pH 7.0) at -80°C 
until reverse transcription. RNA was reverse transcribed to create cDNA using the High-Capacity 
cDNA Reverse Transcription kit (Applied Biosystems) in 20 µl reactions using RNA samples  
Primer Sequence (5'-3') Reaction component 
Volume 
(µl) 
       
FcγRI forward TAA TGC CAC CAA GGT TGT GA 
SYBR Green Fast 
Mastermix 10 
FcγRI reverse CCT GTA TTC GCC ACT GTC CT Forward Primer 10 µM 0.4 
    Reverse Primer 10 µM 0.4 
FcγRIIβ 
forward CGG CTG TCC ACA GTA GCA TA H2O 7.2 
FcγRIIβ reverse TTT CAC TTC CCC ATT TGG AC Total 18 
    Sample 2 
FcαµR forward TCT TGC TCA GGA CTA ACA TGG AC   
FcαµR reverse CTG GCA AGT GAG GTG CTT TTG   
      
FcRn forward 
ACC CTG GAG AAG ATA TTA AAT GGG 
A   
FcRn reverse TCA GGC TGC TTC ATC CAC AG   
 
Table 2.5 Primer sequences and reaction components for qPCR reactions. Olfactory bulb, epithelium, and NALT 
samples were processed in parallel. 
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diluted to 0.3 µg/µl according to Table 2.4. cDNA was used in reactions with SYBR Green master 




Mice used for electrophysiology experiments were infected four times with live GAS as described 
above. Two days after the fourth infection, mice were swabbed with a Group A Streptococcus 
clinical test (QuickVue In-Line Strep A Test, Quidel) to ensure mice were not infectious, then 
shipped overnight to Duke University.  
Electrophysiological local field potential (LFP) recordings were performed as described 
previously in [242]. Briefly, following four inoculations either with PBS or live GAS, mice were 
surgically fitted with a custom machined head plate to allow for awake, head-fixed recording from 
the olfactory bulb. The head plate was positioned with a Piezo arm so the entirety of the skull 
overlaying the OB was visible within the head plate window. The plate was sealed to the skull 
with dental cement, and mice were treated post-operatively with antibiotic ointment and i.p. 
buprenorphine. After recovery from surgery for two days, mice were inoculated with HK-GAS or 
PBS to recall the immune response. Electrophysiological recordings were performed in a liquid 
dilution, ten channel olfactometer. The morning after recall infections, inoculated mice were 
anesthetized with isoflurane (1% in O2) and a craniotomy and durotomy was opened over the 
posterolateral area of one olfactory bulb. A 32-site polytrode acute probe (A1 × 32-Poly3-5mm-
25s-177, Neuronexus, Ann Arbor, MI) was lowered into the posterior OB to the ventromedial M/T 
layer, where sustained tonic activity was observed in contrast to the electrically quiet granular 
layer, typically at a depth of 1.5-2.2mm, at a 4° angle with respect to vertical in the coronal plane. 
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Once the probe was placed, blackout curtains were closed over the mouse and the recording rig 
was left to acclimate for 1 hour.  
Signals were collected through an A32-OM32 adaptor (Neuronexus) connected to a 
Cereplex digital headstage (Blackrock Microsystems, Salt Lake City UT). Unfiltered signals were 
digitized at 30 kHz at the headstage and recorded by a Cerebus multichannel data acquisition 
system (BlackRock Microsystems). Experimental events and respiration signal were acquired at 2 
kHz by analog inputs of the Cerebus system. Respiration was monitored with a microbridge mass 
airflow sensor (Honeywell AWM3300V, Morris Plains, NJ) positioned directly opposite the 
animal’s nose. Negative airflow corresponds to inhalation and negative changes in the voltage of 
the sensor output. Prior to recording, the back of the probe was painted with a fluorescent dye (DiI, 
Life Technologies) and probe position was confirmed post hoc in histological sections. Odors were 
presented to the animals using a custom-made flow-dilution olfactometer at 0.04%, 0.2%, and 1% 
of saturated vapor with an inter-trial interval of 10 s. Odor presentation and delivery were  














Table 2.6 Odorant stimuli used in electrophysiology recordings. Odors were classified as neutral or innately valent 
from [243]. Trials using neutral and valent odors were analyzed separately. 
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controlled by a custom MATLAB program. All recordings were performed blind with respect to 
genotype. One recording was made from each OB, for a total of two recordings per animal 
performed on consecutive days. Ten monomolecular odorants were diluted in mineral oil for use 
as odor stimuli, listed in Table 2.6. Innately valent stimuli were excluded from analysis because 
different anatomical circuitry processes innately valent odors through the cortical amygdala, 
presenting a potential confound in grouping all odors together for analysis [243]. Thus, only data 
for the following odor stimuli were analyzed: methyl tiglate [Alfa Aesar (Haverhill, MA) A11964], 
g-terpinene (Sigma, 223190-5ML), 2-hexanone [Fluka (Mexico), 02473], isoamyl acetate [Tokyo 
Chemical Industry (Cambridge, MA), A0033], ethyl butyrate (Aldrich E15701), and valeraldehyde 
(Sigma, 110132). Fifteen trials per odor-concentration stimulus were presented for 1s each, with 
each trial lasting approximately 10 s; recordings typically lasted 90 min total. Single units were 
automatically sorted using Spyking Circus (https://www.github.com/spyking-circus). A typical 
recording yielded 19.7 ± 5.5 units. Analysis was performed in MATLAB (MathWorks, Natick, 
Massachusetts, USA). Significantly active units were defined after computing smoothed kernel 
density functions (KDFs) for to visualize averaged firing rates as a function of time after odor 
onset, and identify response latencies for each cell-odor pair. KDFs were computed for the first 
500 ms following inhalation after odor onset. Response index was computed from the area under 
the receiver operating characteristic curve, and comparing the reliability of odor response to 
mineral oil response, with -1 indicating absolute suppression, 0 indicating no change, and 1 
reflecting absolute activation relative to mineral oil. Significantly different responses were 
identified using a Wilcoxon rank-sum test with spike count distributions. 
 
2.2 Behavioral tests 
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Before beginning the inoculation series, mice were handled to prevent stress responses from 
confounding future test sessions. For handling, mice were acclimated to the test room for 30 
minutes, then individually handled for three minutes per day for three successive days. 
Intranasally infected mice used for behavioral experiments received the first four infections 
with live GAS suspensions followed by a fifth infection using HK-GAS to minimize pathogen 
exposure for the experimenter. Subcutaneously immunized mice used for behavioral tests were 
immunized as above. Prior to beginning behavioral tests, mice were acclimated to the test room 
for at least 45 minutes in their home cage. In all cases where mice were tested together, groups 
were counterbalanced for treatment, genotype and sex where applicable. 
 
2.2.1 Olfactory habituation-dishabituation test 
Olfactory function was assessed using the olfactory habituation-dishabituation test adapted from 
[244] at 6 h after the last infection. Mice were habituated singly to a clean empty cage in the testing 
room for 30 minutes prior to testing. Animals were tested in groups of 2-3 and filmed for analysis. 
For testing, mice were allowed to investigate wooden long-handled Q-tips impregnated with 10µl 
of odorant or vehicle (water) for two minutes per trial, with approximately one minute between 
trials to change Q-tips. Each odorant was presented three times in succession, with water being the 
first odorant. Time spent sniffing the Q-tip for each two-minute trial was timed using videotapes. 
Data were analyzed with repeated-measures ANOVA followed by Newman-Keuls post-hoc test. 
 
2.2.2 Open field test 
   62 
Mice were tested in either black open field boxes with bedding or white open field boxes with bare 
bottoms. Mice were filmed from above for tracking and allowed to ambulate freely for 10 minutes. 
Activity was quantified with AnyMaze software.  
 
2.2.3 Beam walking challenge 
Mice were trained to cross a wide 1.5cm wooden beam covered with duct tape oriented towards 
their home cage until they successfully crossed three times. For testing, mice were filmed while 
crossing three times each on 1.5 cm, 1.0 cm, and 0.5 cm beams, with gentle assistance from the 
experimenter if needed. Films were analyzed for time to cross the beam, foot slips, and maximum 
speed in AnyMaze software. 
 
2.2.4 Ladder beam test 
Mice were trained to cross a custom machined ladder with white fiberglass sides and 100 metal 
rungs 4 mm in diameter until they could successfully cross the whole ladder without stopping or 
turning around. On test day, mice were filmed from below to capture footfalls on each rung for 
three trials each. Films were scored for slips of hind- and forelimbs on each rung. 
  
2.2.5 Marble burying test 
The marble burying test measures anxiety-like behavior that prompts digging and burying of items 
in the mouse’s cage. For testing, twelve 1-cm glass marbles were arranged in a 3x4 grid atop 5 cm 
of corncob bedding, and mice were allowed to explore the cage and marbles for five minutes. After 
returning the test mouse to its home cage, the experimenter counted how many marbles were buried 
at the end of the testing session. Mice were filmed during testing to quantify ambulation with 
   63 
AnyMaze software, and to assess marble displacement from beginning to end of the testing 
session.  
 
2.2.6 Induced grooming test 
This test uses water spray to prompt grooming behavior above baseline to elicit underlying 
repetitive behavior. Mice were acclimated singly to an empty cage for 30 minutes prior to testing. 
Filming then began for a 10-minute pre-spray phase. Mice were then sprayed three times with 
distilled water from a distance of ~20 cm, and then filmed for a 20-minute post-spray phase. Videos 
were analyzed for ambulation with AnyMaze, and manually scored for grooming bout number and 
duration, as well as rearing behavior and jumps or backflips.   
 
2.3 Statistical analyses and figure preparation 
Images were prepared using ImageJ software, and figures were assembled using Adobe Illustrator. 
T cell counts were performed live using a cell counter, with experimenter blind to genotype. 
Microglia counts were obtained from tiled images and counted using the ImageJ cell counter 
plugin. Electrophysiology data were analyzed in MATLAB and exported for statistical analysis. 
Statistical analyses of electrophysiological measures, flow cytometry data, behavioral analyses, 
cell count data, normalized Western blot band intensities, and barrier leakage data were performed 
using GraphPad Prism. Data were analyzed by Student’s t-test, 1-way, 2-way, or repeated-
measures (RM) ANOVA followed by Sidak’s, Tukey’s, or Bonferroni’s post-hoc test. Significance 
(a) was set at 0.05. Data are represented as mean ± SEM or SD as denoted in figure legends. 
  
   64 
Chapter 3: Th17 lymphocytes drive neurovascular dysfunction and olfactory circuit 
deficits in post-Streptococcal autoimmune encephalitis 
3.1 Introduction 
 Antibody-mediated CNS autoimmune disease is initiated when circulating antibodies 
inappropriately recognize neuronal receptors or synaptic proteins as foreign epitopes. Perhaps the 
most well-known of these autoimmune encephalitic (AE) syndromes is anti-NMDA receptor 
(NMDAR) encephalitis, but limbic encephalitis and post-infectious basal ganglia encephalitis also 
trigger abrupt onset of neuropsychiatric symptoms in otherwise healthy individuals. Many 
autoantibodies that have been described to date, including anti-nuclear antibodies (ANAs), and 
anti-NMDAR antibodies, are pathogenically implicated in several autoimmune disorders [e.g. 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren syndrome, poly/dermato-
myositis, multiple sclerosis (MS) and AE]. Group A Streptococcus (GAS, S. pyogenes) infections 
have been linked to later development of autoimmunity for centuries. Discovery of anti-neuronal 
antibodies that target dopamine D1R/D2R receptors in sera from patients with Sydenham’s chorea, 
as well as positive response to immune treatment like IVIg, are consistent with an autoimmune 
mechanism for post-infectious BGE [47, 78, 156, 237]. These autoantibodies elicit behavioral 
abnormalities when infused directly into rodent brains, or when administered i.v. along with BBB-
disrupting agents [6, 78, 80, 81, 206, 238] Because the BBB normally prevents antibody entry to 
the CNS parenchyma, the mechanisms by which autoantibodies may enter the brain to trigger 
neuropathology remain unclear for most AE syndromes.  
 A compelling immune-mediated mechanism for BBB disruption is through the action of T 
cells, which have been shown to play essential yet distinct roles in pathogenesis of MS and its 
animal model, experimental autoimmune encephalomyelitis (EAE) [94, 97, 100, 150]. Although 
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Th17 cells initiate disease and propagate pathology and neurovascular dysfunction in EAE [92, 
165, 245], their contribution to AE pathogenesis remains unexplored. Postmortem and biopsy 
samples of AE patients have shown that CD3+ T cells collect as large perivascular infiltrates in 
anti-Hu and anti-LGI1 AE syndromes [246]. Recent work from our lab has established a mouse 
model for post-infectious BGE using multiple intranasal (i.n.) inoculations with live GAS bacteria 
[93]. The mouse immune response closely mimics the human response to infection, inducing a 
GAS-specific CD4+ Th17 cell response in the nasal-associated lymphoid tissue (NALT), a 
structural analog of the human tonsils [93, 166, 234, 235, 247]. GAS-specific T cells migrate from 
the nose to the parenchyma of olfactory bulbs anteriorly in the CNS before spreading more 
posteriorly in the brain. T cell infiltration is accompanied by impaired BBB function, deposition 
of IgG in the brain, activated microglial populations in the olfactory bulb (OB), and loss of 
excitatory synaptic proteins [93]. Although olfactory dysfunction has been reported in MS and 
SLE patients [248-252], as well as during EAE [253], it is unclear whether recurrent GAS 
infections and ensuing post-infectious BGE may impair olfactory circuit function.  
 Inflammatory conditions (e.g., multiple sclerosis, systemic lupus erythematosus, 
Alzheimer’s disease, and Parkinson’s disease) have been linked to olfactory dysfunction in human 
populations [250, 253-255] and demonstrated in rodent models of these diseases [253, 255, 256]. 
It is possible that inflammation in the OE alone is sufficient to affect OSN function, but the 
presence inflammatory cells in the OB or other brain regions (immune cells infiltrate the 
parenchyma in MS lesion areas) may also contribute to hyposmia observed in these conditions. 
Glia from the OB seem to be more plastic than glia from other brain regions, and they are more 
competent antigen presenters. After systemic inflammation with lipopolysaccharide (LPS), 
myeloid cells harvested from the OB and meninges closely interact with T cells in vitro, a behavior 
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not shared by cortical myeloid cells [256]. By contrast, local inflammation induced with LPS 
intranasally results in partially reversible shrinkage of the glomerular and external plexiform layers 
of the OB (Figure 3.1) [257]. In a mouse model of CNS lupus, olfactory-driven behaviors were 
blunted [258]. These behavioral abnormalities were accompanied by decreased cell density in the  
 
Figure 3.1 Olfactory bulb glomerular connectivity in healthy or inflammatory conditions. Odor perception is a unique 
sense in that the substrate, odor molecules, directly contact sensory neurons in the olfactory epithelium (OE) in the 
nose [259]. Each olfactory sensory neuron (OSN) expresses just one of ~1,200 odorant receptor genes, and neurons 
expressing a particular odorant receptor are randomly distributed within localized zones in the OE [260-262]. From 
the OE, OSNs project through the cribriform plate (CP) into the OB, where axons from OSNs expressing the same 
odorant receptor converge to terminate in roughly spherical bundles of synapses, or glomeruli (Glom), with local 
periglomerular interneurons (PG) and excitatory output mitral/tufted (M/T) cells [263]. Individual glomeruli are highly 
specific for a single odorant receptor. OB granule cells (GC) constantly turn over throughout life. A fresh supply of 
neuroblasts flows from the rostral migratory stream and integrates into the olfactory circuit guided by 
CXCL12/CXCR4 signaling, providing a way to shape adult olfactory circuitry independently of synaptic scaling 
mechanisms [188, 264].  
 
rostral migratory stream, suggesting that neurogenesis may be impaired in this systemic 
inflammatory disease [258]. Inflammation and reduced neurogenesis in the SVZ have been 
reported in EAE, which would certainly affect upkeep of olfactory circuits as described above 
[253]. Th17 cells migrating into the brain are known to express inflammatory cytokines IFNγ, IL-
6, IL-23, and IL-17A, among others [40, 265, 266]. We hypothesized that inflammatory cytokines 
secreted by infiltrating Th17 cells after recurrent GAS inoculations were responsible for TJ 
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structural abnormalities, BBB functional permeability, and microglial activation. Studies 
described here test the requirement of Th17 cells for these processes, as well as probing 
physiological consequences in olfactory circuitry in the presence of neuroinflammation after 
recurrent GAS infections. 
 
3.2 Deletion of RORgt eliminates Th17 lymphocytes after intranasal GAS inoculations 
 We have previously shown that recurrent intranasal (i.n.) GAS infections promote 
migration of CD4+ T cells from the NALT to the CNS, a subset of which are bacterial-specific 
Th17 (IL-17A+) and autoreactive Th17 (IL-17A+ IFNγ+) [235]. To more fully understand the role  
 
Figure 3.2 Immunocompromised RORgt-/- mice are more susceptible to sepsis than RORgt+/- mice. a Schematic 
representation of Th17 status in the RORcγt-eGFP mouse line, in which the RORcγt locus is replaced with eGFP. 
Survival curves in b for GAS-infected RORgt+/- and RORgt-/- mice after beginning infection course. RORgt-/- mice die 
from the infections at a higher rate than RORgt+/- mice (C2=7.51; **p=0.0063). c Immunofluorescence staining for 
GAS surface carbohydrate (red) and CD4 (green) confirms that infection is restricted to the nose in both RORgt+/- and 
RORgt-/- mice. No bacterial labeling was detected in brain. Scale bar = 20 µm. 
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of Th17 cells in neuropathology, we performed i.n. GAS infections in the RORcγt-eGFP knockout-
knockin mouse line, in which the RORcγt locus, encoding a transcription factor necessary for Th17  
differentiation, is replaced with GFP (Figure 3.2a). Since RORgt-/- mice are immunocompromised 
and Th17 cells are recruited in large numbers to control GAS infections, approximately 70% of all 
RORgt-/- mice died from sepsis, in contrast to RORgt+/- mice, which had only a ~20% mortality 
rate, consistent with previous findings (Figure 3.2b) [93, 235]. It was important to ensure that 
GAS bacteria were confined to the nose in immunocompromised RORgt-/- mice, with no frank 
brain infection. Restriction of infection to the nose (with no spread to the brain) was confirmed 
with immunofluorescence for GAS surface carbohydrates (red), CD4 (green), and DAPI (Figure 
3.2c). While CD4+ cells were detected in OE and OB of GAS-infected RORgt+/- and RORgt-/- mice, 
bacterial immunolabeling was restricted to the OE. 
 
 
Figure 3.3 Sex-specific Th17 driven peripheral immune cell infiltration. Left, female RORgt+/- immunocompetent 
mice recruit more T cells to the brain than male RORgt+/- mice. There is equivalent T cell recruitment to the brain in 
GAS-inoculated male and female RORgt-/- mice. Data represent n=2 male RORgt+/-, n=9 female RORgt+/-, n=5 male 
RORgt-/-, and n=9 female RORgt-/- mice. RM-ANOVA found no significant effects of sex and distance from bregma 
on T cell counts.  
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 Pilot experiments to understand the contribution of Th17 lymphocytes to CNS pathology 
were initially performed using both male and female mice. Male and female RORgt+/- and RORgt-
/- mice were recurrently infected with GAS, and T cell populations along the rostrocaudal axis of 
the brain were analyzed. Surprisingly, while RORgt-/- female mice showed a significant reduction 
in CNS T cell infiltration after GAS inoculations (Figure 3.3a), RORgt-/- males had similar 
numbers of CNS T lymphocytes as RORgt-/- littermates (Figure 3.3b). Thus, females show a Th17-
dependent T cell expansion in the brain that is absent in males. Given that autoimmunity is sex-
skewed to females (along with many specific autoimmune diseases), these findings agree with data 
showing sex differences in animal models of other autoimmune diseases [167, 267, 268]. For the 
rest of this study, we focused primarily on females. Phenotypes in males were analyzed separately 
in parallel to females. 
 Next, we mapped the fraction and spatial distribution of GFP+ Th17 cells in the CNS after 
recurrent GAS infections using immunofluorescence. Consistent with previous results, ~36% of 
CD4+ T cells were GFP+ [93], indicating Th17 identity, and most GFP+ CD4+ Th17 cells were 
located in the anterior part of the brain (bregma 4.28-2.46; data not shown). In RORgt+/- mice, 
GFP+ Th17 cells are concentrated in the olfactory bulb and anterior olfactory nucleus (AON) 
anteriorly (Figure 3.4a); in posterior brain regions, Th17 cells are mostly found in the choroid 
plexus and meninges (bregma -1.70, -2.46, Figure 3.4b). Comparison of total CD4+ T cell infiltrate 
in GAS-infected RORgt+/- and RORgt-/- brains illustrated that in RORgt-/- mice lacking Th17 cells, 
total T cell infiltrate was reduced by 58%, with no detectable GFP+ cells (Figure 3.4abc). Because 
the Th17 fraction in RORgt+/- brains is only 34% (Figure 3.5b, [93]), there must be some non-cell 
autonomous recruitment of other T cell populations by Th17 cells. Thus, CNS Th17 cell infiltration  
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Figure 3.4 T cells infiltrate the brains of RORgt+/- and RORgt-/- mice after recurrent GAS infections. CD4+ T cells are 
visible throughout the brains of both RORgt+/- and RORgt-/- mice (anterior regions in a and choroid plexus in b). GFP+ 
CD4+ T cells are only found in RORgt+/- brains. c Quantification of total CD4+ T cell distribution along the 
anteroposterior axis of the brain in PBS (gray), GAS-infected RORgt+/- (black) and RORgt-/- (red) mice. The x-axis 
represents distance from bregma and the y-axis shows numbers of CD4+ T cells per 12 µm section. Dashed red and 
blue vertical lines represent relative positions in the brain cartoon above (solid lines). Data represent n=5 PBS, n=9 
GAS RORgt+/-, and n=9 GAS RORgt-/-. RM-ANOVA found significant main effects of treatment (F(2,20)=10.43, 
p=0.0008) and bregma (F(12,240)=13.4, p<0.0001), as well as an interaction between treatment and bregma 
(F(24,240)=4.690, p<0.0001); Tukey’s MC test reveals significant differences at bregmas +4.28, +3.7, +3.2 
(****p<0.0001) and bregma 2.8 (**p=0.0062); Asterisks denote significance between GAS RORgt+/- and RORgt-/-. 
Scale bar = 20 µm. 
 
seems to have non-cell autonomous effects on other T cell subtypes, which could be due to 
secretion of chemokines in the nose or brain by Th17 cells.  
 Flow cytometric analysis of T cell subtypes in the NALT/OE and anterior CNS was then 
performed after recurrent i.n. GAS inoculations. In RORgt+/- brains, CD4+ population is comprised 
mainly of autoreactive IFNg+ IL-17A+ Th17 (42.75%), followed by IFNg+ Th1 (25.57%), IL-17A+ 
Th17 (19.25%), and 12.1% Tregs (Figure 3.5abc). The proportions of T cell subtypes are similar 
between brain and NALT/OE CD4+ populations in RORgt+/- mice (Figure 3.5abdf). In GAS-
infected RORgt-/- mice, autoreactive Th17 (IL-17A+ IFNg+) and Th17 (IL-17A+) populations were 
drastically reduced (to 10.96% and 6.4%, respectively), along with a concomitant expansion of the 
IFNg+ population to 49.8%. Treg populations also decreased in RORgt-/- brains (7.4%, Figure  
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Figure 3.5 Flow cytometric analysis of lymphocytes recruited to brain and NALT/OE after recurrent GAS infections. 
a Representative flow cytometry analyses of CD4+ lymphocytes purified from anterior brain tissue of RORgt+/- and 
RORgt-/- mice stained for intracellular cytokines (left), and representative flow cytometry for CD4+ FoxP3+ Treg cells 
from RORgt+/- and RORgt-/- brains (right). b Quantification of cytokine profile analysis of lymphocytes purified from 
brain of GAS-infected RORgt+/- and RORgt-/- mice. Data represented as mean ± SEM for n=6 GAS RORgt+/- and n=4 
GAS RORgt-/- mice. Two-way ANOVA found main effects of cytokine (F(2,16)=21.04, p<0.0001) and genotype 
(F(1,8)=12.58, p=0.0075), as well as an interaction between cytokine and genotype (F(2,16)=27.86, p<0.0001). 
Sidak’s post-hoc test revealed differences in IL-17A+, *p=0.353; IFNg+ (***p=0.0001); IL17A+ IFNg+ 
(****p<0.0001). c Treg population analysis of lymphocytes from brain in RORgt+/- and RORgt-/- mice after GAS 
infections. Data are represented as mean ± SEM from n=3 GAS RORgt+/- and n=6 GAS RORgt-/- mice, analyzed by 
two-tailed Student’s t-test with Welch’s correction for unequal variance (t=10.29, ***p=0.0001). (d, left) 
Representative cytokine expression profiles from lymphocytes in NALT/OE of RORgt+/- and RORgt-/- mice, and (d, 
right) representative plots of FoxP3+ Tregs from NALT/OE. e Quantification of cytokine expression in lymphocytes 
purified from NALT/OE of GAS-infected RORgt+/- and RORgt-/- mice. Data represent (continued on following page) 
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mean ± SEM from n=3 GAS RORgt+/- and n=3 GAS RORgt-/- mice. Two-way ANOVA found a main effect of cytokine 
(F(2,8)=93.14, p<0.0001) but not genotype (F(1,4)=3.675, p=0.1277), and found an interaction between cytokine and 
genotype (F(2,8)=17.96, p=0.0011). Sidak’s post-hoc test revealed differences in IFNg+ (***p=0.0115) and IL17A+ 
IFNg+ (****p=0.0006), but not IL-17A+ (p=0.353). f Quantification of FoxP3+ Treg populations in NALT/OE 
lymphocytes from RORgt+/- and RORgt-/- mice. Data are represented as mean ± SEM from n=3 GAS RORgt+/- and n=8 
GAS RORgt-/- mice; unpaired two-tailed Student’s t-test showed no difference between genotypes (t=0.7416, 
p=0.7442).   
 
3.5c). These changes in T cell subtype distribution in RORgt-/- brain CD4+ cell populations mirror 
those seen in the NALT/OE (Figure 3.5def), reinforcing prior work suggesting that CNS T cells 
originate in the NALT.  Despite their immunocompromised state, surviving RORgt-/- mice generate 
a robust CD4+ cellular immune response in the NALT/OE, restricting bacterial infection to the 
nose.  
 
Figure 3.6 T cells recruited to the olfactory epithelium after recurrent GAS infections in RORgt+/- and RORgt-/- mice. 
a Immunofluorescence for GFP (green) and CD4 (red) shows colocalization in a subset of cells (Th17, arrows) in 
RORgt+/- but not RORgt-/- olfactory epithelium. Remaining cells are CD4+ GFP- (arrowheads). b Quantification of 
different cell types illustrates decreased total T cell recruitment due to selective loss of CD4+ GFP+ Th17 cells, with 
no change in CD4+ GFP- and CD4- GFP+ cell populations. Data represent mean ± SEM from n=6 GAS RORgt+/- and 
n=5 GAS RORgt-/- animals. RM-ANOVA showed main effects of genotype (F(1,9)=5.169, p=0.0491) and cell type 
(F(3,27)=75.42, p<0.0001) on T cell populations in the nose, as well as an interaction between cell type and genotype 
(F(3,27)=4.317, p=0.0131). Sidak’s multiple comparisons test revealed significant differences in total cells 
(*p=0.0119) and CD4+ GFP+ (*p=0.0214), but not CD4+ GFP- (p>0.999) and CD4- GFP+ (p=0.9995). Scale bar = 20 
µm. 
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 To confirm our findings from flow cytometric experiments, we performed 
immunohistochemical analysis of total CD4+ and CD4+ GFP+ Th17 lymphocyte recruitment to the 
OE. In Figure 3.6a, histological examination of immunostained OE tissue sections shows 
recruitment of CD4+ GFP- (arrowheads) and CD4+ GFP+ cells (arrows) to the OE in RORgt+/- GAS-
infected mice. However, RORgt-/- OE contain only CD4+ GFP- cells (arrowheads), with small 
populations of CD4- GFP+ cells found in both genotypes (Figure 3.6a). GAS-infected RORgt-/- 
mice recruit 32.7% fewer total T cells to the OE (158.7 ± 12 T cells per FOV) compared to GAS- 
infected RORgt+/- mice (232.2 ± 31.1 T cells per FOV), which is accounted for by a loss of CD4+ 
GFP+ Th17 cells of approximately the same magnitude (decrease of 68.24 CD4+ GFP+ cells per 
FOV, Figure 3.6b).  
  
 
Figure 3.7 Flow cytometric analysis of splenic CD4+ T cells confirms that immune response is local to olfactory 
tissues. Representative cytometry plots in a show lack of significant splenocyte activation in RORgt+/- and RORgt-/- 
mice after GAS infections. b Quantification of cytokine expression indicates only a small increase in IFNg+ T cells in 
RORgt-/- mice. Data represent mean ± SEM from n=6 GAS RORgt+/- and n=4 GAS RORgt-/- mice. Two-way ANOVA 
revealed a main effect of cytokine (F(2,16)=15.23, p=0.0002), but not genotype (F(1,8)=4.731, p=0.0613); there was 
also significant interaction between cytokine and genotype (F(2,16)=6.660, p=0.0079). Sidak’s post-hoc test revealed 
differences in IFNg+ (**p=0.0011); but not IL17A+ IFNg+ (p>0.999) or IL-17A+ (p=0.9797). c Treg populations are 
unchanged in splenocytes from RORgt+/- and RORgt-/- mice. Data are represented as mean ± SEM from n=3 GAS 
RORgt+/- and n=6 GAS RORgt-/- mice. Unpaired Student’s t-test showed no difference between genotypes (t=0.3559, 
p=0.7324).  
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 The response to GAS is local to the OE and brain, as splenic lymphocytes were not 
activated in large numbers (Figure 3.7a). GAS-inoculated RORgt+/- and RORgt-/- mice show only 
a very small population of activated CD4+ IFNg+ splenocytes (Figure 3.7b). Moreover, the Treg 
population remains stable around 15%, which is typical of healthy mouse spleen (Figure 3.7c) 
[269]. Thus, in immunocompromised RORgt-/- mice, immune responses are confined to the 
olfactory epithelium, NALT, and brain. Both IL-17A and IFNg are secreted by autoreactive Th17 
cells found in the CNS of RORgt+/- mice infected with GAS, and these cytokines have been 
demonstrated in vitro and in vivo in EAE experiments to cause BBB permeability [165, 169]. BBB 
integrity in the presence and absence of Th17 cells recruited to the CNS after recurrent GAS 
infections was then investigated.  
 
3.3 Th17 cells enhance BBB permeability in a size-dependent manner 
 The contribution of Th17 cells to BBB disruption after recurrent GAS infections was 
assessed because both IL-17A and IFNg have been shown to disrupt endothelial tight junctions in 
vitro and in vivo [100, 169, 266]. First, permeability via disrupted tight junction integrity 
(paracellular permeability) was assessed using an i.v. injection of the small molecular weight tracer 
biocytin- TMR (870 Da) into PBS-inoculated controls and GAS-inoculated RORgt+/- and RORgt-/- 
mice at 48 h after the final infection. All GAS-inoculated mice showed increased BBB 
permeability in various brain regions, and heatmaps showing areas of tracer deposition in brains 
indicate no difference in area with BBB disruption between genotypes when compared to 
uninfected controls (Figure 3.8a). Quantification of tracer staining intensity in OB regions 
revealed that although both RORgt+/- and RORgt-/- mice showed increased BBB permeability in the  
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Figure 3.8 Increased permeability to a small molecular weight tracer in GAS-inoculated brains. a Heatmaps indicating 
areas of the OB with biocytin-TMR tracer deposition relative to uninfected controls. Darker red indicates more mice 
with biocytin-TMR staining in that region. b PBS-inoculated control mice show very little tracer deposition in 
glomerular and granular layer of the OB. GAS-inoculated mice show significant biocytin-TMR uptake by neurons 
(arrows) in both glomerular and granular OB layers. Quantification of biocytin-TMR staining intensity in c glomerular 
and d granular layers of the OB. Data were collected from n=4 PBS, n=6 GAS RORgt+/-, and n=4 GAS RORgt-/- mice, 
represented as mean ± SEM. c One-way ANOVA showed significant differences in biotin intensity in glomerular 
layer (F(2,12)=4.986, p=0.0265). Tukey’s post-hoc test revealed significant differences in PBS vs GAS RORgt+/- 
(*p=0.0431), and PBS vs GAS RORgt-/- (*p=0.047), but not GAS RORgt+/- vs GAS RORgt-/- (p=0.97). d No condition 
effect in granular biotin intensity was found by one-way ANOVA (F(2,12)=1.519, p=0.2582). Scale bar = 20 µm. 
 
glomerular layer after GAS infections, granular layer BBB permeability was mild and not 
significantly different from uninfected controls (Figure 3.8bcd). Thus, Th17 cells are not 
necessary for tight junction degradation after recurrent GAS infections. 
 Second, permeability caused by increased transcellular vesicular traffic (by Cav1+ vesicles 
or clathrin-coated vesicles) was investigated by mapping and quantifying intensity of serum IgG 
deposition. Heatmaps showing areas of increased IgG deposition relative to uninfected mice again  
show no effect of Th17 cells on areas with BBB permeability (Figure 3.9a). In contrast to biocytin- 
TMR leakage, GAS-infected RORgt-/- mice had significantly less intense IgG staining in both  
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Figure 3.9 Increased deposition of IgG in OB regions in RORgt+/- but not RORgt-/- mice inoculated with GAS. a 
Heatmaps indicating areas of increased serum IgG deposition in the OB of GAS-infected RORgt+/- and RORgt-/- brains 
compared to PBS controls. b PBS-inoculated mice showed no BBB permeability to IgG in glomerular and granular 
OB layers. GAS RORgt+/- brains show heavy deposition of serum IgG (arrows) in both glomerular and granular layers, 
whereas GAS RORgt-/- mice show significantly less IgG deposition in the same regions. c,d Quantification of IgG 
leakage in glomerular and granular OB. Data represented as mean ± SEM from n=4 PBS, n=4 GAS RORgt+/-, and n=3 
GAS RORgt-/- mice. c One-way ANOVA was used to assess differences in IgG intensity in glomerular layer 
(F(2,8)=39.01, p<0.0001). Tukey’s post-hoc test revealed significant differences in PBS vs GAS RORgt+/- 
(****p<0.0001), and GAS RORgt+/- vs GAS RORgt-/- (**p=0.001), but not PBS vs RORgt-/- (p=0.1466). d IgG 
deposition in the granular layer was assessed by one-way ANOVA (F(2,8)=35.35, p=0.0001). Tukey’s post-hoc test 
revealed significant differences in PBS vs GAS RORgt+/- (****p<0.0001), and GAS RORgt+/- vs GAS RORgt-/- 
(**p=0.0022), but not PBS vs GAS RORgt-/- (p=0.0829). Scale bar = 20 µm. 
 
granular and glomerular OB compared to GAS-infected RORgt+/- mice (Figure 3.9bcd). PBS-
inoculated control mice had very little detectable IgG in the parenchyma, indicating an intact BBB 
(Figure 3.9bcd). Th17 cells therefore act on the endothelium directly or indirectly to modulate 
entry of IgG, potentially through increased rates of transcytosis or receptor-mediated transport.  
 Finally, to investigate the size limits of BBB leakage after GAS infections, brain sections 
of PBS-inoculated controls and GAS-infected RORgt+/- and RORgt-/- mice were stained for 
fibrinogen, a large (340 kDa) non-immunogenic serum glycoprotein that enters the CNS during  
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Figure 3.10 BBB permeability after recurrent GAS inoculations is size-restricted. Immunofluorescence for fibrinogen 
(green) in olfactory bulb tissue probes for massive disruption of TJs. EAE lumbar spinal cord served as a positive 
control, where fibrinogen can be seen in dorsal and ventral funiculi (dashed lines, white arrows). PBS- and GAS-
inoculated RORgt+/- or RORgt-/- mice had no detectable fibrinogen deposition despite BBB permeability to biocytin-
TMR and serum IgG in the same region. Intravascular and olfactory nerve (outside the BBB) fibrinogen indicated by 
red arrows. Scale bar = 200 µm. 
 
massive BBB breakdown as seen in acute EAE lesions [270, 271]. Figure 3.10 illustrates that 
vasculature in GAS-inoculated RORgt+/- and RORgt-/- mice remains impermeable to fibrinogen, in 
contrast to vessels in mice with active EAE, where fibrinogen deposition in the parenchyma can 
be seen in lesion areas (white arrows and dashed lines). The only detectable fibrinogen in GAS-
infected brains was found in the olfactory axon tract with no BBB, or within the vasculature itself 
(red arrows, GAS RORgt+/- and GAS RORgt-/- panels). Increased concentration of fibrinogen in in 
vitro culture systems has been shown to alter VE-Cadherin levels and promote paracellular EC 
permeability, as well as promoting caveolae formation to increase transcytosis [271]. Absence of 
frank fibrinogen leakage in otherwise leaky brains after GAS infections indicates that either tight 
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junction complexes are not disrupted enough to allow passage of fibrinogen, or that transport of 
molecules like IgG is mediated through selective transport mechanisms.  
 To determine the mechanism of selective barrier exclusion of IgG in GAS-inoculated 
RORgt-/- mice, we analyzed expression and localization of tight and adherens junction protein  
 
Figure 3.11 Tight junction (TJ) protein abnormalities after GAS infection in RORgt+/- and RORgt-/- brains. a TJ strands 
show abnormalities in GAS-infected RORgt+/- and RORgt-/- vessels (white arrows indicate gaps in tight junction 
strands, yellow arrowheads indicate extensive loss of protein staining, and green arrows point to protrusions 
perpendicular to the TJ strand). b Larger magnification images from boxed areas in a. Yellow arrowheads indicate 
absence of TJs. Scale bars are 20 µm in a and 5 µm in b. c Quantification for aberrant TJ strands in OB glomerular 
vessels of GAS-inoculated mice. Data were collected from n=4 GAS RORgt+/- and n=7 GAS RORgt-/- animals, 
expressed as mean ± SEM. Two-way ANOVA revealed no main effects of genotype (F(1,9)=0.05095, p=0.4934) or 
abnormality (F(1,9)=0.1763, p=0.6844) on TJ malformations, as well as no interaction between malformation and 
genotype (F(1,9)=0.9943, p=0.3447). d Representative Western blot bands for selected adherens junction, tight 
junction, and transcytotic proteins. e Quantification of protein expression. Optical density was normalized within 
sample to b-actin first, followed by normalization to mean PBS levels (dashed horizontal line). Data represent mean 
± SEM from n=6 PBS, n=4 GAS RORgt+/-, and n=5 GAS RORgt-/- animals. Significant differences in expression were 
detected for Occludin (F(2,14)=7.554, p=0.006) between PBS vs GAS RORgt-/- (**p=0.0049) but not PBS vs GAS 
RORgt+/-(p=0.0783); ZO-1 (F(2,12)=3.844, p=0.05) between PBS vs GAS RORgt-/- (*p=0.0422) but not PBS vs GAS 
RORgt+/-(p=0.3826); and Caveolin-1 (F(2,13)=4.969, p=0.0249) between PBS vs GAS RORgt+/- (*p=0.036) but not 
PBS vs GAS RORgt-/-(p=0.0619). Cadherin-5 levels were not significantly different between conditions 
(F(2,13)=2.767, p=0.0997). 
 
   79 
levels. In OB glomerular layer vessels in RORgt+/- and RORgt-/- mice infected with GAS, 
immunofluorescence for TJ components Occludin and ZO-1 allowed for quantification of missing 
1-3 µm lengths of TJ seams (gaps), and large >5 µm lengths of missing TJ strands (loss of staining). 
These abnormalities are associated with BBB dysfunction in several neurological diseases [13, 91-
93]. Fractions of vessels with abnormal TJ strands were similar between GAS-inoculated RORgt+/- 
and RORgt-/- mice; PBS-inoculated animals showed normal TJ structures (Figure 3.11abc; data 
not shown). Protein expression of Occludin and ZO-1 were significantly reduced in GAS-
inoculated RORgt-/- mice compared to PBS controls (Figure 3.11de). Total Caveolin-1 levels 
significantly decreased in GAS-inoculated RORgt+/- mice, and trended towards decreasing in 
RORgt-/- mice as well (p=0.0619; Figure 3.11de). 
 A second possible candidate for selective transport of IgG in RORgt+/- mice is Fc receptor-
mediated transcytosis. Fc receptors (FcRs) are expressed in ECs basally and normally remove IgG 
from the parenchyma and shuttle it back to the bloodstream. It has been hypothesized that in certain 
disease states, directionality reverses and FcRs pump IgG from the blood into the brain. There are 
several different FcRs, each with affinity for different Ig molecules. For example, three isoforms 
of FcgR (FcgRI, FcgRIIa, FcgRIIb) have affinity for IgG, while FcaµR is highly specific for IgA 
and IgM. We probed RNA expression from olfactory tissues isolated from mice receiving 5 PBS 
or GAS inoculations and sacrificed at 6 h or 48 h after the final infection. qRT-PCR revealed that 
FcgRI and FcRn are modestly upregulated after GAS infections, with FcgRIIb expression 
increasing in OE and NALT but not brain tissue (Figure 3.12a). In situ hybridization confirmed 
expression of FcgRIIb in OB. However, FcgRIIb expression was not exclusively colocalized with 
Caveolin1 immunostaining in the OB (Figure 3.12b). This indicates that changes in vascular 
expression of Fc receptors may be drowned out by other more numerous cell types. Isolation of  
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Figure 3.12 Fc receptor mRNA expression changes in olfactory tissues after recurrent PBS or GAS inoculations. a 
Quantitative real-time PCR assessed fold change in mRNA levels of FcgRI, FcgRIIb, FcaµR, and FcRn in GAS and 
PBS mice at 6 h and 48 h after the final infection. None of the Fc receptor targets had significant elevation by two-
way ANOVA analyzing the interaction of tissue and treatment. In situ hybridization b confirmed expression of 
FcgRIIb (red) in OB brain sections, with vasculature labeled with Caveolin1 (green). mRNA expression was detected 
both vascularly (arrowheads) and outside of vessels (arrows) in the glomerular layer. Scale bar = 50 µm. 
 
microvessels to examine receptor changes more closely may be necessary to fully resolve this 
issue. Alternatively, assays that directly test the action of Fc receptors in vivo without paracellular 
transport of solutes could clarify changes in Fc-mediated transport in BECs after GAS infections. 
 
3.4 Neuroinflammation induces synaptic dysfunction in olfactory circuits 
 Elimination of Th17 cells resulting in a 48% decrease in CNS T cell burden should reduce 
overall cytokine load in the CNS, thus reducing microglial activation. We then examined whether 
loss of Th17 cells affects activation of brain-resident microglia and infiltration of peripheral 
macrophages after recurrent GAS infections. Compared to PBS-inoculated controls, GAS-infected 
RORgt+/- mice showed a 2.1-fold increase in the number of activated microglia, and GAS-infected 
RORgt-/- mice had a non-significant 1.4-fold increase in activated microglia relative to PBS (Figure  
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Figure 3.13 Neuroinflammation by activated microglia/macrophages after GAS inoculations. Iba1+ CD68+ microglia 
are present in the OB glomerular layer of PBS control and GAS-inoculated RORgt+/- and RORgt-/- brains by 
immunofluorescence, left, for CD68 (green) and Iba1 (red). Right, quantification of activated (CD68+ Iba1+) microglia 
in the glomerular layer relative to PBS microglia counts. Control and GAS-inoculated ROR-/- mice have few highly 
activated microglia, but GAS-inoculated RORgt+/- mice have substantial microglial activation in the glomerular layer. 
Data represent n=4 PBS, n=11 GAS RORgt+/-, and n=5 GAS RORgt-/- animals, expressed as mean ± SEM. One-way 
ANOVA assessed differences in microglia levels (F(2,17)=8.924, p=0.0022). Tukey’s test for multiple comparisons 
revealed significant differences between PBS vs GAS RORgt+/- (**p=0.0034) and GAS RORgt+/- vs GAS RORgt-/- 
(*p=0.0347), but not PBS vs GAS RORgt-/- (p=0.4956). Scale bar = 20 µm. 
 
3.13). Therefore, infiltrating Th17 cells promote microglial activation or co-infiltration of 
peripheral macrophages after GAS infections. 
 We have previously shown that GAS-inoculated mice have very little vesicular glutamate 
transporter 2 (vGluT2) protein in olfactory bulb glomeruli [93]. To address whether these changes 
are Th17-dependent, we analyzed levels of vGluT2 and glutamate decarboxylase 67 (GAD67), an 
enzyme expressed by inhibitory periglomerular cells, within OB glomeruli of GAS-inoculated 
RORgt+/- and RORgt-/- mice (Figure 3.14a). The ratio of excitatory vGluT2 to inhibitory GAD67 
in glomeruli was reduced to equal degree in GAS-infected RORgt+/- and RORgt-/- mice compared 
to PBS controls (Figure 3.14b). In conjunction with persistent loss of vGluT2 in OB glomeruli, 
the glomerular structures themselves are aberrant in GAS-infected RORgt+/- and RORgt-/- mice, 
with mean glomerular diameter reduced by 20.5% in GAS RORgt+/- and by 26.6% in GAS RORgt-
/- mice compared to PBS controls (Figure 3.14c). This is consistent with a decrease in excitatory 
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input to glomeruli from OSNs onto M/T cells. Thus, Th17 cells are not required for loss of vGluT2 
in OSN terminals.  
 
Figure 3.14 GAS-induced synapse protein degradation is Th17-independent. Synapse proteins vGluT2 and GAD67 
are markers of the major components comprising the neuropil of glomeruli. PBS-inoculated mice show robust 
expression of both proteins, a however in GAS-inoculated RORgt+/- and RORgt-/- mice, vGluT2 is significantly 
downregulated b Data represented as mean ± SEM for n=3 PBS, n=7 GAS RORgt+/-, and n=3 GAS RORgt-/-. One-way 
ANOVA showed significant differences between conditions (F(2,10)=9.070, p=0.0057). Tukey’s post-hoc test 
revealed differences between PBS vs GAS RORgt+/- (**p=0.0059) and PBS vs GAS RORgt-/- (*p=0.016), but not GAS 
RORgt+/- vs GAS RORgt-/- (p>0.999). c Glomerular diameter is similarly smaller in GAS-infected mice compared to 
PBS controls Data represented as mean ± SEM for n=8 PBS, n=5 GAS RORgt+/- and n=5 GAS RORgt-/- mice. One-
way ANOVA revealed a condition effect (F(2,11) = 11.93). Tukey’s multiple comparisons test revealed significant 
differences between PBS vs GAS RORgt+/- (**p=0.0098) and PBS vs GAS RORgt-/- (**p=0.0016), but not GAS 
RORgt+/- vs GAS RORgt-/- (p=0.4907). Scale bar = 20 µm. 
 
 Histological findings presented here predict that olfactory function is likely impaired in 
GAS-inoculated mice. This prediction was tested with a behavioral test for olfactory function, the 
habituation-dishabituation test [244], which leverages a mouse’s innate curiosity for new stimuli 
to measure odor detection and discrimination. The mouse is presented for two minutes with a Q-
tip impregnated with 10 µl of odorant or vehicle diluted in water. Time spent investigating (i.e., 
sniffing) the Q-tip is quantified, and with repeated trials using the same odorant, the mouse rapidly 
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loses interest and sniffs less (habituation). If the Q-tip is then odorized, the mouse increases 
investigation time again (dishabituation), demonstrating odor detection. Changing odorant 
stimulus will also prompt a dishabituation response, demonstrating odor discrimination. PBS 
control mice exhibit normal odor detection and discrimination (Figure 3.15). GAS-infected  
 
 
Figure 3.15 GAS-inoculated RORgt+/- and RORgt-/- mice are hyposmic. Odor detection and discrimination are 
impaired in GAS-inoculated RORgt+/- and RORgt-/- mice compared to PBS control RORgt+/- mice. RM-ANOVA 
analyzed for main effects of treatment (F(2,13)=6.122, p=0.0134) and odor (F(8,104)=34.15, p<0.0001), as well as 
interaction (F(16,104)=2.163, p=0.0106). Tukey’s multiple comparisons test showed significantly impaired odor 
detection in GAS-inoculated mice compared to PBS (almond: PBS vs GAS RORgt+/- ****p<0.0001; PBS vs GAS 
RORgt-/- ****p<0.0001), and significantly impaired odor discrimination (vanilla: PBS vs GAS RORgt+/- *p=0.0436; 
PBS vs GAS RORgt-/- *p=0.0456). 
 
RORgt+/- and RORgt-/- mice, however, both show blunted odor detection and no discernible odor 
discrimination capability (Figure 3.15), consistent with abnormal vGluT2 expression in glomeruli 
(Figure 3.14ab). There was no difference in baseline locomotion between treatment groups, 
suggesting that this result is not due to sickness behavior. 
 To localize deficits in olfactory processing, we recorded odor-evoked spiking activity in 
populations of mitral and tufted (M/T) cells from OB of awake, head-fixed mice for both RORgt+/- 
and RORgt-/- groups [242, 272]. We anticipated that mitral cell responses to odor in GAS-infected 
RORgt+/- and RORgt-/- mice would be blunted or abolished to an equal degree. To test this 
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prediction, multi-unit recordings using a 32-channel multi electrode probe were performed in male 
and female RORgt+/- and RORgt-/- mice inoculated with either PBS or GAS in the laboratory of Dr.  
Kevin Franks at Duke University. In these experiments, mice were presented with a battery of 11 
odor stimuli listed in Table 2.6 across a 25-fold dilution range.   
 
Figure 3.16 Electrophysiological recordings from mitral cell populations. a Schematic of headplates surgically fitted 
to the mouse skull prior to recording. A craniotomy was performed immediately prior to recording. b Representative 
electrode tracts in PBS and GAS mice terminating in the M/T layer of the olfactory bulb (arrow). Tracts were marked 
using DiI (DiIC18(3)) painted on the reverse side of the probe. Scale bar = 100 µm. 
 
 Mice were fitted with custom headplates to allow for head-fixed, awake recordings from 
the OB M/T layer, as illustrated in Figure 3.16a. Probe placement within the brain was determined 
by breath-locked high spontaneous activity across the electrode array, ~1.5-2 mm deep from the 
surface of the brain. Prior to electrode insertion into the brain, the fluorescent lipophilic cationic 
indocarbocyanine dye DiI (DiIC18(3)) was painted on the back face of the probe to mark the 
electrode tract. Electrode placement was confirmed to terminate in the M/T layer post-hoc (Figure 
3.16b).  
 Mitral cells in the OB respond to odor in awake mice by modulation of a baseline firing 
rate. Increased concentration of odorant generally increases the magnitude of mitral cell responses. 
For each of four treatment groups, heatmaps showing coded responses for all mitral cells were 
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Figure 3.17 Heatmaps showing mitral cell activation and suppression responses. Changes in unit firing rate at odor 
onset are coded using a response index ranging from -1 to 1, with suppression indicated by negative values and 
activation represented by positive values. GAS-infected RORgt+/- mice have blunted responses to increased odor 
concentration, in contrast to PBS controls and GAS-infected RORgt-/- mice. 
 
generated to investigate overall response quality. It is clear that PBS mice show increased 
activation and suppression to increased odor concentration, and that the same mitral cell may be 
activated or suppressed, depending on the odor (Figure 3.17a). GAS-infected RORgt+/- mice do 
show mild odor responses, but there is no readily discernible concentration-dependent increase in 
responsivity with concentration (Figure 3.17b, left). In contrast, GAS infected RORgt-/- mitral cells 
recapitulate concentration-dependent increase in response magnitude like PBS mice, indicating a 
preservation of some mitral cell function (Figure 3.17b, right). 
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Figure 3.18 Th17-dependent ablation of mitral cell odor response in GAS-inoculated mice. Control mice a show 
increased mitral cell responses from representative units to ethyl butyrate with increased odor concentration in peri-
stimulus time histograms (PSTH). In b, GAS-infected RORgt+/- mice have blunted odor responses to ethyl butyrate, 
while GAS RORgt-/- mice maintain concentration-dependent increase in mitral cell response. Vertical line denotes start 
of the first inhalation after odor onset. Responses averaged across all odor-concentration stimuli in c,d,e,f.  Data in 
c,d,e,f were collected from n=120 cells from 6 recordings in 4 PBS RORgt+/- mice, n=140 cells from 7 recordings in 4 
PBS RORgt-/- mice, n=130 cells from 7 recordings in 5 GAS RORgt+/-  mice, and n=144 cells from 4 recordings in 5 
GAS RORgt-/- mice. Scale bar at left = 70 Hz. 
 
 Odor-evoked responses were then aligned to the first inhalation after odor onset (defined 
as t=0 preceding a 1 sec odor stimulus) and averaged within concentration across all odor stimuli 
to generate a peri-stimulus time histogram (PSTH). This allows for assessment of mitral cell 
responses to odor over a 25-fold odor dilution series. Both RORgt+/- and RORgt-/- control PBS- 
inoculated mice showed increased odor-evoked response with increasing odor concentration 
(Figure 3.18a). In GAS-infected mice (Figure 3.18b), RORgt+/- mice do not show odor-evoked 
responses, even at the highest odor concentration, while RORgt-/- mice do show evoked activity in 
response to odor presentation. PSTHs were then averaged across concentrations to show overall 
odor-evoked activity; PBS RORgt+/- and RORgt-/- mice showed clear responses at odor onset 
(Figure 3.18cd). This odor response was absent in GAS-inoculated RORgt+/- mice (Figure 3.18e), 
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and partially restored in GAS-inoculated RORgt-/- mice (Figure 3.18f). This indicates that Th17-
induced neuroinflammation may be particularly damaging to mitral cell function.  
 Individual mitral cells respond to input from only a few glomeruli, so only a fraction of a 
mitral cell population will respond to a given odor. However, the fraction of mitral cells activated 
by any odor should increase with odor concentration as more mitral cells get recruited. 
Calculations of the fraction of active cell-odor pairs for no odor (MO, mineral oil trials) through 
increasing odor concentrations for PBS and GAS-infected RORgt+/- or RORgt-/- mice show that 
mitral cell recruitment to increasing concentration of odor is impaired in GAS-infected RORgt+/-  
 
 
Figure 3.19 Percentage of significantly active cell-odor pairs in female RORgt+/- and RORgt-/- mice after GAS 
infections. a GAS-infected RORgt+/- mice do not show concentration-dependent increases in mitral cell recruitment, 
while control PBS-infected RORgt+/- mice show tonic increase in fraction of cells significantly activated by odor. 
RORgt-/- mice do not show a treatment effect. Data were collected from n=120 cells from 6 recordings in 4 PBS 
RORgt+/- mice, n=140 cells from 7 recordings in 4 PBS RORgt-/- mice, n=130 cells from 7 recordings in 5 GAS RORgt+/- 
mice, and n=144 cells from 4 recordings in 5 GAS RORgt-/- mice represented as mean ± SEM with symbols 
representing independent recordings.  Two-way ANOVA assessed effects of treatment and odor concentration on 
activated mitral cell populations. For RORgt+/- mice, there was a treatment effect (F(1,11)=6.381, p=0.0282) and  
concentration effect (F(3,33)=24.52, p<0.0001) and interaction between treatment and concentration (F(3,33)=10.34, 
p<0.0001). Sidak’s multiple comparisons test revealed differences between PBS and GAS-treated animals at 0.2% 
odor (*p=0.0449) and 1% (****p<0.0001), but not at baseline (MO, p=0.9863) or 0.04% odor (p=0.9987). For RORgt-
/- mice, there was a main concentration effect (F(3,36)=32.42, p<0.0001), but no treatment effect (F(1,12)=2.373, 
p=0.1494), or interaction (F(3,36)=0.6419, p=0.5931). Sidak’s multiple comparisons test indicated no significant 
differences between PBS and GAS-inoculated mice at any concentration. c Firing rate (FR) over the first inhalation 
after stimulus onset for 0.2% mineral oil stimuli remains constant across treatment groups. Data were collected from 
n=120 cells from 6 recordings in 4 PBS RORgt+/- mice, n=140 cells from 7 recordings in 4 PBS RORgt-/- mice, n=130 
cells from 7 recordings in 5 GAS RORgt+/- mice, and n=144 cells from 4 recordings in 5 GAS RORgt-/- mice represented 
as mean (open bars) with trials (dots). One-way ANOVA found no significant differences in firing rate between 
treatment groups (F(3,511)=2.323, p=0.0742).  
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mice (Figure 3.18a). This effect is not observed in RORgt-/- mice, where GAS-infected mice still 
demonstrate concentration-dependent mitral cell recruitment (Figure 3.18b). These effects are not 
due to alterations in baseline firing rate, which remained constant across all four treatment groups 
(Figure 3.18c). This indicates that mechanosensitive mitral cells are responding normally after 
GAS infections, and that mitral cells are still healthy and fire at a normal baseline rate. Changes in 
responsive mitral cell fractions are therefore due to physiological changes in either input from 
OSNs, inflammation-induced disruption in mitral cell processing, or inflammatory effects on other 
cell types participating in olfactory processing (e.g., external tufted cells). 
 Taken together, it is clear that inflammation in the nose after GAS treatment causes frank 
malfunction of OB mitral neurons separated from nasal infection by a layer of synapses. Infiltration 
of Th17 cells from the nose into the surrounding brain parenchyma, and subsequent secretion of 
inflammatory cytokines, is sufficient to affect firing properties of M/T cells in the OB. These 
experiments show that while olfactory circuit function may be preserved in the absence of Th17 
cells, functionally, GAS-infected RORgt-/- mice seem equally hyposmic. There may be a threshold 
of T cell infiltration or cytokine expression that dampens olfactory circuitry function.  
 
3.5 Olfactory circuit deficits after recurrent GAS infections are Th17- and sex-dependent 
Sex effects are well-documented for autoimmune conditions, including Sydenham’s chorea, 
rheumatic fever, PANDAS, and multiple sclerosis. In the mouse model used here, female mice 
demonstrate a Th17-dependent recruitment of T cells to the brain after recurrent GAS infections, 
whereas males do not show this response (Figure 3.3b). Despite smaller initial CNS T cell 
populations in male mice, comparison of cytokine expression profiles from lymphocytes isolated 
from male and female RORgt+/- brains showed similar populations of IL-17A+, IFNg+, and IL-17A+ 
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IFNg+ lymphocytes. Both male and female RORgt-/- mice showed equivalent decreases in IL-17A+ 
and IL-17A+ IFNg+ populations and expansion of the IFNg+ population compared to RORgt+/- mice  
  
Figure 3.20 Heatmaps of mitral cell activation and suppression responses in male mice. a PBS and b GAS-inoculated 
mice mitral cells show relatively normal responses to odor, regardless of treatment and genotype. GAS-inoculated 
RORgt-/- mice appear to have blunted responses to increasing odor concentration, if anything. c, d PSTHs aligned to 
onset of the first inhalation after odor presentation (defined as t=0) in RORgt+/- and RORgt-/- mitral cells. PSTHs are 
averaged for all odor-concentration stimuli, and all groups show odor-evoked firing with stimulus onset. GAS-
inoculated mice in d have elevated baseline firing rate before odor onset, but maintain odor-evoked activity tied to 
stimulus presentation. Data presented as mean ± SEM in c and d collected from n=48 cells from 4 recordings in 3 PBS 
RORgt+/- mice, n=65 cells from 5 recordings in 4 PBS RORgt-/- mice, n=71 cells from 5 recordings in 3 GAS RORgt+/- 
mice, and n=83 cells from 4 recordings in 3 GAS RORgt-/- mice. 
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(data not shown).  It remained unclear whether the T cells that do infiltrate the brain in male 
RORgt+/- and RORgt-/- mice are capable of inciting the same inflammatory damage to olfactory 
processing seen in female RORgt+/- mice after GAS infections. 
 To examine olfactory circuit function in male mice, electrophysiological recordings in the 
mitral cell layer were performed in the same manner as in females. In male mice, 
electrophysiological recordings from mitral cells showed quite different trends than in female 
mice.  In heatmaps of mitral cell activation and suppression by odor stimuli in male mice, all 
treatment groups showed units responding with activation and suppression to odor (Figure 
3.20ab). PSTHs aligned to the first breath after odor presentation show that PBS control mice 
again demonstrate odor-evoked firing at stimulus onset, and both genotypes of GAS-inoculated 
mice show robust odor responses equivalent to control animals (Figure 3.20c). However, firing 
rate before odor onset appears elevated in GAS-inoculated RORgt+/- and RORgt-/- mice (Figure 
3.20d). In male mice, mitral cells show odor-evoked activity regardless of genotype and treatment.  
 Population-level mitral cell responses were then examined more closely to further 
investigate these observations. Recruitment of mitral cells with increasing odor concentration was 
examined by calculating the percent of significantly activated cell-odor pairs for RORgt+/- and 
RORgt-/- mice. RORgt+/- mice effectively recruit mitral cells with increasing concentration of odor 
(Figure 3.21a), but GAS-inoculated RORgt-/- mice show blunted mitral cell recruitment, with a 
significantly smaller fraction of mitral cells responding to high odor concentrations compared to 
PBS RORgt-/- mice (Figure 3.21b). This could be due to either noisier mitral cells that are losing 
stimulus specificity, or a decrease in excitatory input onto mitral cells, causing them to respond 
less robustly to odor. Examination of firing rate during control (mineral oil) trials showed that  
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Figure 3.21 Aberrant mitral cell firing properties with increasing odor concentration in GAS-inoculated male mice. a 
Fraction of mitral cells significantly activated by odor is unchanged between PBS and GAS RORgt+/- mice. Data 
represented as mean ± SEM from n=48 cells from 4 recordings in 3 PBS RORgt+/- mice and n=71 cells from 5 
recordings in 3 GAS RORgt+/- mice. Two-way ANOVA showed a main effect of concentration (F(3,21)=29.14, 
p<0.0001) but not treatment (F(1,7)=3.450, p=0.1056) or interaction (F(3,21)=0.2728, p=0.8443). b RORgt-/- GAS-
inoculated mice showed significantly impaired mitral cell recruitment only at the highest odor concentration. Data 
represented as mean ± SEM from n=65 cells from 5 recordings in 4 PBS RORgt-/- mice and n=83 cells from 4 
recordings in 3 GAS RORgt-/- mice. Two-way ANOVA showed a main effect of concentration (F(3,24)=36.66, 
p<0.0001), no main effect of treatment (F(1,8)=1.793, p=0.2173), and an interaction of concentration and treatment 
(F(3,24)=3.539, p=0.0298). Sidak’s multiple comparisons test revealed a significant difference between PBS and GAS 
only at 1% odor (*p=0.0488). c Baseline firing rate is elevated in GAS-inoculated mice, but PBS control mice have 
equivalent FRs. Data are represented as mean (open bars) with individual trials (dots) from n=48 cells from 4 
recordings in 3 PBS RORgt+/- mice, n=71 cells from 5 recordings in 3 GAS RORgt+/- mice, n=65 cells from 5 recordings 
in 4 PBS RORgt-/- mice, and n=83 cells from 4 recordings in 3 GAS RORgt-/- mice. One-way ANOVA showed 
significant differences between groups (F(3,279)=4.05, p=0.0077); Sidak’s multiple comparisons test showed a 
difference in FR in RORgt-/- mice (**p=0.0042), but not RORgt+/- mice (p=0.3319). 
 
mitral cells in male GAS-infected RORgt-/- mice had higher baseline firing rates (Figure 3.21c). 
While mitral cells in GAS-infected RORgt-/- mice are certainly able to fire, it remains unclear why 
they would respond with less specificity to odor in an inflammatory environment. Future 
experiments could parse whether mitral cells have increased AP threshold after GAS infections, 
or are receiving more or noisier input from OSN terminals or other cell types in the OB. 
 
3.6 Concluding remarks 
 AE syndromes trigger acute neurological and psychiatric symptoms, and are widely 
recognized now that CNS antigens are being validated, yet the mechanisms that underlie antibody-
triggered encephalitis remain poorly understood [11, 220, 231], and it is unclear how 
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autoantibodies breach the BBB to react with neuronal targets [50]. Neuropathological studies have 
shown infiltration of peripheral T cells in the brains of AE patients [246], and we have previously 
shown that GAS-specific Th17 cells enter the brain and are associated with vascular dysfunction, 
neuroinflammation, and synaptic defects in our mouse model of post-infectious BGE [93]. The 
precise contribution of the cellular immune mechanisms to observed neuropathology, as well as 
potential functional deficits, remained unclear. Here, we found that Th17 cells recruited to the 
NALT and OE travel to the brain, where they are required for selective permeability of the BBB, 
neuroinflammation, and olfactory circuit malfunction. It is necessary to consider these findings in 
light of what is known about other CNS autoimmune diseases (specifically MS/EAE), and to 
consider implications for pathogenesis of human AE.  
 Sex effects are described in autoimmunity overall, MS, Sydenham’s chorea, PANDAS, 
and adults with rheumatic heart disease (but not children with rheumatic fever) [17, 150, 267, 273, 
274]. Our original investigations on neuroinflammation used all female SJL/J mice prone to 
autoimmunity [93]. Current investigations using both male and female mice bred in-house 
necessitated investigation of possible sex effects in this model. We discovered that in a C57Bl6/J 
background, the Th17 response to recurrent GAS infections is much larger in female mice than 
males. This mirrors findings in EAE experiments, where female mice in the C57Bl6/J and SJL/J 
backgrounds are more susceptible to disease induction than males [121]. After recurrent GAS 
infections, both female and male mice showed recruitment of Th1/Th17 populations to the NALT 
and brain, but Th17 expansion in both regions was more marked in females than males (Figure 
3.3). There was no difference in T cell infiltration in male brains in the absence of Th17 cells in 
RORgt-/-, indicating that there may be sex-dependent changes in immune responses to pathogens. 
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 Th17 lymphocytes and their effector cytokines mediate host defense mechanisms to 
extracellular bacterial infections, but also underlie pathogenesis of many autoimmune conditions 
[275]. For example, progression of EAE is delayed or blunted, but not completely eliminated, in 
mice where Th17 function or differentiation is compromised [169, 173]. Consistent with this role 
in EAE, Th17 cells play an important role in GAS-induced selective BBB permeability permitting 
antibody entry into the CNS after recurrent GAS infections. However, Th17 cells do not affect 
permeability to smaller molecules, nor the loss of excitatory synaptic proteins in OB glomeruli. 
Th1 lymphocytes present in the brains of GAS-inoculated RORgt-/- mice secrete IFNg, which is 
known to induce tight junction degradation and activate microglia in vitro and in vivo, although 
less efficiently than IL-17A [164, 266, 276]. In addition to IFNg, other cytokines secreted by Th17 
and Th1 may contribute to persistent vascular and neuropathological dysfunction observed in our 
mouse model of post-infectious BGE. Both effector T cell populations are necessary to induce the 
full spectrum of disease pathology, similar to proposed synergistic models of inflammation and 
demyelination in MS/EAE [150]. Targeting CNS Th17/Th1 cells therapeutically may therefore 
mitigate AE disease course. 
 How are distinct T cell subtypes recruited to the brain during multiple GAS infections? In 
EAE, Th17 cell numbers peak in the spinal cord 7 days post-immunization, but Th1 cells are rare 
until day 14 [164]. Adoptive transfer of myelin-specific, ex vivo differentiated Th17 cells induces 
EAE than transfer of Th1 cells, suggesting that Th17 cells predominate during disease initiation, 
but Th1 cells are important for disease maintenance [277]. Recurrent, but not single, GAS 
inoculations in mice induce differentiation of IL-17A+ IFNg+ autoreactive Th17 cells in the nose, 
dependent on IL-6 and TGFb [234, 235]. This T cell population may subsequently recruit other T 
cell subtypes to the CNS as BGE progresses, as in EAE [165]. 
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Figure 3.22 Inflammatory Th17 response after GAS infections drives selective BBB permeability, microglial 
activation, and aberrant mitral cell function. In RORgt+/- mice, top, Th1 and Th17 cells migrate from NALT to brain 
where IL-17A and IFNg initiate BBB breakdown, neuroinflammation, and mitral cell dysfunction. At bottom, RORgt-
/- female mice recruit a Th1 response in the NALT and OE. These Th1 cells then migrate in to the brain, where IFNg 
secretion is less efficient at permeabilizing the BBB, activating microglia, and initiating changes to mitral cell 
processing.  
  
 In female mice, the role of Th17 are clear in inciting neuroinflammation after recurrent 
GAS infections. Th17 serve a non-cell autonomous role in T cell recruitment to the brain from OE, 
as Treg populations in the brain are affected by Th17 deletion (Figures 3.5 and 3.7). Interestingly, 
Tregs are not absent from the brain. The interplay between Th17 and Tregs have been noted in 
various autoimmune disorders, including MS, SLE, rheumatoid arthritis, and thyroid 
autoimmunity, and it would be interesting to examine the effects of Treg deletion in the context of 
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recurrent GAS infections. Exposure of Tregs to IL-1b and IL-6 can override FoxP3 binding 
inhibition to RORgt, allowing a second route to generate Th17 cells from Tregs [278, 279]. 
Disruption of the Treg/Th17 axis could therefore compensate for loss of Th17 cells in RORgt-/- 
mice, and provides a potential mechanism for initiation of GAS-induced autoimmunity. It is 
possible that Tregs serve an important role to limit inflammation after GAS infections, and further 
experiments should address when they are recruited to the OE and brain.  
 The presence of Th17/Th1 lymphocytes in the CNS is associated with BBB permeability 
in post-infectious BGE. Barrier malfunction is an early and persistent feature of 
neuroinflammation, and play a key role in MS/EAE progression, promoting microglial activation 
and thus further entry of peripheral immune cells and antibodies [165, 280]. Our findings reinforce 
the idea that BBB breakdown is not an all-or-none phenomenon, as Th17 cells are not necessary 
for leakage of small molecules or TJ degradation after GAS infections. Th1 cells present in the 
CNS can partially affect barrier permeability, degrading TJ proteins and causing structural 
alterations to a similar degree as Th17 cells, as has been reported for EAE [115]. Th17 cells are 
critical for inducing selective BBB permeability to larger molecules, as their elimination 
significantly reduces extravasation of IgG into the parenchyma after recurrent GAS inoculations. 
Conversely, cytokines secreted by Th17 cells may act indirectly on the endothelium by a different 
mechanism to promote BBB permeability to larger molecules [100, 280]. IL-17A or IL-23, both 
cytokines produced by Th17, may be important for inducing selective transport of larger proteins 
like albumin and IgG.  
 Inflammatory cytokines IL-17A and IFNg secreted by Th17 and Th1 cells lead to local 
production of TNFa, IL-6, and IL-1b in the CNS, sustaining neuroinflammation. Th17 cells are 
more potent activators of microglia, although effects of both Th17 and Th1 can induce expression 
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of MHC class II on microglial membranes [164]. Our findings agree with these results from the 
EAE literature, with reduced microglial activation in GAS-inoculated RORgt-/- mice compared to 
RORgt+/- mice. In addition to their role in immune surveillance, synaptic sculpting in development 
and disease is dependent on microglia [180, 281-283]. Thus, microglial synaptic sculpting may 
partially explain synaptic deficits seen in RORgt+/- mice, as compared to RORgt-/- mice with 
minimal microglial activation (Figure 3.14). 
 Hyposmia and anosmia have been linked to prodromal symptoms in Alzheimer’s disease, 
multiple sclerosis, motor neuron disease, and Huntington’s disease [248, 249, 284]. Immune 
dysfunction in Alzheimer’s disease and MS provide a further link to our mouse model of basal 
ganglia encephalitis with hyposmia [143, 265, 282]. Most convincingly, mouse models of 
Alzheimer’s disease show that complement deposition guides microglia to degrade synaptic 
circuits [282]. Excessive immune infiltration and microglial activation in the OB of GAS-infected 
mice accompany hyposmia; these mice show severe physiological deficits in mitral and tufted 
(M/T) cell responses to odor presentation, consistent with a decrease in vesicular glutamate 
packing protein vGluT2 within glomeruli. While downregulation of vGluT2 in olfactory sensory 
neuron terminals is the parsimonious explanation for reduced neurotransmission in M/T cells, 
vGluT2 is also expressed in external tufted cell dendrites, which are the major drivers of mitral 
cell responses in vitro [285]. It is possible that either OSN terminals or ET dendrites contribute to 
the reduction in vGluT2 within glomeruli. Future experiments comparing responses in external 
tufted cells versus periglomerular cells versus OSN output will distinguish between these two 
possibilities. Nevertheless, vGluT2 loss in OB glomeruli translates to blunted odor responses of 
mitral cells, propagating the effects of intranasal infections down the olfactory processing pathway 
in GAS-infected mice. These deficits are Th17-dependent, but whether Th17 cells act directly to 
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impair neural function, or indirectly via activated microglia or infiltrating autoantibodies remains 
unclear. In the present studies, these deficits are all significantly blunted in RORgt-/- mice, so 
further experiments will be necessary to tease apart the mechanisms of Th17 action. It also remains 
unclear how long these olfactory processing deficits persist after GAS infections, and if the 
changes seen in OB circuits affect more complex olfactory processing dependent on the piriform, 
AON, or amygdala [242, 272].  
 These results indicate that GAS-induced neuroinflammation in mice is dependent on Th17 
cells, and reinforce the multiple hit hypothesis for post-Streptococcal BGE (SC/PANDAS) 
pathogenesis in children. Development of rheumatic fever is directly linked to untreated GAS 
infections, and cross-reactive antibodies generated by these processes can act in the brain to 
interfere with neuronal transmission. However, BBB breakdown is a critical step in this process, 
and the results of experiments described here suggest that Th17 cells generated to fight infection 
in the NALT promote inflammation in the brain as well. Apart from facilitating BBB breach, Th17 
cells may play an independent role in interfering with neuronal signaling. In the future, 
experiments using rodent models of post-infectious BGE should address outstanding questions 
about disease process such as: contribution of paracellular vs transcellular routes of BBB breach 
to antibody delivery to the brain; the potential role of microglia in synapse degradation; and which 
cells are primarily driving vGluT2 loss in olfactory circuit breakdown.  
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Chapter 4: Chemokine signaling via CCL2/CCR2 and CCL20/CCR6 is required for CNS T 
cell recruitment in post-Streptococcal BGE 
4.1 Introduction 
 Immune cell trafficking through blood and lymphatic vasculature is regulated by 
interconnected networks of chemokine ligand/receptor signaling. While chemokines do not 
necessarily share high sequence homology, conserved structural elements link these proteins as a 
family [193]. In neuroinflammation, chemokines are instrumental in recruiting peripheral immune 
cells to the CNS. Monocytes, macrophages, dendritic cells, B cells, and T cells all respond to 
chemokine cues to infections, and then drain back to peripheral lymph nodes. Distinct T cell 
subtypes also express different chemokine receptors, summarized in Figure 4.1, where warmer 
colors indicate higher expression and cooler colors indicate lower expression. Expression of most 
chemokine receptors is very low on naïve T cells, and increases once T cells have differentiated to 
their terminal phenotype [286]. Th17 cells and regulatory T cells (Tregs) express many of the same 
chemokine receptors, while the chemokine receptor profile expressed on Th1 and Th2 cells is 
distinct from the Th17/Treg panel [286]. CCR6 is highly expressed on Th17 and Treg cells. CCR6 
is unique in the chemokine receptor family because it only binds a single ligand, CCL20 [188]. 
CCL20 is expressed at low levels basally in mucosal epithelia, and is upregulated in olfactory 
epithelia under inflammatory conditions [287]. This chemokine axis is an attractive target to 
interfere with recruitment Th17 chemotaxis. In EAE, interfering with CCR6 function or expression 
limits entry of Th17 cells into the CNS via the choroid plexus [129, 165, 245]. CCR6 facilitates 
initial entry of T lymphocytes into the CNS [288]; this first population of T cells then recruit a 
second wave of immune cells to enter through the inflamed BBB [115]. 
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 CCL2 is expressed by astrocytes and neurons in the CNS to signal to microglia in 
inflammatory states [198, 200, 240]. Its receptor CCR2 is expressed by a large number of immune 
cells, including Th1 and Th2 lymphocytes. In the spinal cord in EAE, neuron- and astrocyte-
derived CCL2 efficiently promote homing of Th1 and Th2 to the CNS [200, 289]. While CCR4 
and CCR5 are highly expressed on Th1, Th2, and Th17 cells, the strongest evidence implicating 
CCR4 in CNS autoimmunity shows that it is strongly chemotactic for dendritic cells and 
macrophages rather than T lymphocytes [290, 291]. In EAE, it has been shown that dendritic cells 
  
 
Figure 4.1 Chemokine receptor expression on T cell subsets. Relative expression (arbitrary units) of selected 
chemokine receptors on T lymphocyte subsets, excerpted from [286]. Warmer colors correspond to higher relative 
expression, cooler colors indicate lower expression. 
 
are recruited to the CNS in a CCR2-dependent manner, and then exit via lymphatic drainage guided 
by CCL21/CCL19/CCR7 signaling [146, 201]. CCR2 is also expressed on microglia, which links 
innate and adaptive immunity in the CNS.  
 CCR4 and CCR5 are also highly expressed on Th1, Th2, and Th17 lymphocyte 
populations. The strongest evidence implicating CCR4 signaling in CNS autoimmunity is not 
linked to lymphocyte recruitment, but rather to dendritic cell and macrophage homing in CNS 
autoimmunity [288, 289]. The overarching goal of experiments described in this chapter is to 
investigate the temporal dynamics of T cell entry into the CNS after recurrent GAS inoculations, 
and how chemokines may guide T lymphocytes in this process.  
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4.2 Temporal dynamics of CCL2 and CCL20 expression 
 To assess the temporal dynamics of T cell entry into the CNS over multiple GAS 
inoculations, mice were inoculated intranasally with GAS as described (see Chapter 2), sacrificed 
at 48h after each infection, and  T cell distribution was analyzed as described [93]. T cells 
accumulate gradually in the OB over the course of five inoculations. After 2 infections (2i), there 
is significant infiltration in the brain compared to PBS controls (Figure 4.2). However, the most 
significant increase in T cell numbers was seen at 4i. PBS control mice showed minimal numbers 
of T cells after both 1 and 5 infections, and were pooled for this analysis. Changes in T cell 
infiltration at 2i and 4i correspond to induction of TGFb-1 and IL-6 in NALT, which are both 
essential factors for Th17 differentiation [234, 235].  
 
 
Figure 4.2 T cells accumulate in anterior brain over the course of several infections. Cohorts of mice were sacrificed 
48h after 1, 2, 3, 4, and 5 GAS inoculations (i) and 1 or 5 PBS inoculations, and anterior T cell counts were assessed. 
Left, mean T cell count per 12 µm brain section over 4 sections spanning bregma 4.28-2.46. Schematic at right shows 
brain region analyzed between red and blue vertical lines. Data collected from n=4 mice per group, with PBS 1i and 
PBS 5i groups pooled. One-way ANOVA assessed differences between groups (F(5,22)=17.17, p<0.0001). 
Bonferroni’s multiple comparisons test revealed significant differences between PBS vs GAS 2i (*p=0.024); PBS vs 
GAS 3i (**p=0.0084); PBS vs GAS 4i (****p<0.0001); PBS vs GAS 5i (****p<0.0001); GAS 1i vs GAS 4i 
(**p=0.0018); and GAS 1i vs GAS 5i (****p=0.0009). 
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Previous studies have shown that TGFb (together with IL-6) is necessary for Th17 expansion in 
the NALT after GAS infections; TGFb is significantly upregulated at 2i, and expression remains 
high after subsequent infections [234]. Therefore, upregulation in chemokine expression at 2i and 
4i may be critical for entry of T cells into the CNS. 
 
4.3 Chemokines CCL2 and CCL20 expressed in olfactory tissues after GAS infections 
 We have shown that Th17 cells enter the CNS via the olfactory route to promote 
neuroinflammation and neural circuit damage after recurrent GAS inoculations. In order to identify 
chemokine cues that may recruit T cells from OE to the CNS, 18 candidate chemokine ligands 
were screened for expression changes in olfactory tissues of GAS and PBS mice. OE, OB, and 
NALT tissue were harvested at 6 h and 48 h after the fifth infection, and cDNA was generated 
from RNA isolated from these tissues. We then performed qRT-PCR on OB cDNA first to assess  
 
 
Figure 4.3 qRT-PCR screen for chemokine and cytokine expression after recurrent GAS infections in olfactory 
tissues. a Screen in olfactory bulb cDNA from control and recurrently infected mice sacrificed at 6 h and 48 h after 
the final GAS infection revealed candidates CXCL5, CXCL13, CCL2, and CCL20. Data represented as mean from 
n=4 PBS 6 h, n=4 PBS 48 h, n=3 GAS 6 h, and n=4 GAS 48 h. b Probing NALT and olfactory epithelium cDNA 
showed significant upregulation at different time points for CCL2 and CCL20, with only slight changes in 
expression of CXCL5 and CXCL13. All data are relative to b-actin, then normalized to PBS expression. Data 
represented as mean ± SEM from n=4 per group with matched OE and NALT samples. 
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chemokine ligands differentially expressed in brains of PBS and GAS-inoculated animals (Figure 
4.3a). We identified upregulation of CXCL5, CXCL13, CCL2, and CCL20 (vertical arrows) in OB 
cDNA from GAS-inoculated mice compared to PBS controls. These ligands are implicated in T 
cell chemotaxis [98, 201, 265]. Inflammatory cytokines IL-6, IFNg, TNFa, and IL-1b were also 
significantly upregulated in the OB of GAS-inoculated mice compared to PBS controls. These 
cytokines are a known signature of bacterial GAS infection in olfactory tissues, and served as 
positive controls. Expression of chemokines that were upregulated in the OB of GAS-infected 
mice was then analyzed in NALT and olfactory epithelium. While changes in CXCL5 and CXCL13 
expression in NALT and OE were modest, CCL2 was highly upregulated in NALT and OE at 6 h 
after 5 infections, and CCL20 was upregulated in NALT at 6 and 48 h and in OE at 6 h (Figure 
4.3b). These data two candidate chemokines may play a role in T cell recruitment to the brain after 
recurrent GAS infections.  
 
Figure 4.4 Olfactory expression of CCL2 and CCL20 confirmed by in situ hybridization. Olfactory epithelia and 
olfactory bulb of control and GAS-infected mice probed for CCL2 and CCL20 at different points after 1, 2, or 5 
infections (1i, 2i, 5i). Expression of CCL20 is visible in GAS-infected OE at all time points, while CCL2 is only 
expressed after 5i. In brain, CCL20 is expressed after 2i and 5i, while CCL2 expression was not detected in brain at 
any time point. Scale bar = 100 µm. 
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 Expression of CCL2 and CCL20 mRNA was confirmed in olfactory tissues by in situ 
hybridization. CCL20 is expressed in OE at all time points examined after GAS infections, while 
OE expression of CCL2 is robust at 6 h after 5i (Figure 4.4). Its expression returns to baseline by 
48 h after 5i, and appears to span the olfactory sensory neuron layer. In the olfactory bulb, CCL20 
is detectable at 6 h after 2i, but is absent at later timepoints. After 5 infections, expression in the 
brain is robust and persists to 48 h. CCL2 was not detected in brain at any time point. These data 
indicate that temporal dynamics of chemokine expression may induce migration of different T cell 
subsets over time both after each infection and with increasing infection number. There was only 
minimal expression of CCL2 and CCL20 mRNA in PBS-inoculated tissues at all time points 
(Figure 4.4). 
 
4.4 CCR2 and CCR6 guide T cells into the CNS after recurrent GAS inoculations 
 Interfering with CCL20/CCR6 chemokine signaling in EAE delays disease onset and 
lessens clinical severity due to reduced Th17 cell chemotaxis into the CNS [245, 292]. Since 
CCL20 is upregulated in OE, NALT, and brain after 5 GAS inoculations, we tested the role of 
CCL20/CCR6 signaling in T cell recruitment to the CNS after multiple GAS inoculations using 
CCR6-deficient mice.  CCR6+/-, CCR6-/-, and WT littermates were recurrently infected with GAS 
and analyzed for T cell trafficking into the CNS. After recurrent GAS infections, CCR6+/- mice 
showed reduced T cell infiltration (65% of WT), but surprisingly, CD4+ T cell numbers in CCR6-
/- mice were equivalent to WT (Figure 4.5a). CCL20 is upregulated in brain tissue after only two 
infections (Figure 4.4), giving ample time for compensatory signaling changes. Since CCR6 is 
highly expressed on Th17 cells (Figure 4.1), we investigated whether the Th17 cell fraction was 
affected in CCR6+/- and CCR6-/- mice after GAS infections by crossing CCR6 knockout mice to 
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RORgt-GFP mice, generating progeny with fluorescently labeled Th17 cells and lacking CCR6 
expression. After recurrent GAS infections, we saw equivalent Th17 fractions in the brains of 
CCR6+/- RORgt+/- and CCR6-/- RORgt+/- (37.5% in CCR6+/- RORgt+/- and 37.7% in CCR6-/- 
RORgt+/-, Figure 4.5b). The Th17 fraction in these mice was similar to Th17 fraction in CCR6+/+  
 
 
Figure 4.5 Blunted T cell infiltration in CCR6 chemokine receptor mutant mice.. a CCR6+/- and CCR6-/- brain CD4+ 
T cell counts along the rostrocaudal axis. Total T cell counts are reduced by 38% in CCR6+/-, and increased by 145% 
in CCR6-/- mice compared to WT. Data represent mean ± SEM from n=5 WT, n=9 CCR6+/-, and n=7 CCR6-/- animals. 
Dashed red and blue lines correspond to locations in the brain as denoted in the schematic c. b CD4+ GFP+ Th17 cells 
were counted in CCR6+/- ROR+/- and CCR6-/- ROR+/- brains after GAS inoculations. Data represent mean ± SEM from 
n=4 CCR6+/- ROR+/- and n=3 CCR6-/- ROR+/- mice. Th17 fraction was not significantly different between genotypes 
by Student’s t-test (t=0.02672, p=0.9797). 
 
 
RORgt+/- brains (~34%). This implies that Th17 cells may use other chemokines in addition to 
CCL20/CCR6 pathway to migrate from the OE/NALT to the CNS. 
 We then investigated the effect of CCL2/CCR2 signaling on T cell recruitment to the brain 
after GAS infections. Since CCL2 is upregulated in OE after 5i, that this signaling axis might have 
a more modest effect on T cell infiltration than CCL20/CCR6 signaling. To this end, we analyzed 
T cell numbers in the brains of WT, CCR2+/- and CCR2-/- mice after 5 GAS infections. T cell 
infiltration was reduced in both CCR2+/- (by 53.3%) and CCR2-/- (by 44.7%) brains compared to 
WT (Figure 4.6a). In contrast to CCR6 mutants, loss of one or both alleles of CCR2 shows a  
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Figure 4.6 CCR2 signaling recruits T cells to the brain, but does not affect T cell differentiation. CCR2+/- and CCR2-
/- brain CD4+ T cell counts along the rostrocaudal axis. T cell counts are reduced by 53% in CCR2+/- and 45% in CCR2-
/- mice compared to WT. Data represent mean ± SEM from n=5 WT, n=6 CCR2+/-, and n=6 CCR2-/- animals. b 
Cytokine expression in brain CD4+ lymphocytes was equivalent between WT, CCR2+/-, and CCR2-/- mice. Data 
represent mean ± SEM from n=3 WT, n=2 CCR2+/-, and n=3 CCR2-/- animals. Two way ANOVA showed a significant 
main effect of cytokine (F(2,10)=17.64, p=0.0005), but no main effect of genotype (F(2,5)=1.044, p=0.4181). c 
Cytokine expression in NALT/OE CD4+ lymphocytes was equivalent between WT, CCR2+/-, and CCR2-/- mice. Data 
represent mean ± SEM from n=3 WT, n=2 CCR2+/-, and n=3 CCR2-/- animals, matched to brain samples. Two way 
ANOVA showed a significant main effect of cytokine (F(2,10)=19.14, p=0.0004), but no main effect of genotype 
(F(2,5)=1.744, p=0.2663).  
 
similar effect on T cell trafficking, indicating that any disruption of CCL2/CCR2 signaling impairs 
T cell chemotaxis into the brain. To examine whether CCL2/CCR2 signaling affects recruitment 
of distinct lymphocyte subtypes to NALT or brain after recurrent GAS infections, or differentiation 
in the NALT,  we examined subtype distributions by cytokine expression (IFNg+ vs IL-17A+ vs 
IL-17A+ IFNg+) using flow cytometry (Figure 4.6bc). Disruption of CCR2/CCL2 signaling did 
not affect specification of T cell subtypes in peripheral lymphoid tissue (NALT). Although T cell 
numbers were reduced in CCR2+/- and CCR2-/- brains, there was no difference in populations of 
distinct subtypes, suggesting that their recruitment to the CNS is equally affected by loss of this 
signaling pathway (Figure 4.6b). Taken together, these data indicate that CCR2 signaling 
contributes to CNS T cell homing, but not differentiation, after recurrent GAS inoculations. 
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 To determine whether CCL2 and CCL20 signaling may crosstalk to recruit T cells to the 
CNS after GAS inoculations, CCR6+/- and CCR2+/- mice were interbred to generate mice lacking 
3 or 4 alleles from both chemokine receptors. The resulting progeny (CCR6+/- CCR2+/-, CCR6+/- 
CCR2-/-, and CCR6-/- CCR2-/-) were infected with GAS as described, and T cell populations in the  
 
 
Figure 4.7 Interrupted chemokine axes influence T cell homing to brain. a Immunostained OB sections from CCR6+/- 
CCR2+/- (left), CCR6+/- CCR2-/- (center), and CCR6-/- CCR2-/- (right) brains for CD4 (green), GLUT1 (red) and DAPI 
(blue). CD4+ T cells (arrows) are numerous in glomerular and granular layers of CCR6+/- CCR2+/- and CCR6-/- CCR2-
/- brains, with less infiltrate in OB layers in CCR6+/- CCR2-/- brains. In all cases, there are more T cells in the glomerular 
and olfactory nerve layers than the granular layer. b Mean CD4+ T cell count from three olfactory bulb tissue sections 
in WT, CCR6+/- CCR2+/-, CCR6+/- CCR2-/-, and CCR6-/- CCR2-/- brains. Data represent mean ± SEM from n=5 WT, 
n=6 CCR6+/- CCR2+/-, n=6 CCR6+/- CCR2-/-, and n=5 CCR6-/- CCR2-/- mice. One-way ANOVA revealed a genotype 
effect (F(3,18)=6.778, **p=0.003). Tukey’s MC test revealed significant differences in WT vs CCR6+/- CCR2+/- 
(*p=0.0205); and WT vs CCR6+/- CCR2-/- (**p=0.0019). c CD4+ T cell distribution along the rostrocaudal axis in WT 
(black), CCR6+/- CCR2+/- (blue), and CCR6+/- CCR2-/- (green) brains. Dramatic reduction in T cell counts is clear in 
CCR6+/- CCR2-/- brains in anterior and posterior regions. d CD4+ T cell distribution along the rostrocaudal axis in WT 
(black) and CCR6-/- CCR2-/- (gray) brains. Chemokine receptor double knockout mice have a modest reduction in T 
cell counts, but less dramatically than genotypes represented in c. Dashed vertical red and blue lines (c, d) correspond 
to locations denoted in the brain schematic (lower right). Scale bar = 20 µm. 
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brain were analyzed and compared to WT mice. There was a significant reduction in numbers of 
CD4+ T cells in brains of mice lacking 3 or 4 alleles of CCR2 and CCR6 when compared to WT 
controls (Figure 4.7ab). This decrease was most notable in and CCR6+/- CCR2-/- mice within the 
glomerular layer of the OB (white arrows). T cells were not associated with blood vessels (labeled 
with GLUT1), and most have clearly infiltrated the brain parenchyma. Comparison of average T 
cell counts in OB sections in chemokine receptor allele knockouts show that loss of any 
combination of chemokine receptor alleles results in a significant reduction in T cell populations 
in OB tissue sections (Figure 4.7b). CCR6+/- CCR2+/- and CCR6+/- CCR2-/- have significantly 
reduced OB T cell counts compared to WT (31.9% and 13.8% of WT levels, respectively). OB T 
cells in CCR6-/- CCR2-/- mice are reduced to 40.0% WT levels. The difference in T cell counts 
between CCR6+/- CCR2+/- and CCR6+/- CCR2-/- mice is most clear in OB sections, but T cell 
populations in posterior brain regions are reduced as well in CCR6+/- CCR2+/- and CCR6+/- CCR2-
/- compared to WT (Figure 4.7c). This indicates that CCL2/CCR2 signaling may contribute to 
initial entry of T cells into anterior regions of the brain, as full loss of CCR2 in the CCR6+/- 
background more strongly affects anterior T cell populations; CCRL20/CCR6 may play a larger 
role in chemotaxis to posterior brain regions. Finally, CCR6-/- CCR2-/- have modest reductions in 
anterior T cell populations, and the loss of posterior T cells is less marked than in CCR6+/- CCR2+/- 
and CCR6+/- CCR2-/- brains (Figure 4.7d). There may be compensation for loss of CCR6 in the 
CCR2 axis, and when CCR2 is eliminated, T cells are particularly limited in migration into anterior 
brain regions.  
 Since loss of alleles from both chemokine receptors CCR6 and CCR2 results in reduced T 
cell trafficking into the CNS after recurrent GAS inoculations, we analyzed the consequences of 
limited CNS T cell populations on neuroinflammation. We assessed microglial activation in the 
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glomerular layer of the OB after recurrent GAS infections in WT, CCR6+/- CCR2+/-, CCR6+/- 
CCR2-/-, and CCR6-/- CCR2-/- mice. Microglia were highly ramified in CCR6+/- CCR2-/- brains, and 
more amoeboid in WT, CCR6+/- CCR2+/-, and CCR6-/- CCR2-/- brains (Figure 4.8a). Quantification 
of CD68+ Iba1+ microglia in each genotype revealed that CCR6+/- CCR2-/- brains have significantly  
 
Figure 4.8 Attenuated neuroinflammation in chemokine receptor mutants. Microglial activation after recurrent GAS 
infections in CCR6/CCR2 chemokine receptor mutant mice. a Olfactory bulb microglia from WT, CCR6+/- CCR2+/-, 
CCR6+/- CCR2-/-, and CCR6-/- CCR2-/- mice shown using immunohistochemistry for Iba1 (red), CD68 (green) to mark 
microglial lysosomes, and DAPI (blue). Ramified resting microglia are seen in CCR6+/- CCR2-/- brains (arrowheads), 
and amoeboid CD68+ microglia are seen in WT, CCR6+/- CCR2+/-, and CCR6-/- CCR2-/- brains (arrows). b 
Quantification of average CD68+ Iba1+ microglia counts from three 12 µm OB tissue sections in PBS WT, GAS WT, 
CCR6+/- CCR2+/-, CCR6+/- CCR2-/-, and CCR6-/- CCR2-/- brains. Data represent mean ± SEM from n=4 PBS WT, n=4 
GAS WT, n=6 CCR6+/- CCR2+/-, n=4 CCR6+/- CCR2-/-, and n=4 CCR6-/- CCR2-/- mice. One-way ANOVA revealed a 
significant effect of genotype (F(4,17)=21.21, p<0.0001). Tukey’s multiple comparisons test showed significant 
differences between GAS WT and CCR6+/- CCR2-/- (*p=0.0196), PBS WT and GAS WT (p<0.0001), PBS WT and 
CCR6+/- CCR2+/- (p<0.0001), PBS WT and CCR6+/- CCR2-/- (p=0.0009), and PBS WT vs CCR6-/- CCR2-/- (p<0.0001). 
Significance lines to PBS WT are omitted on the graph for clarity. Scale bar = 20 µm. 
 
fewer activated microglia than WT, indicative of less  neuroinflammation (Figure 4.8b). However, 
microglial activation in CCR6+/- CCR2-/- brains does not return to the level of PBS controls, 
indicating some residual neuroinflammation, possibly due to complement-mediated inflammation, 
infiltrating monocytes and macrophages, or cytokines from remaining, albeit few, infiltrating T 
cells.  
  
4.5 Concluding remarks 
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 Chemokine cues are critical for recruiting T cell populations to the site of inflammation 
and infection by invading pathogens. In neuroinflammatory disease, these chemokine cues are co-
opted to recruit T cells to inflamed, yet sterile, brain, where they secrete inflammatory cytokines 
and incite damage to the surrounding tissue. In these experiments, a targeted screen identified 
CCL2 and CCL20 as chemokine candidates that recruit T cells to the brain from the OE after GAS 
infections. CCL20 is an important chemokine in the context of EAE, and is highly upregulated in 
the choroid plexus before disease onset to facilitate Th17 infiltration via the choroid plexus [188, 
197, 287, 292]. CCL2/CCR2 signaling is critical for recruiting immune cells to the CNS in EAE 
[201]. After recurrent GAS inoculations, these chemokines both serve to drive lymphocytes from 
the NALT/OE to the brain. Chemokine expression in olfactory epithelium and brain changes over 
the course of five i.n. GAS infections, and rapid changes in ligand expression probably drive 
expansion of different T cell subsets.  
 
Figure 4.9 Olfactory tissues in close proximity within the skull. Schematic representation of olfactory tissues, left, 
show close proximity of olfactory epithelium to the brain. Right, olfactory epithelium covers olfactory turbinates in 
the nose. Olfactory sensory neurons are supported by a variety of tissues and cells in the OE. 
 
 In the olfactory epithelium, chemokine cues are expressed by several different cell types, 
but signals are frequently seen in the sustentacular layer most superficial, and in the basal lamina 
at the base of the olfactory sensory neuronal layer (Figure 4.9). Pathogens are cleared from the 
nasal lumen after neutralization by the action of cilia on the mucus covering the sustentacular 
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layer. Chemokine gradients control immune cell entry and egress from lymph nodes as well as 
homing to sites of infection. These gradients are maintained by tethering the secreted chemokines 
to glycoproteins on vascular surfaces [188, 195]. This eliminates the need to continually refresh 
chemokine gradients, and prolongs their signaling power. Interference with these glycoproteins 
that tether and maintain chemokine gradients could provide a useful target for limiting trafficking 
of T cells into the brain. 
 Chemokine signaling adapts rapidly to changes in immune status. CNS T cells both 
accumulate slowly over the first four infections, and persist in the brain up to 56 days post-infection 
[93], making chemokine signaling a dynamic process that shapes the immune profile in the brain  
over the course of repeated infections. Indeed, in situ hybridization for CCL20 shows that it is and 
CNS, as their cognate receptors are expressed on different T cell populations. Therefore, it follows 
that early induction of TGFb and IL-6 after 2 infections [234, 235] skew NALT and OE T cell 
populations to Th17, which are also recruited by CCL20 signaling. Following expansion of the 
Th17 population, Th1 cells respond to later induction of CCL2 signaling. As this was a limited 
screen that only examined a subset of all chemokines, it is possible that other chemokines recruit 
T cells to the OE or OB. Future experiments could examine differences between the T cell 
populations in the nose vs the brain by RNAseq, which would provide a true unbiased view of 
chemokine receptor expression on these populations, and give a clear idea of what may be 
recruiting T cells differentially to the OE or brain. 
 These experiments also show that near-elimination of T cell entry to the brain (in CCR6+/- 
CCR2-/- mice) does not abrogate microglial activation to the same extent (Figure 4.8). Therefore, 
the immune cells that do enter the brain seem capable of initiating some microglial activation, 
probably by secreting inflammatory cytokines known to activate microglia [164]. It is possible that  
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Figure 4.10 Chemokine expression influences T cell homing to the CNS after recurrent GAS inoculations. CCL20 
and CCL2 are robustly upregulated in the NALT and olfactory epithelium, while CCL20 is expressed periglomerularly 
in the olfactory bulb. Disruption of CCL2/CCR2 and CCL20/CCR6 signaling does not fully calm neuroinflammation 
by activated microglia. 
 
microglia are activated via innate immunity, as the complement cascade is initiated in the OE in 
response to GAS infections. Complement activity may also spread to the CNS, where C1q and C3 
may deposit in the OB. Microglia (and potentially infiltrating macrophages) express the C3 
receptor and C1qR, allowing complement deposition to activate these cell types. While brain T 
cell subtype distribution is unchanged in CCR2+/- and CCR2-/- brain, NALT, and spleen CD4+ 
populations by flow cytometry (Figure 4.6bc, spleen data not shown), and GFP+ CD4+ Th17 
populations were equivalent to WT in CCR6+/- and CCR6-/- OBs by immunohistochemistry 
(Figure 4.5b), disruption of both CCR6 and CCR2 signaling may differentially homing of T cell 
subtypes. Determining the identity of the T cells that do enter the brain in CCR6+/- CCR2-/- mice 
could provide a mechanistic explanation for reduced but not rescued microglial activation, as IFNg 
produced by Th1 cells is less efficient at activating microglia than IL-17A from Th17 cells.  
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 Recruitment of monocytes and macrophages to the CNS in EAE depends on CCR2/CCL2 
signaling [150, 168, 240, 290, 293]. Peripheral macrophages extravasate through the endothelium 
and sometimes arrest at the basement membrane in the perivascular (Virchow-Robins) space, 
where their secretion of inflammatory cytokines (e.g., IL-12, TNFa) may further permeabilize the 
BBB [294]. In WT mice, microglial activation is robust and Th17-dependent; interfering with 
CCL2/CCR2 signaling may also alter microglial chemotaxis and proliferation to OB glomeruli, 
where their activation after recurrent GAS inoculations is high. Additionally, we cannot discount 
the possibility that peripheral monocytes and macrophages are recruited to the OB via CCL2 
signaling. Monocytes and macrophages are potent phagocytes, and co-infiltrate the spinal cord in 
EAE along with adaptive immune cells [294]. It is possible that the innate immune system drives 
a portion of the neuroinflammation observed after recurrent GAS inoculations; indeed, the spread 
of macrophages from the OE to OB would complement the infiltration of T cells in the CNS.   
 Chemokine signaling plays an important role in recruitment of T cells to the site of 
infection in the OE, and our results indicate that T cells respond to chemokine cues to home to the 
CNS. CCL2/CCR2 and CCL20/CCR6 signaling synergize to recruit T cells to the brain after 
recurrent GAS inoculations, although the timing of when particular T cell subtypes might be 
responding to each chemokine ligand remains unclear. Importantly, disruption of chemokine 
signaling did not interfere with differentiation of T cells in the NALT, which might limit 
therapeutic use of targeting chemokine signaling to minimize contributions of specific pathogenic 
T cell subtypes in the brain. However, we cannot discount the possibility that other chemokine 
cues compensate for disruption of one chemokine signaling axis, especially after recurrent 
infections. Chemokine signaling may be important for initiating microglial and macrophage 
activation per se in the CNS, as has been shown in vitro [289]. Limiting T cell entry to the brain 
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by chemokine disruption would also reduce overall cytokine burden, thereby explaining the 
reduction in activated microglia. Taken together, these data provide a solid foundation for further 
exploration of T cell chemotaxis after recurrent GAS inoculations. To translate these findings to 
post-infectious BGE, it will be essential to determine inflection points for various chemokine 
ligands during disease progression. 
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Chapter 5: General discussion 
 The CNS has long been thought to be immune-privileged; however, recent studies have 
demonstrated active immune surveillance of the CNS basally and in disease states [87, 148, 192], 
and new mechanisms of autoimmunity against brain targets have been identified [6, 177]. 
Discovery of anti-NMDA receptor antibodies as the causative agent in abrupt-onset psychosis in 
young adults (particularly women) lent strength to the hypothesis that autoimmunity can and does 
target the brain [4]. Other targets of autoimmunity have been recently identified, including synaptic 
proteins like the AMPA receptor, GABABR, and GABAAR as well as intracellular antigens 
GAD65, amphiphysin, LGI1, and Caspr2 [22, 246]. Predisposition to some AE syndromes is 
linked to specific HLA alleles, the presence of tumors ectopically expressing neural proteins, and 
some infections. One particularly pressing step in AE pathogenesis remained unexplored: namely, 
how autoantibodies generated in the periphery enter the CNS to react with their neuronal targets.  
 Here, we demonstrated a vital contribution of the adaptive immune system to 
neuroinflammation induced in a mouse model of post-infectious basal ganglia encephalitis. 
Recruitment of Th17 cells to the olfactory epithelium and NALT to combat GAS infection 
generates populations of lymphocytes that traffic into the CNS in a sex- and Th17-dependent 
manner. Infiltrating lymphocytes secrete inflammatory cytokines known to damage the blood-
brain barrier and activate microglia; the resulting barrier permeability is size-restricted and 
supports previous findings indicating separate regulation of transcellular and paracellular BBB 
permeability. Olfactory circuitry is profoundly affected by infiltrating T cell populations, and we 
observed profound mitral cell dysfunction in female mice where IL-17A-secreting cells comprise 
a large portion of lymphocytic infiltrate (Chapter 3). T lymphocyte infiltration and microglial 
activation are also regulated in part by CCR2 and CCR6 chemokine receptor signaling (Chapter 
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4). Below, these findings are discussed within broader contexts in the fields of immune cell 
trafficking, BBB structure and function, neuroinflammation, and genetic contribution to CNS 
autoimmunity. 
 
5.1 T cell homing depends on concentration gradients of many signaling molecules 
 Homing of T cells to the site of either infection or autoimmune disease is a multi-step 
process that involves interaction of different signaling pathways. In these experiments, we 
identified CCL2 and CCL20 upregulation in olfactory tissues after recurrent GAS inoculations. 
Altering the expression of the cognate chemokine receptors CCR2 and CCR6 interfered with T 
cell homing to the CNS, but not differentiation of T cell subtypes in lymphoid tissue after GAS 
inoculations. Microglial activation was also reduced in CCR6+/- CCR2-/- mice with limited T cell 
populations. Chemokine gradients control monocyte egress from bone marrow, T cell homing to 
infection in the NALT, OE, and OB, and drainage of immune cells to peripheral lymph nodes for 
T and B cell direction to antigen [146, 193, 198, 201, 240, 290, 295]. As discussed previously, 
chemokine signaling plays a large role in immune cell homing to the CNS in neuroinflammation, 
but chemokine signaling pathways are notoriously redundant and promiscuous [193]. 
Lysophospholipid sphingosine-1-phosphate receptor (S1PR) signaling controls T cell egress from 
lymph nodes, and has been shown to sequester activated T cells in lymph nodes in EAE, as well 
as limiting upregulation of transcytotic BBB permeability [121]. FTY720, a lipophilic structural 
analog of S1P, can cross the BBB, binds 4 of the 5 S1PR isoforms, and has been approved for use 
in human MS patients [296]. S1PR signaling links BBB permeability with T cell entry into the 
CNS in inflammation, but its potential role in AE syndromes remains unexplored.  
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 Interplay between neuroinflammation and autoantibody binding would be better 
understood with in vivo experiments where all cell types are present and may be manipulated with 
genetic tools. CCL2 activation of CCR2 on both microglia and neurons is implicated in the 
pathogenesis of neuropathic pain and itch sensation in spinal neurons [297, 298]. This provides 
evidence that neuronal activity can be directly modulated by inflammatory chemokines. It remains 
to be determined whether chemokines secreted mainly in the OE, but present at lower 
concentrations in the OB, directly modulate neuronal firing in vivo, or even what cell types secrete 
CCL2 detected in the OB after recurrent GAS infections. Because CCR2 is expressed on many 
cell types, determining the cellular components of CCL2/CCR2 interactions requires finer tools 
than the global receptor knockout lines used here. Selective deletion of CCR2 expression using 
specific genetic driver lines could define what cells actively signal through this chemokine axis 
during T cell chemotaxis. 
 Eph/Ephrin signaling has been implicated in both NMDARE pathogenesis, by tethering 
NMDAR to the synapse [208, 213], and in EAE, regulating T cell chemotaxis to the CNS [170]. 
Increased EphrinB2 signaling in NMDARE antibody-exposed mice ameliorates memory deficits, 
while deletion of EphrinB2 ameliorates Th1/Th17 differentiation and migration in to spinal cord 
lesions. These findings may be explained by differential roles of Eph/Ephrin signaling in the 
humoral and cellular adaptive immune system. It is possible that B cells and T cells express 
different Eph receptors, or are activated by different Ephrin ligands. Eph and Ephrin signaling may 
contribute to the pathogenesis of other AE syndromes. However, if its sole role in NMDARE 
pathogenesis is maintenance of NMDAR synaptic localization, Ephrins would not necessarily play 
a similar role in scaffolding other neurotransmitter receptors during AE pathogenesis.  
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5.2 Sex specificity in immune and circuit-level processing deficits  
One prominent question raised in our recurrent GAS infection model is the presence of sex 
differences at several levels of pathogenesis. Autoimmune disease as a whole is skewed towards 
females, which holds true for many individual autoimmune diseases including MS, rheumatic heart 
disease, and Sydenham’s chorea [267, 299]. Our results support hyperactivity of the Th17 axis in 
females, as female mice recurrently inoculated with GAS showed Th17-driven CNS lymphocyte 
infiltration that was absent in males (Figure 3.3). Given that these autoimmune diseases have 
reported Th17 pathology, CNS pathology we observe may be part of a larger pattern of 
predisposition to autoreactive Th17 phenotypes in females.  
 Rheumatoid arthritis (RA) is another Th17-driven autoimmune disease which manifests 
more severely in females than males, which holds true in animal models of the disease [300, 301]. 
Patient-derived samples, and in vivo and in vitro data on pathogenesis of RA provide mechanistic 
insight into sex differences observed in Th17-driven autoimmunity. Regulation of T cell 
differentiation by PPARg is sexually dimorphic and estradiol-dependent, and Th17 differentiation 
in particular upon PPARg induction was more efficient in female splenocytes than in male 
splenocytes [302]. In a rat RA model, both overall populations of Th17 cells, and Th17 
differentiation into autoreactive Th17 (IL-17A+ IFNg+) were elevated in females compared to 
males, correlating with symptom severity [301]. Analysis of T cell subtypes circulating in male 
and female RA patients indicate that anti-inflammatory Th2 cells are more numerous in male 
patients, perhaps indicating that in males, anti-inflammatory factors function more efficiently 
[300]. Strain and sex differences have been observed for EAE susceptibility, due in part to 
sphingosine-1-phosphate receptor-2 (S1PR-2) expression, which varies with strain and sex and has 
   118 
been shown to regulate breakdown of adherens junctions and increased rates of caveolar 
transcytosis during disease [121].  
 Sex differences in neuropathology after GAS inoculations extend to physiological deficits 
observed in mitral cell processing. A recent study showed that combinations of activated glomeruli 
(representing odor identity) in female mice were more dissimilar for different odors, and that these 
differences were processed faster by OSNs, compared to male mice. Gonadectomy in female mice 
slowed OSN processing and made glomerular processing more broadly tuned, while 
gonadectomized male mice showed faster processing and sharper glomerular odor maps  [303]. At 
the onset of infections (3-4 weeks of age) mice are sexually immature, but by the end of the 
infection paradigm (~8 weeks of age), mice have sexually matured and would presumably show 
sexually dimorphic processing speed by OSNs. With recurrent inflammation in the OE and, later, 
in the OB by infiltrating immune cells, it seems likely that the time during which infections are 
taking place might interfere with olfaction later in life. It remains to be seen how olfactory 
processing might be affected long term after cessation of recurrent GAS infections, and whether 
olfactory deficits might be ameliorated.  
 The quality of changes observed in mitral cells after recurrent GAS infections is interesting 
in and of itself. In females, loss of sharp odor-evoked mitral cell responses is Th17-dependent, 
whereas no such Th17 dependence exists in male mice (Figures 3.18 and 3.21). OSN function is 
impaired after genetically induced expression of IFNg or TNFa by sustentacular cells in the OE, 
resulting in OSN apoptosis and OE inflammation; importantly, olfactory deficits are apparent 
before OSN death [304, 305]. Prednisone treatment to limit secondary inflammation does not 
restore olfactory sensory function [305]. Inflammation in the nose is therefore sufficient to 
interfere with OSN function. While these studies did not examine later steps in the olfactory 
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processing circuit, EAE studies examining lesion formation in the OB and olfactory function are 
informative [306]. In EAE, not only do T cells and DCs populate the OB [202], but frank lesion 
formation in the OB was associated with olfactory behavioral deficits [306]. Our results support 
the conclusion that olfactory function is differentially affected by inflammation in males and 
females, and that the action of Th17 cells plays a larger role in shaping responses in females. In 
male mice, however, Th17 are dispensable, and it appears that IFNg+ Th1 cells alone are sufficient 
to affect olfactory circuit function (Figure 3.21). In male RORgt-/- mice, we posit that noisy OSNs 
drive increased firing in external tufted and mitral cells, resulting in both elevated baseline firing 
rate of mitral cells and may drown out odor-specific firing of OSNs. Further experiments are 
needed to determine what cells drive observed phenotypes in olfactory response to intranasal 
infection in both sexes.   
 Other groups have described changes in neurotransmitter metabolite concentrations in 
prefrontal cortex after GAS exposure [232], but no investigation of in vivo neuronal function has 
been performed to date. Although recordings from slice preparations or dissociated neurons 
exposed to autoantibodies have clarified mechanisms of autoantibody binding to individual 
receptors and neurons [19, 58, 231], but how these individual antibody binding events may affect 
circuit level function remains unexplored. Furthermore, circuit analyses represent a crucial step in 
translating molecular events to behavioral findings. Recordings from awake, behaving animals can 
be technically challenging, but they do represent a necessary step in understanding how BBB 
breach and entry of brain-targeting autoantibodies might interfere with neuronal signaling and 
cause some behavioral and molecular findings that have been reported [80, 205, 206]. Our 
experiments here show that molecular-level loss of vGluT2 in excitatory OB glomerular synapses 
leads to circuit-level dysfunction in OB mitral cells that may be mediated by external tufted (ET) 
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cells, which are the principal contributors to mitral cell output in vitro (Figures 3.14, 3.17, 3.18, 
3.19) [285]. Inflammation certainly plays an essential role in this circuit, where we showed 
profound microglial activation and BBB dysfunction (Figures 3.9, 3.13). While Th17 cells were 
dispensable for behavioral hyposmia (Figure 3.15), they were necessary for inducing significant 
mitral cell dysfunction (Figure 3.19), which may represent a byproduct of inflammation or direct 
action of Th17 cytokines on mitral or ET populations.  
 
5.3 Size- or route-dependent BBB dysfunction induced by Th17 lymphocytes 
 Breakdown of the BBB can occur via several cellular and molecular mechanisms. ECs 
express tight junction proteins at their apical side, sealing together spaces between adjacent cells. 
In an inflammatory environment, cytokines secreted by immune cells can act both directly and 
indirectly on TJ complexes to destabilize them [90, 94, 100, 266, 270, 280]. This permits 
paracellular permeability. Basal rates of transcytosis by Caveolin1+ vesicles, macropinocytosis, 
and receptor mediated vesicular transport are also very low in ECs, but inflammation causes 
upregulation of vesicular transport and transcellular permeability [90-92, 107, 108]. These two 
pathways (paracellular and transcellular) seem to operate largely independently, as shown by work 
in our lab where BBB permeability due to upregulation of transcytosis occurs prior to leakage 
induced by TJ breakdown [91]. Immune cells also appear to use these two pathways differently, 
as Th1 cells preferentially transmigrate transcellularly, but Th17 cells will transmigrate by either 
route in EAE [92]. Previous studies showed that TJ remodeling and BBB permeability occur after 
recurrent GAS infections [93], however, it remained unclear if this process was due to the presence 
of infiltrating Th17 cells. Our work indicates that breakdown of these two pathways is initiated by 
different processes, supporting the hypothesis that they are under independent control (Figures 
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3.8, 3.9, 3.10, 3.11). Cav1 levels were reduced significantly in RORgt+/- mice, and non-
significantly in RORgt-/- mice, which seems to imply lower rates of transcytosis (Figure 3.11). 
This data bears the caveat that the phospho isoform of Cav1 has been shown to be active in 
internalization of TJ proteins following integrin signaling, and blots probing for the phospho-Cav1 
isoform were unsuccessful [307]. We showed that IgG leakage, which can occur paracellularly or 
transcellularly depending on the extent of TJ disruption, was abrogated in the absence of Th17 
cells, despite persistent TJ abnormalities and vascular permeability to biocytin-TMR, which 
traffics via the paracellular route (Figures 3.8, 3.9, 3.11).  
 Published results on this model from our lab, as well as current results, do not address 
temporal dynamics of BBB permeability, nor do we provide conclusive positive evidence that 
increased rates of transcytosis are the mechanism by which IgG deposition increases after recurrent 
GAS infections. Changes in transcytosis rate can be measured using tracers specifically transported 
via Cav1+ vesicles, and would be ideally suited to address this question [92, 117]. Further 
experiments would be needed to test when the BBB is first permeabilized (via TJ remodeling or 
transcytosis regulation) during the course of recurrent infections, as well as how long the BBB 
takes to close, if at all, after the final infection [91, 92]. Recurrent imaging using intravital 
microscopy may be the most well-suited tool for these experiments, and would reduce variability 
between mouse and bacterial cohorts.  
 In endothelial cells, tight junction (TJ) complexes have been hypothesized to lie in lipid 
rafts, specialized regional domains within the plasma membrane enriched for cholesterol, 
specialized proteins, and various phospholipids [308, 309]. TJ proteins Claudin-4, -5 and Occludin, 
but not Claudin-1, -2, or -3, have been shown both in vivo and in vitro to localize to lipid raft 
fractions; furthermore, infection inducing inflammatory cytokine production results in removal of 
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TJ proteins from rafts in epithelial cells [308-310]. In addition to localizing TJ proteins to the 
apical membrane, ECs may nucleate caveolae within rafts. Cholesterol and flotillin-1 may stabilize 
membrane regions within or around caveolae [95]. In the immune system, T cell receptors (TCRs) 
responsible for initiating T cell activation are also localized to raft domains, and mice deficient for 
raft-scaffolding protein Raftlin-1 showed ameliorated EAE. This was due to impaired TCR 
signaling in T cells, resulting in blunted IL-17 production [311]. Thus, membrane stabilization in 
both Th17 cells and in endothelial cells may play a role in vulnerability to inflammatory insult.  
 In addition to leakage of serum proteins through disrupted tight junctions, immune cells 
also cross the endothelium. The process of T cell transmigration is well described in brain and 
spinal cord vasculature in EAE, with some differences between these two regions [12, 103, 120]. 
VCAM-1, ICAM-1, MCAM, and ALCAM have all been shown to interact with T cells and 
promote arrest, crawling, and transmigration in vitro and in vivo [103, 105, 132, 288, 312, 313]. 
The roles of ICAM-1 and VCAM-1 are most well-documented in this process, and could provide 
a mechanism for T cell transmigration after initial BBB permeabilization. Our work supports 
upregulation of cell adhesion molecules in OB capillaries, but it is also possible that the leaky 
vasculature in the olfactory nerve provides an entry point for immune cells that then travel to the 
brain within the parenchyma, circumventing the BBB. While cell adhesion molecule expression 
was not directly investigated in these studies, the presence of T cells in the brain raises the 
possibility that adhesion molecules are upregulated to promote their entry later in disease course. 
Future experiments should address the possibility that vasculature in the OB or choroid plexus 
may express cell adhesion molecules to promote T cell entry into the brain via this route. It is also 
unclear if these changes might precede or follow initial T cell entry via the olfactory route.  
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 The multi-hit hypothesis of post-infectious BGE necessitates BBB breakdown, but in most 
human pathologies, BBB permeability is localized in lesion areas [280, 314]. Seizures, whether 
they are caused by epilepsy or other underlying neurological condition, are both a byproduct of 
local disturbances in ion, metabolite, and neurotransmitter concentration from BBB permeability, 
as well as a cause of BBB dysfunction, owing to excitotoxic release of ions from astrocytes and 
neurons [315]. Over the course of NMDARE progression, patients frequently develop seizures, 
putatively caused by pathogenic NMDAR antibodies binding in excitable temporal lobe regions 
[2, 16, 246]. However, it is possible that these seizure events are actually caused by localized flares 
in BBB permeability, which serve to allow a fresh wave of blood-borne NMDAR antibodies to 
enter the CNS and progress disease. Our previous and present results indicate that BBB breakdown 
is neither uniform spatially across the brain, nor temporally after infection (Figures 3.8, 3.9) [93]. 
Molecular regulation of the BBB during AE disease flares is therefore a critical area of 
investigation. It remains unclear how BBB permeability is regulated over the course of AE 
syndromes, and future clinical studies examining this would significantly progress the field 
towards greater understanding of diseases progression.  
 
5.4 Invitations to the T cell party in the brain 
 Although our experiments here did not address the role of dendritic cells in promoting 
neurovascular pathology after recurrent GAS infections, there is a distinct role that they may fill. 
CD4+ T cells persist in the CNS for up to 56 days after the final infection [93], and to date we have 
not identified a plausible explanation for the persistence of this population in the brain so long 
after infection. Dendritic cells infiltrate the CNS in EAE guided by CCR2-dependent cues, and 
contribute to persistence of CNS-infiltrating T cells by continually presenting myelin antigen [201, 
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202]. DCs circulate through the brain and drain via CCR7 signaling into the deep cervical lymph 
nodes; epitope spreading in the nodes then contributes to disease progression; however, 
interference with CCR7 signaling and drainage via the cribriform plate results in DC accumulation 
in the brain and exacerbated clinical progression [146, 192]. DCs may also migrate to the CNS via 
the meningeal lymphatic vessels and passage into interstitial fluid, then drain through perivenous 
lymphatic vessels into deep cervical lymph nodes [316]. These data indicate that DC circulation 
through the CNS and back to peripheral lymph nodes drives EAE progression. 
 The role of dendritic cells in post-infectious autoimmune encephalitic syndromes remains 
unexplored, however. Our results showing upregulation of CCL2 in olfactory bulb after recurrent, 
but not single, infections, allow for the possibility that DCs initially recruited to the OE to respond 
to infection subsequently traffic into the CNS. It is possible that DCs recruited to the brain after 
recurrent GAS infections sample additional CNS antigens, contributing to antigen spreading after 
clearance to deep cervical lymph nodes [93, 235]. DCs infiltrating in the brain also provide an 
attractive mechanistic explanation for the of T cells in the brain for prolonged periods after GAS 
infections. After initial recruitment by chemokine signaling, DC populations with broadened 
epitope specificity may help maintain T cell presence in the CNS after resolution of frank infection. 
It is possible that dendritic cells do not migrate to the CNS, and are instead restricted to the OE. 
Preliminary results from our lab tracked dendritic cell populations after recurrent infection in the 
CD11c-eYFP transgenic mouse line, in which a fluorescent reporter is expressed under control of 
a DC-specific promoter (Appendix B), and indicated GAS-induced DC influx into the anterior 
brain. While it is unclear how long DCs persist in the brain, they could be responsible for 
maintenance of lymphocytes in the CNS after resolution of infection, restimulation of T cells in 
the CNS, or epitope spreading if DCs drain to deep cervical lymph nodes in the same manner as 
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in EAE [146, 235]. Examination of epitope specificity of T cells harvested from PANDAS patient 
tonsils could indirectly address the role of DCs in progression of GAS pharyngitis to GAS-induced 
autoimmunity. 
 One question that remains unanswered is the spatial localization of T cells along olfactory 
axons. While visualization of T cells along axons in a continuous path to the OB is an important 
step in confirming their potential use of the olfactory route to enter the CNS, the relative 
contributions of the olfactory tract versus transmigration through the endothelium remains 
unexplored. Preliminary experiments indicate that the majority of T cells appear to traffic along 
olfactory axon tracts between the axon bundles and the ensheathing glia, potentially along the 
lymphatics that line these tracts (Appendix C), as has been demonstrated in EAE [192, 202]. T 
cells appear localized along the periphery of olfactory axon bundles, with some sparse T cells 
present within axon bundles themselves. Live imaging experiments could track immune cells 
traveling over time, resolving the questions of directionality of T cell travel and how long it takes 
T cells to migrate from nose to brain. Future experiments using fluorescently labeled T cells in 
mice with i.v. fluorescent dextran to label vasculature could track T cell progress through a cranial 
window over the OE and cribriform plate, or in the OB to examine trafficking through the leaky 
BBB. It has been hypothesized that viruses and bacteria co-opt the olfactory route to cause 
encephalitis and infect the CNS [317]. It is possible that T cells responding to the infection in the 
OE use this route preferentially, with entry from a permeabilized BBB possible after initial barrier 
breach.   
 
5.5 Microglia: more than neuroinflammation 
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 Microgliosis and infiltration of peripheral macrophages into inflamed CNS lesion areas are 
well-described in MS, neuropsychiatric lupus, and EAE [164, 187, 318, 319]. Th17 cells 
expressing IL-17A or both IL-17A and IFNg are potent activators of microglia, inducing 
expression of MHC-II and other costimulatory molecules [164]. IFNg-expressing Th1 cells are 
less efficient in this process.  
 Several years ago, microglia were shown to play an active role in circuit sculpting during 
development, following cues from complement C1q deposition to prune underused synapses in 
the retinogeniculate pathway [180]. In the ensuing years, this function of microglia has been 
demonstrated in neurogenerative and genetic disease states as well [282, 320]. Loss of olfactory 
sensation has been documented for several neurodegenerative diseases, including as a prodromal 
biomarker for Alzheimer’s disease [248, 284, 321]. In peripheral nervous autoimmunity mediated 
by G1q antibodies, the combination of complement and autoantibody deposition is necessary for 
neuromuscular junction dysfunction, indicating a role for potential peripheral synaptic tagging and 
innate immune mechanisms in altering neural transmission in autoimmunity [224]. Although we 
see microglial activation in our mouse model, the most parsimonious explanation for loss of 
vGluT2 staining in olfactory glomeruli would be a downregulation of this packaging protein in 
OSN terminals. However, mitral cells also receive input from external tufted cells (ET), and we 
cannot rule out the possibility that vGluT2 expression decreases in these cells [285]. Indeed, 
pruning of ET-mitral cell synapses by activated microglia would explain both loss of odor-driven 
activity in mitral cells and decreased vGluT2 expression in glomeruli. OSN-mitral cell synapses 
are probably not pruned by microglia, as vGluT2 loss within glomeruli was not accompanied by a 
decrease in post-synaptic marker PSD95 [93], which would indicate preservation of the entire 
synapse. Thus, if OSNs are the source of the loss-of-vGluT2 phenotype observed after GAS 
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infections, their presynaptic terminals are still present, but do not contain loaded glutamatergic 
vesicles. Further experiments using ex vivo OB slice preparations from GAS-inoculated mice could 
help determine whether OSN terminals contain either (1) an equivalent number to control mice of 
empty, unloaded excitatory vesicles, or (2) comparatively very few loaded glutamatergic vesicles. 
  The action of infiltrating monocytes and macrophages versus microglia in effecting circuit 
damage in CNS autoimmunity and neuroinflammatory diseases has not been thoroughly explored. 
Most of the literature discusses the coexistence of peripheral macrophage and monocyte 
infiltration with activated microglia in animal models of neuroinflammation, however, few have 
tried to untangle the specific effects of these two cell types. It may be disingenuous to attempt to 
separate these two immune populations, given their similar abilities as phagocytes and secreted 
cytokines profiles. In EAE, a recent study has shown that infiltrating macrophages and microglia 
may play opposite roles, where macrophages associate with nodes of Ranvier to effect myelin 
damage, and microglia phagocytose the debris and clean up lesion areas [322]. Specific depletion 
of microglia with colony stimulating factor 1 receptor (CSF1R) inhibitors (CSF1R is expressed on 
microglia and macrophages, but antagonists more potently affect microglial survival) would 
permit independent examination of microglial contributions to disease pathogenesis [281, 323]. 
CSF1R inhibitor treatment shows minimal effect on macrophages in healthy WT mice, but reduces 
macrophage presence in tumors; 99% of microglia are eliminated with CSF1R inhibitor treatment 
[323]. This treatment also presents an opportunity to refresh activated microglia; in acute 
neuroinflammation, repopulating microglia have diminished activation and more efficiently 
phagocytose debris [324].  
 Potential involvement of macrophages and monocytes has been explored very little in 
animal models of post-infectious BGE. Overt infection in the OE will recruit macrophages to the 
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nose; macrophages constitute the first line of defense upon bacterial recognition by Toll-like 
receptors [325]. However, while recruitment of monocytes from bone marrow upon infection is 
CCR2-dependent, CCR2 signaling does not determine target tissue infiltration by macrophages 
[295]. Induction of CCL2 in OE should recruit monocytes and macrophages to the site of infection 
to initiate an innate immune response. Macrophages and antibody creation are generally efficient 
at eliminating bacterial infection from the nose, however, GAS has been shown to create 
intracellular reservoirs in macrophages and epithelial cells in vivo [326]. T cell trafficking into the 
brain was hypothesized here to be CCR2-dependent, however, we cannot exclude the possibility 
that macrophages and monocytes recruited to the OE also traffic along olfactory sensory axons or 
via a disrupted BBB to enter the CNS parenchyma. To probe this question, use of live imaging of 
olfactory axon tracts in infected CCR2-RFP monocyte transgenic reporter mice could clarify 
whether monocytes in the nose directly enter the brain.  
 
5.6 Host and pathogen genetic contribution to post-infectious BGE and other AE syndromes 
 Genetic vulnerability to various AE syndromes, and to their associated tumors and 
infectious triggers, is surprisingly variable, depending on the autoantigen implicated in 
pathogenesis [6, 25, 44, 57, 327]. Anti-LGI1 encephalitis has relatively stronger genetic linkage, 
with 27 SNPs in an HLA locus, and although it is not associated with a specific tumor, comorbid 
cancers have been reported [44-46]. NMDAR encephalitis has relatively weaker genetic link, but 
strong association with ovarian teratoma [17, 44, 207]. Species differences in the HLA locus 
between humans and mice complicates interpretation of immunological studies performed in mice. 
Use of mice with a humanized HLA locus could provide a more accurate picture of both 
autoimmunity initiation and epitope spreading occur in human AE. In this mouse, GAS antigen 
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would be processed and presented to B and T cells according to human MHC rather than mouse. 
Antigen processing and recognition by mouse MHC may differ significantly, especially for a 
uniquely human pathogen like GAS.  
 Even though host genetics undoubtedly play a role in either proper control of GAS 
infection or development of autoimmunity after recurrent infections, GAS bacterial strains have 
very plastic genomes. This susceptibility to genome changes may underlie shifts in the presentation 
of autoimmunity since the 1600s [66, 328, 329]. Historically, GAS infections caused more motor 
disturbances in children with rheumatic fever, with motor changes present in up to 30% of children 
with rheumatic fever. Today, however, pure motor symptoms in rheumatic fever are rarer, and 
there has been a reported increase in the frequency of psychiatric symptoms accompanying 
rheumatic fever [6, 65, 77]. GAS genetic drift has been posited to explain this shift in 
symptomatology, with mutations in superantigens and surface proteins causing slight changes in 
the antibody repertoire generated from GAS infections over time [63]. Our lab has access to several 
superantigen mutant GAS strains, with either dominant negative or deleted SAg proteins. Future 
experiments using the i.n. GAS infection mouse model could probe the role of SAgs in recruitment 
of T cells to the NALT and brain, as well as investigating the role of superantigens in generation 
of autoreactive Th17 cells which drive BBB permeability and microglial activation.  
 Olfactory function is uniquely vulnerable to repeated inflammatory insult. Olfactory 
sensitivity sharpens over the course of childhood, becoming sexually dimorphic as children pass 
through puberty [330, 331]. It would be possible to detect loss of olfactory function in children 
with suspected post-infectious autoimmune encephalitis, provided tests were appropriately 
calibrated for age and sex. If recurrent GAS infections during childhood interfere with olfactory 
ability later in life, this may be detectable with a clinical test. However, given sex-dependent 
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differences in olfactory ability over the course of development, this necessitates careful 
consideration of how metrics are defined for girls and boys of different ages [330]. Onset of 
PANDAS and SC is defined as pediatric, so use of an olfactory assay to determine either onset of 
symptom flares or persistent vulnerability to future flares could hold promise. 
 
5.7 Concluding remarks 
 This study investigated the peripheral immune cell recruitment to the brains of mice after 
recurrent GAS infections. Here, we show the requirement of Th17 lymphocytes in initiating size-
dependent BBB permeability, microglial activation, and olfactory bulb mitral cell dysfunction. 
Additionally, we identified chemokine signaling cues that contribute to CNS T cell infiltration, 
and show that interrupting chemokine signaling partially ameliorates neuroinflammation after 
recurrent GAS infections. Our results suggest that infiltrating Th17 cells in the CNS may promote 
BBB permeability via increased transcytosis rather than tight junction remodeling, mechanistically 
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Appendix A: Comparison of route of GAS exposure: neuroinflammation and behavioral 
studies  
 Animal models of CNS autoimmunity frequently feature peripheral activation of the 
immune system in conjunction with permeabilization of the BBB to allow access to CNS targets. 
This produces a robust CNS antigen-directed response in immunized animals; in the case of 
MOG35-55 EAE immunization, demyelination, BBB breach, and immune cell infiltration occur ~8-
12 days post immunization (dpi) [167]. However, many different types of EAE exist, none of 
which perfectly model the human disease multiple sclerosis [332, 333]. For instance, differing 
lengths of myelin peptide antigen produce slightly different immune cell profiles in the periphery 
and as CNS infiltrate. Toxin- or viral-induced demyelination models more accurately capture 
mechanisms of brain demyelination, as opposed to classical EAE, which primarily affects the 
spinal cord [333]. Differences in localization of pathology, degree of vascular dysfunction, and 
immune profile all separate different MS animal models [332]. Initial investigation into GAS-
induced CNS autoimmunity directly translated the EAE model of antigen-directed immunization 
to expose rodents to GAS antigens together with adjuvants that activate the immune system and 
permeabilize the BBB. 
 The discovery that brain antigens drove pathogenic autoantibodies into the CNS in AE 
syndromes drew an attractive parallel to various EAE models. To investigate the pathogenesis of 
these diseases, new animal models of GAS-induced BGE featured immunization with GAS 
bacterial antigens in conjunction with adjuvants to disrupt the BBB and activate the immune 
system. Recurrent boosts with antigen alone every two weeks mimic recurrent exposure to GAS 
over long periods of time in these models. In this manner, subcutaneous (s.c.) GAS immunizations 
were reported to induce behavioral abnormalities reminiscent of PANDAS and SC in rats and mice 
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[80, 205, 206]. In addition to behavioral abnormalities, these studies described microgliosis in the 
striatum and deposition of serum IgG in the deep cerebellar nuclei, striatum, hippocampus, 
thalamus, and frontal cortex of GAS-exposed rodents [80, 81, 205, 206, 232]. In EAE, T cell, B 
cell, and peripheral monocyte/macrophage infiltration is a key feature of disease seen in various 
brain regions and in spinal cord lesion areas [115, 202, 280]. However, differences in methodology 
in GAS immunization models necessitates critical review in how fully their findings may be 
translated to human post-infectious BGE. 
 Behavioral and motor abnormalities were reported in subcutaneously (s.c.) GAS-
immunized rodents [80, 205, 206]; however in mice, intranasal (i.n.), but not i.v. or s.c., GAS 
exposure generates a robust autoreactive Th17 response that mimics GAS pharyngitis in humans 
[93, 235]. Therefore, different routes of GAS exposure may skew immune responses. Reports of 
both s.c. and i.n. GAS exposure are helpful in clarifying potential mechanisms of post-infectious 
BGE, but thorough, direct comparison of immune and neurodegenerative outcomes in s.c. and i.n. 
GAS models has not been performed to date. To adequately compare s.c. GAS immunization to 
i.n. GAS inoculation models, experiments within our lab directly compared T cell infiltration, 
microglial activation, serum IgG binding profiles to GAS and brain antigens, and behavioral 
phenotypes. 
 
A.1 Different immunological responses to intranasal versus subcutaneous GAS exposure  
 By comparing infiltration of CD4+ T cells in Figure A.1, it is clear that i.n. inoculations 
are far more efficient at prompting a CNS inflammatory response, even with BBB breach in the 
s.c. model providing an entry to the CNS. T cells collect in i.n. brains anteriorly in the olfactory 
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bulb, and while some T cells are seen in the OB meninges in s.c. brains, the bulk of CD4 infiltrate 
in s.c. brains is periventricular and within the choroid plexus. It appears that the T cells in the  
 
Figure A.1 CD4+ T cells in brains of subcutaneously immunized SJL/J mice. a T cells do not colocalize with lymphatic 
marker LYVE1, but b they do colocalize with blood vessel marker GLUT1. In the choroid plexus, immunized mice 
show collections of CD4+ T cells contained by the BCSFB. c Quantification of CD4+ T cells over the rostrocaudal 
axis of the brain. Data represent mean ± SEM from n=4 mice per group. There was a significant effect of bregma 
(F(12,72)=12.00, p<0.0001), but no main treatment effect (F(1,6)=1.439, p=0.2755) or interaction between bregma 
and treatment (F(12,72)=0.8039, p=0.6453). Scale bar = 20 µm. 
 
choroid plexus of s.c. GAS brains do not cross into the CSF; rather, they are limited by the BCSFB. 
T cell counts between i.n. and s.c. GAS brains equalize in more posterior regions of the brain. 
 Neuroinflammation in anterior brain regions was then assessed in s.c. and i.n. GAS-
exposed mice. Microglia counts in the olfactory bulb glomerular layer of s.c. GAS-immunized 
mice are not significantly different from uninfected control mice, which is not surprising given the 
lack of peripheral immune infiltration in the OB. Intranasally-infected mice have significantly 
more activated microglia in the OB than s.c.-immunized mice (Figure A.2). Looking more 
posteriorly, microglia counts in the dorsal striatum are also not elevated in s.c.-GAS mice 
compared to vehicle controls.  
 
A.2 Humoral anti-GAS and anti-brain immune responses induced by s.c. and i.n. GAS 
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 Given that there seems to be a mild effect on the cellular immune system after s.c. GAS 
infections, we also compared humoral immune system to investigate Ab production. Serum 
harvested from i.n. and s.c. GAS mice (as well as their respective vehicle controls, and healthy 
controls) was assayed by Western blot for binding affinity for GAS bacterial protein lysate and  
 
Figure A.2 Microglial activation is not GAS-specific in the s.c. GAS immunization protocol. a Immunohistochemical 
labeling of CD68 (green), Iba1 (red), and DAPI (blue) in OB tissue sections of s.c. GAS-immunized mice and 
CFA/PTx controls. b Quantification of microglia in OB sections of naïve, CFA/PTx, GAS/CFA, acutely i.n. GAS-
inoculated (1i) and recurrently i.n. GAS-inoculated (4i) mice. Data represent mean ± SEM from n=4 naïve, n=5 
CFA/PTx, n=5 GAS/CFA, n=4 GAS 1i, and n=4 GAS 4i animals. One-way ANOVA showed an effect of treatment 
(F(4,17)=12.18, p<0.0001). Tukey’s MC test showed significant differences between naïve vs CFA/PTx (*p=0.0372), 
naïve vs GAS/CFA (*p=0.0494), naïve vs GAS 4i (****p<0.0001), CFA/PTx vs GAS 4i (*p=0.0212), GAS/CFA vs 
GAS 4i (*p=0.0158), and GAS 1i vs GAS 4i (***p=0.0003). 
 
mouse brain endothelial cell (mBEC) protein lysate, and by immunofluorescence for binding 
affinity to fresh frozen brain tissue. These two techniques in combination allow investigation of 
antibodies that recognize both denatured and native protein structures, which has been a point of 
note in previous work [205]. Serum IgG from both i.n. and s.c. GAS mice recognize denatured 
GAS protein lysate, with stronger binding by i.n. GAS sera (Figure A.3a). Vehicle control mice 
do not produce antibodies against GAS. Binding affinity for mBEC lysate would be a clue towards 
a direct mechanism for antibodies to interact with ECs and cause BBB permeability. When serum 
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antibodies are reacted with mBEC lysate, some binding is evident in sera samples from i.n. and 
s.c. GAS-exposed mice, but binding is also clear in uninfected controls (Figure A.3b). This 
indicates that, similar to the human population, anti-EC antibodies are physiologic in a subset of 
mice [43]. This holds true with human patient data where anti-brain antibodies can be found in 
~10% of healthy populations [14, 41]. 
 
Figure A.3 Sera harvested from i.n. or s.c. GAS-exposed mice react with GAS bacterial proteins and endothelial cell 
antigens. a Western blot where GAS protein lysate is probed with diluted primary mouse sera; PBS-inoculated sera 
show no binding to GAS proteins on the Western membrane, but s.c. and i.n. GAS-exposed mice show robust 
generation of polyclonal antibodies against GAS. b Mouse brain endothelial cell (mBEC) protein lysate probed with 
diluted primary sera from PBS control mice do not show reactivity, but sera from s.c. and i.n. GAS-exposed mice do 
mBEC antigens.  
 
 Based on the presence of brain-binding autoantibodies in sera of s.c. GAS-immunized 
mice, barrier properties were investigated to ascertain whether Ab deposition via a disrupted BBB 
would be possible after s.c. GAS exposure. BBB integrity was measured using biocytin-TMR i.v. 
tracer injections after the final boost with GAS/IFA emulsion. Figure A.4ab details areas of BBB 
disruption, which were minimal in this model. Intensity of BBB leakage (i.e., amount of tracer 
taken up by surrounding brain tissue) was only elevated in the glomerular OB (Figure A.4c), 
compared to mice immunized without GAS homogenate. Permeability to serum IgG provides a 
measure of transcytotic leakage, and compared to healthy controls, there was no GAS-specific IgG 
leakage. In Figure A.4d, it is clear that there are only very small areas of BBB leakage that are 
different from vehicle-immunized mice, confirming that adjuvants efficiently permeabilize the  
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Figure A.4 GAS immunized mice have largely intact BBB. BBB permeability to small molecular weight tracer 
biocytin-TMR in OB regions a and posterior brain b. Quantification of tracer deposition intensity c shows significant 
BBB breakdown in OB glomerular regions. Data represent mean ± SEM from n=2 CFA/PTx and n=5 GAS/CFA mice. 
Glomerular vessels only were permeable to biocytin-TMR (F(3,22)=1.926, p=0.1548; OB granular, *p=0.011). d IgG 
deposition in GAS-immunized mice was minimal in comparison to both vehicle control and healthy mice. e 
Quantification of IgG deposition intensity immunized mice relative to IgG intensity in healthy controls. Data represent 
mean ± SEM from n=4 healthy, n=4 CFA/PTx, and n=4 GAS/CFA animals. IgG deposition was largely adjuvant-
dependent and not GAS-specific (F(2,18)=2.25; glomerular GAS vs healthy, *p=0.0478; granular CFA/PTx vs 
healthy, *p= 0.0315; granular GAS vs healthy, ****p<0.0001). 
 
BBB. When IgG staining intensity in vehicle- and GAS-immunized mice is normalized to staining 
intensity in healthy controls, IgG leakage is significantly elevated in the OB of both groups. Again, 
this confirms an adjuvant vehicle effect with no GAS-specific effect on IgG leakage (Figure A.4e). 
The relatively mild immune infiltration phenotype seen in s.c. GAS immunized mice led us to 
investigate behavioral phenotypes that have been previously reported [78, 81, 206, 334], as well 
as testing behavioral outcomes in i.n. GAS inoculated mice. 
 
A.3 Behavioral phenotypes after s.c. or i.n. GAS exposure  
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 Finally, we assessed motor and anxiety-like behaviors in i.n. and s.c. GAS exposed mice 
to compare published behavioral findings after s.c. GAS immunization with our i.n. GAS 
inoculation model (Figure A.5). While we replicated these assays several times, i.n. GAS-
inoculated mice only showed modest alterations in behavior (representative results from one 
experiment showed here with no significant differences between PBS and GAS inoculated mice). 
In the open field assay, mice showed no differences in ambulation or pathlength (Figure A.5a). 
Gross motor behavior was intact as assayed by the ladder beam test in which mice cross a 
horizontal ladder and footslips are counted as errors of either forelimb or hindlimb placement 
(Figure AI.5b). In an attempt to elicit stereotypy or repetitive behaviors, we elicited grooming 
behavior in the induced grooming task, but found no differences in grooming bout number of bout 
length in GAS-inoculated mice (Figure A.5cd). We then compared performances by healthy 
unimmunized mice, s.c. CFA/PTx vehicle controls, and s.c. GAS/CFA mice in the same behavioral 
test battery. In the open field test, vehicle control mice traveled slightly less than healthy mice, 
with s.c. GAS mice showing a similar but not significant trend towards less ambulation (Figure 
A.5e; healthy vs GAS/CFA, p=0.102). GAS-immunized mice showed some motor deficiencies on 
the ladder beam, with GAS-immunized mice making significantly more forelimb errors than 
vehicle controls (Figure A.5f). In the induced grooming task, both vehicle and GAS s.c. 
immunized mice initiated fewer grooming bouts, with no significant change in bout length (Figure 
A.5gh).  
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Figure A.5 Behavioral battery in i.n. and s.c. GAS-exposed mice show mild phenotypes. Intranasally-infected mice 
performed equivalently to controls in the open field (a), ladder beam (b), and in grooming behaviors elicited by the 
induced grooming test (c,d). Data represent mean ± SEM from n=10 PBS and n=9 GAS mice, symbols denote 
performance of individual animals. e S.c. immunized mice showed a vehicle effect in reduced ambulation in the open 
field (F(2,6)=5.35, p=0.0113; healthy vs CFA/PTx **p=0.0091). f In the ladder beam cross, s.c. immunized mice 
showed a GAS-specific effect of increased forelimb slips (continued on following page)  
 
   157 
(treatment F(2,26)=7.654, p=0.0024; CFA/PTx vs GAS/CFA **p=0.0039). In the induced grooming assay, s.c. 
immunized mice again showed a vehicle effect g on post-spray number of grooming bouts (treatment effect 
F(2,22)=7.87, p=0.0026; healthy vs CFA/PTx, p<0.0001; healthy vs GAS/CFA, p<0.0001). However, no significant 
differences were observed in grooming bout length in s.c. immunized mice h. Data represent mean ± SEM from n=10 
healthy, n=10 CFA/PTx mice, and n=10 GAS/CFA mice; symbols denote performance of individual animals. 
 
A.4 Concluding remarks 
 In modeling human diseases for study in non-humans, some liberties must be taken in 
translating human biology into rodents. While no disease model is a perfect recapitulation of 
human pathology, it is critical to understand the inherent limitations of the animal model [332]. 
Numerous animal models of multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and SLE 
(in a very abbreviated list of diseases relevant here) exist, which capture various facets of human 
disease, whether it be genetic contribution to pathology, immune response, behavioral and 
cognitive outcomes, or vascular pathology. Here, we directly compared the cellular and humoral 
immune responses, BBB permeability, and behavioral abnormalities elicited by s.c. GAS 
immunizations and i.n. GAS inoculations.  
 Our experiments comparing two routes of GAS exposure show that while we confirmed 
previous reports of a humoral immune response following s.c. GAS immunization [81, 205, 206], 
the BBB remains impermeable to small molecules and serum IgG, and infiltration of peripheral 
immune cells is minimal (and not GAS-specific, Figure A.1c). Interestingly, CD4+ infiltrate 
present in immunized mice localized to the choroid plexus, a site of initial immune infiltration in 
EAE [129]. We did not examine s.c. GAS-immunized animals’ spinal cord or cerebellum for 
pathology, which are affected more by classical EAE [97], and further examination of pathology 
in these brain regions may indeed show immune infiltrate or serum protein deposition. 
Neuroinflammation was also attenuated in s.c. GAS immunized mice compared to recurrent i.n. 
GAS-inoculated mice (Figure A.2b). It is possible that neuroinflammation was only present in i.n. 
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inoculated mice in the OB where we examined microglia carefully, and that s.c. GAS-immunized 
mice would display microglial activation in other regions; however, our observations indicate that 
microglia in s.c. GAS immunized mice were ramified and not amoeboid, indicating low 
inflammation.  
 One hallmark of AE pathologies is the development of antibodies that cross-react with 
brain antigens. Sera from GAS-immunized rodents has been shown to colocalize with GAS 
proteins, and to bind to ex vivo brain tissue with native-conformation brain antigens [80-82, 206]. 
Some groups have illustrated the importance of using CNS antigens in their native conformation 
rather than denatured samples, as patient-derived autoantibodies are sensitive to tertiary structures 
of their antigens [1]. Current methods for detecting CNS-specific autoantibodies include cell- and 
tissue-based assays, Western blots with brain lysate or specific antigens, and ELISA-like plate-
based assays [1, 6]. We confirmed that both s.c. and i.n. GAS exposed mice generate robust 
humoral immune responses targeting GAS, and that a subset of GAS-exposed mice (both s.c. and 
i.n.) generate antibodies recognizing brain endothelial cell lysate (Figure A.3ab). Importantly, 
anti-endothelial cell antibodies are present in a subset of the healthy population [43], and could 
represent non-specific inflammation in GAS-exposed animals. More convincingly, sera from 
GAS-exposed mice react strongly with unfixed, unpermeabilized brain tissue, whereas sera from 
healthy mice do not react (Figure A.3cde). Taken together, our results agree with previous 
findings of robust, specific anti-GAS and anti-brain humoral antibody responses in GAS-exposed 
mice, and with BBB permeability, is likely that cross-reactive anti-brain antibodies could interfere 
with neuronal function. 
 Vascular pathology in EAE begins before onset of disease, and the endothelium is 
permeable to Th17 cells quite early in disease course. Adjuvants used to immunize mice may 
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promote BBB permeability after s.c. GAS immunizations. Our results indicate that even after 
recurrent exposures to s.c. GAS and adjuvants, BBB permeability to the small molecular weight 
tracer biocytin-TMR is mild, and only deposited significantly in the OB glomerular layer (relative 
to CFA/PTx controls, Figure A.4abc). By contrast, there is an adjuvant effect on permeability to 
IgG, where both vehicle control and s.c. GAS immunized mice show increased IgG deposition 
compared to healthy mice in examined regions. These results support differential breakdown of 
the BBB to different size molecules, but compared to massive BBB permeability seen in i.n. GAS 
inoculated animals, vascular pathology in s.c. immunized mice was relatively mild. 
 Finally, behavioral tests showed that GAS-exposed mice had mild motor deficits on the 
ladder beam. GAS-immunized mice also showed mild anxiety-like phenotypes by burying more 
marbles than vehicle control mice, but this phenotype did not extend to repetitive behaviors 
assayed by the induced grooming task. To play the devil’s advocate, positive results showing 
motor deficits in s.c. immunized mice could be due to site of injection chosen for our 
immunizations. We immunize for EAE and for s.c. GAS boosts in the chest, near axillary lymph 
nodes. In behaviors dependent on forelimb strength or walking, immunized mice may be showing 
deficits simply because they have large boli of emulsion on their chests. The fact that some of 
these findings are GAS-specific and not solely an effect of vehicle lends some weight, however, 
and our findings largely concur with previous reports showing motor deficits after s.c. GAS 
immunization or intracerebral infusion of autoantibodies. Thus, the s.c. route of GAS exposure 
may be a better model for the humoral immune response and circuit-level changes in behavior, but 
careful choice of immunization site should be considered. The s.c. GAS model is unfit for studies 
of how the immune response to GAS infections changes with repeated exposures, as the cellular 
immune system remains largely unaffected in these mice.  
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 These experiments support validation of findings in multiple disease models, and highlight 
the vast differences in pathology induced by different routes of GAS exposure. It is possible that, 
like in EAE, pathology induced by s.c. GAS is more pronounced in the spinal cord, but given that 
spinal circuits were not grossly affected (MPP, personal observation), this seems unlikely. The 
time scale for autoantibodies generation, as well as potential changes in splenic T and B cell 
population remains unclear. A combined approach where i.n. and s.c. GAS are administered to the 
same animal may yield synergistic effects on both immune response in the CNS and behavioral 
changes. Future work that more closely examines changes in the B cell and plasma cell populations 
in both models are warranted. 
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Appendix B: Dendritic cells infiltrate the CNS after recurrent GAS inoculations  
B.1 Dendritic cell populations increase in anterior brain after GAS infections 
 Dendritic cells (DCs) are the professional antigen presenting cells (APCs) of the adaptive 
immune system, surveying the body for foreign peptides and returning to draining lymph nodes to 
synapse with naïve T and B cells. This directs the effector populations to target foreign epitopes. 
In terminal tissues, DCs maintain T and B effector populations in situ by refreshing their antigen 
direction [335]. After recurrent GAS inoculations, T cells persist in the brain up to 8 weeks after 
the final infection. T cells should not remain in a tissue for that long without an APC to refresh 
their direction; after neutralizing the infection, lymphocytes exit the tissue or undergo apoptosis.  
 
 Figure B.1 Dendritic cell populations increase the CNS after recurrent GAS inoculations. a Immunohistochemistry 
for transgenic eYFP reporter shows that infiltrating DCs (green, arrows) are in close proximity to infiltrating CD4+ T 
cells (red, open arrowheads) and not vascular (labeled with Glut1, white). b Immunohistochemistry for transgenic 
eYFP reporter shows that infiltrating DCs (green, arrows) colocalize with a subset of microglia (Iba1, red) in OB brain 
sections. c Quantification of eYFP+ DCs in brain sections shows that DCs infiltrate the brain after recurrent GAS 
inoculations, elevated from basal populations present in PBS controls. Data represent mean ± SEM from n=3 PBS and 
n=3 GAS mice. Two-way ANOVA reveals a significant main effect of bregma (F(11,44)=3.257, p=0.0025), as well 
as an interaction between treatment and bregma (F(11,44)=2.335, p=0.0231). Sidak’s MC test shows a significant 
difference with treatment at bregma +4.28 (**p=0.0012). Scale bar = 20 µm.  
 
 We hypothesized that DC populations may be responsible for maintaining the T cell 
presence in the CNS for an extended period of time. To examine DC populations in mice, we 
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utilized the CD11c-eYFP transgenic line, in which eYFP is inserted in the genome under the 
control of the dendritic cell-specific promoter CD11c. We performed recurrent inoculations with 
either GAS or vehicle in this mouse line, then examined both T lymphocyte and dendritic cell 
populations in the brain. GAS-inoculated mice showed a specific increase in DC populations in 
anterior brain regions compared to vehicle control mice, indicating that they are possibly recruited 
to the OB along with T cells to maintain the CNS lymphocyte population (Figure B.1).  
 Next, we assessed T cell counts in parallel with DC numbers in GAS-inoculated mice. 
Here, it was clear that DC populations roughly correlated with T lymphocyte infiltration. In 
anterior brain regions where the most T cells are observed, DC populations are also elevated 
(Figure B.2). In posterior brain regions, however, T cell numbers rapidly fall, while DC 
populations stabilize at their baseline counts (as determined in Figure B.1).  
 
Figure B.2 T cell and dendritic cell populations are present in GAS-inoculated mice. T cell counts (black line) are 
elevated anteriorly in GAS-inoculated mice, and dendritic cell numbers (green line) are elevated in similar regions. 
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B.2 Concluding remarks 
 Our data here agree with published studies reporting basal levels of eYFP+ dendritic cells 
distributed throughout the brain [336, 337]. We found eYFP+ DCs in the brains of both PBS control 
and GAS-inoculated mice, although there was an increase in DC numbers in OB brain sections. 
These data were collected from mice sacrificed at 48 h after the final infection. To investigate a 
role for DCs as potential APCs in the CNS, it will be important to verify their continued presence 
in the brain at longer time points. These experiments also present the opportunity to compare and 
contrast DC trafficking after GAS inoculations to what has been reported in EAE [146, 192, 201, 
202].  
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Appendix C: T cells localize along olfactory axon tracts after recurrent GAS inoculations 
C.1 Olfactory axon tracts connect OE with OB 
 Recurrent GAS inoculations in mice induce expanded T lymphocyte populations in the 
cervical lymph nodes (CLN), nose-associated lymphoid tissue (NALT, structural analog of the 
human tonsils and adenoids), and brain. CD4+ T cell populations recruited to NALT and olfactory 
bulb express similar cytokine profiles comprised of mainly IL-17A+ IFNg+ and IL-17A+ 
lymphocytes; however, CD4+ T cells from the CLN express mainly IFNg [93]. This suggests that  
 
Figure C.1 Infiltrating T cells localized along olfactory sensory axon tracts. Contiguous olfactory bulb (OB) and 
olfactory epithelia (OE) tissue sections stained for CD4+ T cells (green) and olfactory marker protein (OMP, red) show 
T cells localized mainly to the outer sheath of olfactory sensory axon tracts. a Large axon tracts contain many T cells 
(arrows), although mainly on the perimeter of the axon bundles, and b Smaller field of view image shows T cells 
interspersed within axon bundles and along the outside of tracts. Cyan and magenta rectangles in the schematic at 
right denote approximate location of images in a and b. Images are representative of n=3 GAS-inoculated RORgt+/- 
mice. 
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T cells that are recruited to the nose and secondary lymphoid tissue (NALT) migrate to the CNS, 
and that CLN lymphocytes are draining lymph nodes for Th1 cells from the olfactory epithelium. 
CD4+ T cells were also detected primarily in anterior brain regions, concentrated in the olfactory 
bulb.  
 We hypothesized from these data that T lymphocytes were recruited to the site of infection 
in the nose and differentiated in the NALT, then migrated along olfactory sensory axon tracts that 
extend from the OE through the cribriform plate into the OB. Access to the brain via the olfactory 
route has been reported for a wide range of cargo, including peptides, small molecule drugs, 
viruses, bacteria, and therapeutic stem cell delivery [50, 138, 144, 145]. Convection in perivascular 
spaces is thought to underlie this, and delivery of biologics depends on cargo size and nasal 
epithelial permeability [144]. T cells are roughly uniform in size, and could conceivably traffic via 
this route. We assessed the feasibility of this process in a pilot experiment in which RORgt+/- mice 
were inoculated with GAS, then sacrificed at 24 h after the final infection. Skulls were dissected 
such that olfactory epithelia remained contiguous with the brain; skulls were then bisected sagitally 
and sectioned parallel to the plane of incoming olfactory axons.  
 
C.2 Concluding remarks 
 Following recurrent GAS inoculations, CD4+ T cells were seen in dense collections in the 
olfactory epithelium, within the OB, and in axon tracts connecting OE and OB (Figure C.1). While 
this data is not conclusive evidence that T cells travel from nose to brain, and not the reverse (as 
has been reported in EAE using newly formed lymphatic vessels [192]), it demonstrates proof-of-
concept for continued investigations. Further studies should examine localization of T cells within 
LYVE1+ lymphatics along olfactory sensory axons, proximity to blood vessels and perivascular 
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spaces, and whether axonal trafficking is an intrinsic property of the T cells recruited to the brain 
(as assessed with adoptive transfer experiments). Of course, live imaging studies would provide 
more conclusive evidence of both directionality of T cell flux and the speed with which 
lymphocytes travel along this route. Signaling pathways, including chemokine ligands, controlling 
this transit could also be more conclusively determined using live imaging studies. It remains to 
be seen whether immune cells can be seen along olfactory axons in uninfected mice, but given the 
relatively lower (but not absent) lymphocyte populations in uninfected olfactory epithelium, it 
seems likely that lymphocyte populations will be restricted to the OE. In conclusion, this work 
represents a proof of concept that T cells can be seen in bulk transit along olfactory sensory axons. 
More work is needed to determine the contribution of this pathway during T cell infiltration 
compared to vascular diapedesis, as well as signaling molecules that may guide T cells to home 
along this route to the brain. 
